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Abstract 
Luminescent dye molecules capable of passive cell delivery may be used as 
molecular probes in cellular and tissue imaging. Inorganic transition metal complexes have 
been under extensive investigation for many years in supramolecular assemblies in 
application ranging from sensing to photovoltaics. This is due to their favourable 
photophysical and redox properties including absorbance and emission in the visible region 
of the spectrum, large stokes shifts, long lifetimes, intense luminescence, good photostability 
and useful photosensitising properties for photodynamic therapy. However, their application 
in cell imaging can be limited by their inability to cross the cell membrane. Recent work by 
our group has shown that the cellular uptake of ruthenium complexes can be promoted 
though their conjugation to a cell penetrating peptide. Peptides combined to Ru(II) provide 
unique opportunities for imaging dynamic processes in living cells avoiding limitations 
associated with fixation.  
 
This thesis continues this work by reporting on the synthesis, characterisation and 
identification of novel ruthenium complex-peptide bioconjugates suitable for 
applications in cellular imaging and the investigation of their sub-cellular targeting and 
localisation. Some preliminary studies of their application in cell imaging are also 
presented.  
 
Chapter 1 introduces metal complexes previously used in cellular imaging and how 
the conjugation of these transition metal complexes to targeting biomolecules has lead to 
successful applications in medical diagnostics, photodynamic therapy, cellular imaging and 
pharmaceutical drug delivery. Chapter 2 outlines the general details of the experimental 
methods used. In chapter 3, the synthesis of 6 novel dye conjugates is detailed, of which 4 
were shown to transport efficiently across the cellular membrane of CHO cells and locate 
throughout the cell’s organelles. The spectral (absorption and emission) and photophysical 
(fluorescence lifetime) properties of these metal-ligand peptide complexes are also 
described. The complex exhibits long-lived, intense and oxygen-sensitive luminescence 
which is relatively unchanged in the conjugates from the parent dies.   Preliminary results on 
their application in cell imaging are also presented which demonstrate excellent nuclear 
permeability and nuclear localisation which depends on the hydrophobicity of the metal 
centre. 
 
xii 
 
Chapter 4 details the preparation of the BID protein, a pro-apoptotic member of the 
BCL-2 family, as a number of overlapping peptides. The aim of this work was to identify a 
functional region of the parent protein. Two BID sequences were selected for conjugation to 
probes for localisation and function studies. Along with the BID sequences, another BCL-2 
family member was investigated.  
Chapter 6 describes the synthesis and characterisation of 2 peptide-metal dye 
conjugates targeting the mitochondria. Photophysical and cellular localisation and cytotoxic 
properties of these metal-ligand peptide complexes are described. Finally, the synthetic route 
to an organic mimic molecule of BAD, another pro-apoptotic protein, was also explored as 
described in Chapter 5. It consists of a convergent synthesis involving 3 separate synthetic 
sequences containing overall 14 reaction steps. Two key synthons were synthesised and 
examined for photophysical and cytotoxicity properties.  
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1.1 Luminescent Cell Imaging 
 
Cell imaging is an important tool in molecular biology research used widely for the 
investigation of biochemical processes in cells. Luminescent cell imaging provides an 
insight into how biological systems function at the sub-cellular level and into cell signalling 
events. This can be achieved by targeting chromophores using peptides to the sub-cellular 
level and monitoring with confocal microscopy.  
 
Thirty years ago, optical microscopy may have been seen as stationary technology. 
One limitation has been the difficulty in imaging in three dimensions. This is not the case 
today, where vast improvements are continuing to take place in cameras, lasers, software 
and probes. These advances in imaging have contributed to cell and microbiology research 
and continue to do so. One of the main techniques used today in such imaging is confocal 
laser scanning microscopy. The concept of the confocal microscope was patented in 1961 by 
Minsky
[1]
 and since then the instrument has been produced and developed, surviving 
challenges from alternative technologies and contributing to countless scientific papers.
[2]
 
Confocal microscopy overcame the limitations associated with conventional wide field 
fluorescence microscopy by eliminating out of focus contributions to the image and has the 
ability to create three dimensional images and to observe deep within cells.
[3]
 
 
In geometry the term confocal means having the same foci and for optics, that, two 
lenses are arranged to focus on the same point. The key feature of confocal microscopy is 
the use of pinholes as a filtering technique to eliminate out of focus light as seen in 
Figure1.1. Light inside the plane of focus is reflected into a pinhole whereas light outside the 
focus is scattered at different angles onto an opaque block, therefore the pin holes only allow 
the light from the plane of focus to reach the detector. This results in excellent clarity and 
resolution, and three dimensional images can be created from optical slices taken at 
successive planes of focus.
[4]
 The combination of digital image collection, three-dimensional 
image building and rapid image formation make the confocal microscope a powerful and 
widely applied analytical tool. 
3 
 
 
 Figure 1.1 Schematic diagram illustrating the components present in a confocal microscope.
[5]
 
 
1.2 Novel Luminescent Chromophores for Living Cells 
 
As research in cell biology has advanced from merely structural characterisation of 
cells towards understanding of dynamic processes, fixed cell fluorescent techniques have 
been eclipsed by new methodologies appropriate for application in live cell imaging. There 
are a large variety of fluorescent labels and probes commercially available for the study of 
living cells
[6]
. Selection of the suitable probes can be a complicated task, due to the wide 
array of prospective imaging agents and several variables that can influence the utility of 
these fluorescent materials for imaging. Progress in the field of optical imaging is becoming 
more and more dependent on the development of novel imaging probes.
[7]
 An appreciation 
as to how probes are designed and operate can help researchers to make informed choice 
about probes to examine and solve technical problems, as well as inspiring the development 
of new probes and new applications. The wide array of imaging agents has been influenced 
by the combination of fluorophores with materials such as peptides, polymers and metals. 
These combined materials have also considerably enhanced the performance of numerous 
optical imaging systems.
[8, 9]
 
 
Traditionally, the most widely used probes in cellular imaging are fluorescent 
organic molecules based on, polycyclic aromatic dyes and chromophores. The short 
4 
 
luminescence lifetimes of such species, typically < 10ns, limits their environmental 
sensitivity, e.g., towards molecular oxygen and their application in fluorescent lifetime 
imaging (FLIM).
[10]
 Another key disadvantage is their tendency to photobleach which can 
lead to unreliable and irreproducible results. 
 
As outlined by Johnson a fluorescent probe for live cell imaging must address the 
following criteria: Delivery, Targeting, Detectability and Fluorescence Response.
[11]
 The 
probe must be delivered in a way that minimise damage to the physiological and structural 
integrity of the cell. Also the ideal technique of delivery would be straightforward, 
economical, rapid, reproducible; applicable to a diverse cell types and capable of uniform 
loading. Probes with lipophilic structural characteristics can usually be introduced to a cell 
by adding some of the probe to the extracellular medium. This can then enter the cell by 
diffusion. More polar probes require further techniques to enable delivery within a cell; 
these include bulk loading or microinjection. Detailed comparison of loading techniques 
have been published previously and discussed at length. 
[12, 13]
 
 
1.3 Introduction to Photoactive Supramolecular Chemistry 
 
In this thesis we take a supramolecular approach to target cell delivery by preparing 
compounds of the type A-L-B, where A is the photoactive Ru centre, L is the bridging linker 
and B is the peptide or targeting agent. Supramolecular component may be defined as a 
“complex system made up of molecular components with definite individual properties”.[14] 
These components retain their individual characteristics which are what distinguishes them 
from a “large molecule“. The original supramolecular studies were typically not covalent but 
the concept has expanded to include a wide range of studies of general type A-L-B as shown 
in Figure 1.2.
[15]
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Figure 1.2 Photochemical and electrochemical criteria used to classify a complex chemical 
species as a supramolecule or as a large molecule.
[15]
 
 
In the system A-L-B of Figure 1.2, if light excitation of a molecule results in the 
excited states that are substantially localised on one of the two components A or B, or causes 
an electron transfer from one to the other (or vice versa), it is defined as a supramolecule as 
seen on the left. Distinguished from when the excited states are substantially delocalized on 
the complete system, the species can be better considered as a large molecule as seen on the 
right of Figure 1.2. Analogous arguments can be applied to changing the redox states of the 
system.  
 
We take a supramolecule approach to designing targeted metal complex imaging 
probes in this thesis where our systems can be thought of as A-L-B dyads. The photoactive 
components (A) consist of, ruthenium (II) polypyridyl coordination compounds, a bridging 
unit (L) acts in the present case as an aliphatic and hopefully, electronically benign linker of 
variable length. The linker connects A to the second components (B), consisting of the 
transmembrane transport/targeting peptide or organic units. In the resulting A-L-B dyad 
assemblies both components; maintain their original properties, i.e. photophysical 
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characteristics and peptide localisation properties but combined form novel and valuable 
targeted probes, a true characteristic of a supramolecular assembly. 
 
1.3.1 The Photoactive component 
 
A molecular chromophore can be irradiated with UV or visible electromagnetic 
radiation leading to the promotion of an electron from a lower energy state to a higher 
energy state, resulting in the formation of an excited state with a discrete lifetime. The 
energy of the excited state can be dissipated by radiative or non radiative decay. 
Luminescence is a radiative process by which the electron returns to the ground state with 
the emission of a photon and if it occurs between states of the same multiplicity it is labelled 
fluorescence (Figure 1.3). 
 
If the electron experiences a change of spin state, i.e. convert from a singlet ground 
to triplet excited state, or less commonly, vice versa, according to the selection rules spin 
change is forbidden. As a result, the energy can become trapped in the triplet state in the 
former example. Typically triplet states are long lived and return slowly to the ground state 
via non radiative intersystem crossing or a radiative process called phosphorescence (Figure 
1.3).  In terms of applications of supramolecular assemblies, emission of radiation by 
luminescence is important in sensing and signalling because triplet excited states have strong 
reactivity with molecular oxygen which, relatively unusually is itself a triplet in the ground 
state.  In addition, the long lived nature of triplet states often leaves sufficient time for 
increased exposure, to diffusive quenchers. 
  
Figure 1.3 shows a Jablonski diagram that is a partial energy diagram that represents 
the energy of photoluminescent molecule in its different energy states. The lowest and 
darkest horizontal line represents the lowest vibrational level in each electronic state of the 
molecule which is the singlet state labelled as So.   
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Figure 1.3 Energy scheme to show the difference between fluorescence and phosphorescence.
[16]
 
 
The upper lines in Figure 1.3 represent the energy state of the three excited 
electronic states: S1 and S2 represent the electronic singlet state (left) and T1represents the 
first electronic triplet state (right).   The energy of the triplet state is always lower than the 
energy of the corresponding singlet state. 
 
Absorption (red lines in Figure 1.3) leads to electronic promotion from the ground 
singlet electronic state (So) to various vibrational levels within the singlet excited vibrational 
states.  Deactivation of the excited state by fluorescence and phosphorescence involve an 
emission of a photon radiation as shown by the straight arrow in Figure 1.3. The curled 
arrows in Figure 1.3 are deactivation processes without the use of radiation.  
 
If inter-system crossing or internal conversion occur, i.e. non-radiative transition to a 
new electronic state, this is followed by vibrational relaxation and possibly radiative 
deactivation through fluorescence or phosphorescence. Intersystem crossing is a process 
where there is a crossover between electronic states of different multiplicity as demonstrated 
in the singlet state to a triplet state (S1 to T1) on Figure 1.3. The probability of intersystem 
crossing is enhanced if molecule contains heavy nuclei, such as a ruthenium complex, 
through a process known as spin orbit coupling. The distinction between fluorescence and 
phosphorescence lies with a change in the spin quantum number between the initial state and 
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the final state. The emission is defined as fluorescence when the transition spin is allowed, 
the spin quantum numbers are the same and ΔS= 0. If there is any change in spin quantum 
number ΔS≠0 then the emission is defined as phosphorescence. Throughout this thesis the 
terms fluorescence and phosphorescence will be referred to as a general luminescence, as in 
ruthenium complex the distinction is somewhat blurred due to heavy atom effect.  
 
For supramolecular assemblies the photoactive components can be transition metal 
complexes. In the case of a mononuclear transition metal complexes, molecular orbitals 
(MO) can be tuned by modifying the individual ligands and complex orbitals leading to 
significant synthetic control over the optical and photophysical properties of the complexes. 
The individual orbitals are labelled M or L depending on whether they are mainly metal or 
ligand centred. A scheme of octahedral metal complex orbitals is shown in Figure 1.4. From 
this orbital diagram the four types of optical transition of metal complexes can be identified.  
The metal orbitals are shown on the left of Figure 1.4 where as the ligand orbitals are shown 
on the right and the molecular orbitals are centered. Absorbance bands are usually assigned 
to electronic transitions which can be regarded as metal centred (MC) transitions, ligand 
centered (LC) transitions or charge transfer (CT). The lowest energy excitation is metal 
centred (MC) transitions (d-d transitions), provide that all the d orbitals are not filled. 
Usually the metal’s d orbitals are partially filled and depend on the oxidation state of the 
metal. These arise from the localised orbitals on the metal centre and are usually very 
weak.
[17]
 Next in order of energy is the charge transfer transitions where metal to ligand 
(MLCT), also known as d-π*, and ligand to metal charge transfer (LMCT) known as π-d are 
the most investigated. Finally in order of energy is ligand to ligand charge transfer (LC) as 
seen in Figure 1.4 , for example π-π* in a bipyridine ligand[17]. In general, in a metal 
complexes’ ground energy state the σL and πL ligand orbitals are full. Other anti-bonding σ*L 
and π*L ligand orbitals are usually empty. 
 
Once light energy is absorbed the population of these orbitals change. Metal centred 
(MC) transitions (or d-d transitions) involves a rearrangement of the metal d-electrons from 
the t2g to eg sets such transitions are LaPorte forbidden in octahedral complexes becoming 
more allowed as the geometry deviates from this symmetry.  The energy of dd transitions 
varies, but depends on the ligand field splitting which is influenced by the -donor and -
acceptor ability of the coordinating ligands.  Interligand charge transfer transitions are 
basicly ligand centrered transitions (LC)  analogous to those occurring in organic molecules, 
they are of much higher energy than dd or CT transitions and generally occur when 
chromophoric ligands are coordinated to the metal centre (Figure 1.4).  
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Charge transfer transitions are typically responsible for the strong colour of many 
coordination compounds.  These are typically allowed transitions with high extinction 
coefficients,  MLCT is particularly common since it involves promotion of an electron from 
a metal based highest occupied molecular orbital (HOMO), t2g in an octahedral field, to the 
lowest unoccupied molecular orbital (LUMO) based on the ligand.
[18]
 All of these excited 
energy states may have singlet or triplet multiplicity. 
 
 
Figure 1.4 Energy level diagram of a transition metal complex showing the various types of 
electronic transitions.
[14]
 
 
1.4 Luminescent Metal Complexes in Cell Imaging 
 
Lanthanide luminescent probes 
[19, 20]
 and organometalic complexes are emerging as 
viable alternatives to organic dyes as fluorescent probes. 
[21-23]
 This is because they are not 
very prone to photobleaching and possess long-lived excited states. In addition they tend to 
display large Stokes shifts. The Stokes shift is the difference between positions of the band 
maxima of the absorption and emission spectra of the same electronic transition. Large 
Stokes shifts will reduce artifacts in imaging due to the amount of self-quenching possible at 
high dye concentrations. Luminescent metal complexes are increasingly desirable applicants 
for cellular imaging as they can also be designed for low toxicity, good cellular uptake and 
targeted intercellular localisation.
[21, 24]
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In recent decades, much attention has been focused on organometallic complexes of 
various heavy metals, including Ru,
[25-27]
 Os,
[25]
 Ir 
[24, 28]
and Pt
[29]
 for their potential use as 
phosphorescent materials across a range of applications. Applications in  biological imaging 
has come relatively late for these materials but the focus has been with the d
6
 transition 
metal complexes, such as Re
I
 
[30]
 Ru
II
 
[31]
 and Ir
III
 
[24]
 in particular polypyridal complexes. As 
part of a continuing effort toward the development of organometallic materials exhibiting 
desired properties, our group are focusing on ruthenium based probes. 
 
1.4.1 Ruthenium (II) Polypyridal Probes 
 
Ruthenium (II) has extensive coordination chemistry. Derivatives of polypyridine, in 
particular  bipyridine, are widely used due to their potential for luminescence the most well 
known being the luminiscent tris-(bipyridine) ruthenium(II) dichloride with the formula 
[Ru(bpy)3]Cl2.
[31]
 In particular, these Ru(II) polypyridine complexes are the class of 
transition metal complexes which have been most extensively studied from a photochemical 
viewpoint. The reason for such great interest in these Ru complexes comes from 
an exclusive combination of chemical stability, excited-state reactivity, luminescence 
emission, redox properties and excited-state lifetime. Ruthenium polypyridine complexes are 
indeed good visible light absorbers, feature relatively intense and long-lived luminescence 
and can undergo reversible redox processes in both the ground and excited states.
[13, 
32]
Although relatively few reports exist on their application in cell imaging, examples of 
ruthenium polypyridyl complexes applied to cell imaging are increasing.
[33-35]
 
 
Many of the photophysical and redox characteristics of [Ru(bpy)3]
2+
 have been 
detailed extensively in the literature
[13, 36-38]
 and it may be used as a example to explain 
similar processes occurring in other ruthenium (II) polypyridyl complexes discussed in this 
thesis. Figure 1.5 shows the typical absorbance and emission profile for the [Ru(bpy)3]
2+
 
complex in acetonitrile solution.[39] The UV-vis spectrum of [Ru(bpy)3]2+ is dominated 
by a spin allowed 1MLCT transition from the ruthenium (dπ (t2g) orbital) to a bipyridyl 
ligand (π*) orbital at 451 nm, a further MLCT transition at a higher energy at 241 nm as 
seen in Figure 1.5.[39] The MLCT transition leads to an excited triplet MLCT state that 
can be explained by the spin-orbit coupling of the d6 metal centres, leading to large 
stokes shifts. Spin-orbit coupling involves mixing of both the singlet and triplet excited 
energy states of the molecule. However, the lowest lying energy state responsible for 
emission remains largely triplet in nature. The efficiency of intersystem crossing 
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following light absorption is known to be close to unity for ruthenium (II) polypyridyl 
complexes.[40] The strong absorbance at 286 nm is ascribed to LC (π-π*) electronic 
transitions within the bipyridyl ligands orbitals.[13]  
 
 
Figure 1.5: Absorbance and normalised emission spectra (excited at 451 nm, slit widths: 5 nm – 
normalised to 1 arbitrary unit) of 20 x 10-6 M [Ru(bpy)3]2+ in acetonitrile solution.
[39]
 
 
The optical transitions of ruthenium polypyridyl complexes may be tuned with the 
addition of certain electron withdrawing or donating ligands, which influence the ligand 
field splitting of the complex, in other words the relative energies of the t2g and eg states. One 
may therefore tune the wavelength of the lowest excited state transition by manipulating the 
ligands. 
[38]
 There are two approaches to shift the dπ-π* bands band to longer wavelengths of 
the spectrum one may add electron withdrawing groups to the polypyridal ligands of 
ruthenium in an effort to lower their π* energy level. Another technique is to introduce an 
electron donating ligand to stabilise the positive hole at the metal centre following MLCT.
[41]
 
 
One of the most common ligands in supramolecular chemistry is the bidentate 
chelate 2,2-bipyridine (bpy Figure 1.6.1).
[14]
 This is the first member of a series of 
polypyridyl ligands used in our supramolecular chemistry assembly. Other members include 
1,10-diphenylphenanthroline (dpp Figure1.6.2) and dipyridophenazine (dppz Figure 1.6.3) 
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Figure 1.6 Polypyridal ligands used in supramolecular chemistry 
 
 Bipyridine ligands are good σ-donor ligands as the lone pair of electrons on the 
nitrogen is able to form a σ-bond with the unoccupied orbital of the metal ion centre. d-
orbitals of a metal can overlap with an unoccupied π* orbital of the acceptor ligands. The σ-
donor bonding increases the electron density on the metal ion; its ability to form a π bond 
with the ligand is enhanced resulting in back bonding. Also the diimine moiety, -N=C-C=N- 
of bpy supports a delocalisation of the electrons around the ring. This produces greater π 
acceptor strength. 
 
The long standing barrier to the utilization of ruthenium (II) complexes in the 
context of cell imaging has been that these complexes do not passively diffuse across the cell 
membrane.
[42]  
 One way to overcome this limitation is to attach the fluorophore to biological 
targeting molecules that are capable of cell penetration.  
 
 
1.5 Delivery Vectors 
 
The key problem of application of metal complexes in therapeutic and imaging 
effectiveness lies in the cellular delivery of therapeutic and imaging agents. The plasma 
membrane forms an impermeable barrier for large hydrophilic therapeutic agents and probes. 
The need to develop efficient strategies for cellular uptake is driven by the cell impermeable 
nature of these agents. Numerous strategies have been developed to facilitate the import of 
these agents and nucleic acids in to cells, among these are viral vectors
[43, 44]
, cationic 
lipids
[45]
, polymers
[46]
 and cell penetrating peptides (CPPs).
[47, 48]
 
 
Several useful delivery vectors have emerged in recent years, including liposomes, 
viral vectors, dendrimers, polymer-based nanoparticles and peptides. In our supramolecular 
assembly approach A-L-B the delivery vector is the B unit linked to the photoactive agent. 
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Drugs and imaging agents with intercellular targets or receptors are required to cross the cell 
membrane. The ideal cellular transporter would be low cost, non-toxic, and could transport 
any cargo across the cellular membrane. 
[49]
 
1.5.1 Liposome 
 
Lipid amphiphilic compounds are a broad class of organic molecules than contain a 
hydrophilic head group and a hydrophobic chain region.  A liposome is a vesicle composed 
of a lipid bilayer. The liposome can be used as a medium for administration 
of nutrients and pharmaceutical drugs. Liposomes are fabricated from reasonably bio-
compatibable and biodegradable material. 
[50]
 They consist of aqueous volume captured by 
one or more bilayers of natural and/or synthetic lipids. Drugs or imaging agents with a wide 
array of lipophilicities can be encapsulated in liposomes, either in the bilayer itself or in the 
aqueous volume (Figure 1.7). Also as seen in Figure 1.7, ligands are on the outside of the 
liposome to target receptors within the cell. 
 
Figure 1.7 Scheme of Liposome formed by phospholipids in an aqueous solution.
[51]
 
 
 
Liposomes can be used to increase cytosolic delivery of certain drugs. The potential 
of liposomes to enable internalization and pharmacological activity of cell-impermeable 
drugs has been documented long ago for drugs such as methotrexate-gamma-aspartate
[52]
 and 
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N-(phosphonacetyl)-L-aspartic acid (PALA) 
[53], that were referred to as “liposome-
dependent drugs.”[54] 
 
A recent study from the Gabizon laboratory in Israel with zoledronic acid, another 
cell-impermeable drug and a potent inhibitor of farnesyl-pyrophosphate synthase, has 
indicated that folate liposomal targeting of zoledronic acid results in a major increase of 
drug uptake and in a »100-fold increase of in vitro cytotoxicity when compared to the free 
drug.
[55]
 They also constructed studies using pegylated liposome doxorubicin (PLD) and 
results clearly showed that PLD was superior to free doxorubicin in all tumour models 
studied.
[54]
 
 
Liposomes have been investigated as carriers of various materials however there are 
limitations associated with them. Some of the problems limiting the manufacture and 
development of liposomes have been stability issues, batch-to-batch reproducibility, 
sterilization methods, low drug entrapment, particle size control, amongst others.
[50]
 
 
1.5.2 Dendrimers 
 
Dendrimers are repetitively branched molecules organised around an inner core.  A 
dendrimer adopts a spherical three-dimensional structure. Applications of dendrimers 
typically involve conjugating other chemical species to their surface that can function as 
detecting agents, such as affinity ligands, targeting components, radioligands, imaging 
agents, or pharmaceutically active compounds. One dendrimer molecule has hundreds of 
probable sites to couple to an active species. The range of chemical structures making up the 
class of dendrimer makes it extremely difficult to generalise on their application in delivery.  
 
A significant example of architecturally-optimized dendritic drug delivery was 
reported by Fréchet and Szoka where an asymmetric doxorubicin-functionalized bow-tie 
dendrimer was prepared by PEGylation of one side of a 2,2-bis(hydroxymethyl)propionic 
acid dendrimer and conjugation of the drug via an acyl hydrazone linkage to the other side 
resulting in 8–10 wt.% doxorubicin content overall (Figure 1.8). These gave a 9 fold 
increase in tumour uptake in comparison to doxorubicin alone. 
[56]
 In comparison to other 
delivery techniques dendrimers are in their infancy. 
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Figure 1.8 Doxorubicin functionalised bow tie dendrimer.
[57]
 
  
1.5.3 Viral Vectors  
 
Viral vectors are a means generally used by molecular biologists to deliver genetic 
material into cells. Viruses have developed specific molecular mechanisms to efficiently 
transport their genomes inside the cells they infect. Delivery of genes by a virus is 
termed transduction.  This machinery was first utilised in the 1970s by  Paul Berg used with a 
tailored SV40 virus containing DNA from the bacteriophage lambda to infect 
monkey kidney cells maintained in culture.
[58]
  
 
Synthetic or modified viruses can carry the therapeutic gene inside their capsid until 
it reaches the intended target. Viral vectors are occasionally created from pathogenic viruses. 
While they are modified in such a way as to minimize the risk of handling them, this is still 
seen as a limitation. Some viruses are also genetically unstable and can quickly rearrange 
their genomes. This unfavourable predictability and reproducibility of the work performed 
using a viral vector is a key limitation in their application.
[59]
 
 
16 
 
1.5.4 Solid Lipid Nanoparticles 
 
Solid Lipid Nanoparticles (SLN) are another type of colloidal carrier system. They 
possess a solid lipid core matrix that can solubilise lipophilic molecules as seen in Figure 
1.9. The ability to incorporate drugs into nanocarriers offers a new prototype in drug 
delivery that could hold great promise for attaining the bioavailability enhancement along 
with controlled and site specific drug delivery. It has been proposed that SLNs combine 
numerous advantages over the other colloidal carriers i.e. incorporation of lipophilic and 
hydrophilic drugs feasible, no biotoxicity of the carrier, avoidance of organic solvents, 
possibility of controlled drug release and targeting, increased drug stability and no problems 
with respect to large scale production. 
[60]
 SLN can also be exploited for different 
administration routes. Like dendrimers, SLN are relatively young drug systems with trends 
increasing.
[61]
 Tumour targeting has been achieved with SLNs loaded with drugs like 
camptothecin.
[62]
 
 
 
Figure 1.9 Generic structure of solid lipid nanoparticle (SLN)
[63]
 
 
1.5.5 Cell Penetrating Peptides 
 
Cell-Penetrating Peptides (CPPs), are short peptides (≤40 amino acids), with the 
capability to enter the interior of almost any cell. The method of penetration remains 
controversial, but there is abundant evidence that they may involve several mechanisms, 
including direct translocation across the plasma membrane and endocytosis. They have the 
outstanding property of carrying into the cells a wide variety of covalently and non-
covalently conjugated cargoes. Therefore they are extremely attractive candidates to 
transport therapeutic agents, imaging agents amongst others to the interior of cells. Evidently 
CPPs have potential as universal delivery agents. Furthermore, their capability to preserve 
the biological activity of their therapeutic cargoes makes the CPP delivery approach truly 
desirable. One of the earliest interest was the Tat peptide, derived from the HIV Tat trans-
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activation protein.
[64]
 It was first revealed that the full-length protein crossed the plasma 
membrane and investigations led to the identification of small fragments that could 
efficiently enter cells.
[65, 66]
 These findings, along with those identifying other peptides with 
membrane crossing activities
[67]
, assisted in the development of cell-penetrating peptides 
(CPPs) as a class of molecular transporters. For this thesis and our supramolecular assembly, 
CPPs were chosen as our delivery system. 
 
CPP are often positively charged sequences of amino acids.
[68]
 Compared with other 
systems, CPPs have numerous advantages due to the capability of simple modification, 
allowing them to target different sub-cellular domains and/ or transport various types of 
cargoes. The main feature of CPPs is their capability to penetrate the cell at low 
concentrations and without causing any significant membrane damage.
[48]
 Also they are 
capable of internally localising biologically active agents and probes with high efficiency 
and low toxicity into a cell.
[69]
 
 
Until recently, extracellular or externally located membrane receptors have been the 
target of peptide-based imaging probes. This limitation occurred mainly due to charge and 
size concerns associated with conventional probes which therefore do not allow for the 
passive uptake into cells. Charged compounds are inhibited from passing into the cells by 
the dielectric constant of the lipid bilayer of the plasma membrane.
[70, 71] 
A few cationic 
peptides have been shown to have a distinctive capability to cross the cytoplasmic 
membrane of cells and subsequently have been used as delivery agents for a variety of 
biopolymers and small molecules. 
[47, 72, 73]
 Peptide-based imaging agents offer high 
molecular target specificity and a great degree of flexibility in their design and ease of 
synthesis.
 
 
 
1.5.5.1 Mechanism of uptake 
 
Many different short peptide sequences have been identified that are able to 
transport diverse types of cargo molecules. Acquiring information about common trends 
governing CPP uptake, such as the effects of peptide length, chemical properties and size, 
has significant implications for designing CPPs. With facts regarding how certain properties 
favour one mechanism of uptake over another, designing new peptides with a required 
uptake mechanism is important to their application.
[49]
 Several investigations have been 
performed to clarify how CPPs gain access to the interior of cells. A variety of uptake 
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mechanisms appear to be operative in different systems and, in some cases, the mechanism 
is cell-type or cargo-speciﬁc. It appears that CPPs can be classified according to three main 
entry mechanisms: translocation through the formation of a transitory structure, direct 
penetration in the membrane and endocytosis-mediated entry as seen in Figure 1.10. 
 
 
 
Figure 1.10 Proposed mechanisms of cellular delivery of cargoes mediated by cell penetrating 
peptides (CPPs). Model 1 represents a mechanism that is assumed to occur through the 
formation of an inverted micelle. Model 2 suggests direct penetration of the plasma membrane. 
Both mechanisms were considered to occur via rapid, energy- and receptor-independent 
pathways. However, more recent observations imply that the uptake of a majority of CPPs and 
cargo-conjugated CPPs results from endocytosis by which small quantities of the conjugates are 
released via an unknown mechanism (Model 3).
[74]
 
 
 
In the early stages of investigation into the mechanism of entry of CPP’s, direct 
permeabilization was evident, (Figure 1.10, Model 2). This was found to be an energy-
independent mechanism. Numerous experiments were conducted in conditions of reduced 
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ATP concentration and low temperatures, which failed to inhibit internalization of Tat
[75]
 and 
pAntp
[76]
, and therefore supported a non-endocytic uptake mechanism. 
 
In 1996, researchers proposed the inverted micelle model (Figure 1.10, Model 1) to 
explain the penetration of the bilayer in terms of receptor-, energy-, and endocytosis-
independence.
[74]
 Inverted micelles are aggregates of colloidal surfactants  within the cell 
membrane with a hydrophilic cavity present within the two bilayers and a hydrophobic 
environment of the phospholipid tails. The structure of the inverted micelles permits the 
peptide to remain in a hydrophilic environment during translocation. This micellar phase in 
the membrane is temporary, and the CPP is subsequently released, directly into the cytosol 
and independent of any vesicular body, as the micelle passes to the cytosolic side of the 
bilayer.
[48]
 
 
Endocytosis is the process of cellular ingestion by which the plasma membrane 
folds inward to bring substances into the cell (Figure 1.10, Model 3). During this process 
cells absorb by engulfing the material from the outside of the cell within their cell 
membrane. Evidence for this process accumulated from 2002 and although it is considered 
that each CPP expresses its own preferred mechanism of uptake
[74]
, this evidence has yet to 
be disproved. 
[48]
 
 
1.6 Cell Penetrating peptides delivery of imaging agents 
 
The capacity to picture internal features and physiological structures of living 
organisms and monitor cellular functions in vivo is vital for understanding, diagnosing and 
treating disease. Non-invasive biomedical imaging methods such as ﬂourescence imaging 
and magnetic resonance imaging (MRI) have been developed for in vivo applications such as 
directly visualising diseased tissue during surgical procedures or following the dynamics of 
the immune cells in living animals.
[49]
 The plasma membrane forms an impermeable barrier 
for large hydrophilic imaging agents and probes and CPPs have proven useful in this ﬁeld as 
delivery vehicles (Figure 1.11).  
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Figure 1.11 CPP (shown as green helices) mediated delivery of imaging agents.
[49]
 
 
 
1.7 Probe Peptide Conjugates of Metal Complexes 
 
The long standing barrier to the utilization of ruthenium (II) complexes in the 
context of cell imaging has been that these complexes do not passively diffuse across the cell 
membrane.
[42]
 Therefore, in the few examples where they have been applied to imaging the 
cells, they must be permeabilised by electroporation, detergent or treated with some other 
transfection agent.
[10, 77] 
This typically damages the cells or causes its biochemistry to 
change.  
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Because targeted delivery of peptide agents to intracellular compartments can enable 
a wide range of novel applications in medicinal imaging, a peptide conjugate with good 
imaging properties, while capable of permeating the plasma membrane is highly desirable. 
Recent work by our group has reported that polyarginine labelled ruthenium complexes 
efficiently and rapidly transport across the cell membrane into the cytoplasm.
[35, 78]
 Such 
chromophores provide unique opportunities for imaging dynamic processes in living cells 
avoiding limitations associated with fixation.   
 
Neugebauer et al were the first to report the synthesis of two novel ruthenium 
polypeptide conjugates for the purpose of cellular imaging, as illustrated in Figure 1.12. 
 
 
Figure 1.12 Structure of the first ruthenium (II) conjugate suitable for cellular imaging. (n=5 or 
8).
[78]
 
 
The highlight of these results was the capacity of the octarginine dye-conjugate 
[Ru(bpy)2(picCOOH)Arg8]
10+
  to passively transport across the cell membrane of SP2 
myeloma cells without the need to use organic solvents. In contrast, the parent dye (without 
peptide) and shorter pentarginine conjugate showed no evidence of distribution across the 
cell membrane. This suggested that the length of the cell penetrating peptide was important 
in its transmembrane capabilities. Diffusion of the parent ruthenium complex across the 
membrane could be achieved using the detergent Triton, DMSO or ethanol to permeabilise 
the cell. The migration of the octarginine dye-peptide in absence of permeabilization was 
established completely after 10-15 minutes at room temperature, in a temperature-dependent 
and by an irreversible process. SP2 myeloma cells in a buffered solution were exposed to 3.5 
x 10
-5
 M of [Ru(bpy)2(picCOOH)Arg8]
10+
 which led to bright luminescence within the cells 
cytoplasm after only 2 minutes as shown in Figure 1.13. Over the next 10 minutes the dye-
peptide continued to distribute throughout the cell in various concentrations across the 
cellular plasma in a non-selective manner. 
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Figure 1.13 Luminescent images of SP2 myeloma cells incubated with 
[Ru(bpy)2(picCOOH)Arg8]
10+ 
after (a) 3 min and (b) 5 min. (c) Myeloma cell incubated with the 
parent complex[Ru(bpy)2(picCOOH)]
2+
 (3.5 × 10
−5
 M in PBS) for 26 min and (d) for 5 min after 
permeabilizing the cell with Triton (1% v/v).
[79]
 
 
 
 
 
In an attempt to assess the distribution of the dye-peptide across SP2 myeloma cell 
organelles, Neugebauer et al.
[78]
 counterstained the cells with a cell permeable localising dye. 
3,3’-Dihexyloxacarbocyanine iodide [DiOC6(3)] was used to selectively stain the 
mitochondria and at higher concentrations the membrane structures within the cell including 
lysosomes and endoplasmic reticulum. Analysis of both [Ru(bpy)2(picCOOH)Arg8]
10+
 and 
[DiOC6(3)] in SP2 cells using confocal fluorescence microscopy showed that their 
luminescence did not coincide and therefore it may be concluded that the ruthenium dye-
peptide does not distribute strongly within the mitochondria or endoplasmic reticulum of 
SP2 cells. 
 
In a more recent paper by the group
[35]
 a [Ru(dppz)2(picCOOH)Arg8]
10+
 complex 
(Figure 1.14) is utilized with the intention of multimodal cellular imaging. As this dye 
demonstrates a ‘molecular switching effect’ only the dye molecules shielded by and 
associated with membrane structures emit phosphorescence and therefore, cannot be used to 
assess the true distribution of the dye in the cell. Nevertheless, resonance Raman mapping 
does not rely on the emission of the dye and is employed here for the first time as a 
complementary technique to assess the localisation of the parent dye and dye-conjugate. 
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Figure 1.14 Chemical structure of [Ru(dppz)2(picCOOH)Arg8]
10+
.
[35]
 
 
Figure 1.15 illustrates the plot intensity of these ruthenium (II) vibrational modes 
and therefore the dye concentration within the cell. It is observed that the parent dye remains 
in the outer cell membrane (Figure 1.15, image B1), while, the dye peptide diffuses across 
the cell membrane (Figure 1.15, image A1) and is distributed throughout the entire cell. 
 
 
 
Figure 1.15 Resonance Raman intensity map of live myeloma cells after incubation with 
[Ru(dppz)2(picCOOH)Arg8]
10+
 (A1) and free parent dye (B1) after excitation at 458 nm. A and B 
represents the brightfield images of the cells in PBS.
[35]
 
 
Another group, the Barton group have demonstrated the potential of using a cell 
penetrating peptide to facilitate entry of a ruthenium dye peptide into HeLa cells. They used 
ruthenium complexes as probes to study the chemical and physical properties of DNA and 
the biological implications of those properties. Their results showed that the parent complex 
[Ru(phen)(bpy)(dppz))]
2+
 showed no transport across a cellular membrane prior to 
conjugation to the octaarginine peptide. Interestingly, the uptake of a labelled peptide 
conjugate ruthenium-Arg8-fluorescein is far greater at lower concentrations when compared 
to the ruthenium-Arg8 conjugate alone.
[80]
 It is thought that the greater lipophilicity of the 
conjugate containing the fluorescein moiety increases the interaction of the labelled 
conjugate with the cellular membrane. 
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The Barton group then went on to use short peptides to target the nucleus, in 
particular DNA.  They studied [Ru(phen)(bpy)(dppz)]
2+
 conjugated to a peptide, RrRK, of 
reduced length and net positive charge.
[81]
 This peptide efficiently targeted the organic 
fluorophore thiazole orange to the nucleus.
[82]
 They found that RrRK conjugation increases 
cellular uptake as compared to analogous unconjugated complexes, and that, above a 
threshold concentration of 30 µM, this peptide targets the ruthenium complex to the nucleus 
as shown in Figure 1.16. 
 
 
Figure 1.16 Subcellular distribution of Ru–RrRK in serum-free medium. HeLa were incubated 
with (A) 20 or (B) 40 µM Ru–RrRK in for 2 h. At 20 µM in medium without serum, most cells 
show only punctuate cytoplasmic staining, while at 40 µM, the majority of cells exhibit 
additional nuclear labelling. Scale bars are 10 µm.
[81]
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1.8 Targeting (homing) Peptides 
 
To achieve an effective local concentration at a disease site by systematic drug 
administration one must use a high concentration of the drug. This can be problematic 
because it may result in nonspecific toxic side-effects. In the 19
th
 century, German scientist 
Paul Ehrlich brought about the concept of targeting drugs to specific sites of the disease, ‘the 
magic bullet’ concept and this remains the goal of pharmaceutical scientists worldwide. [83]  
 
In addition to assisting transport across the plasma membrane, applications of CPPs 
aimed at specific organelles can be envisioned. The capacity to target speciﬁc organelles 
generates opportunities to study biological processes at the subcellular level and to deliver 
therapeutics to targets within cellular compartments. Currently, the nucleus and the 
mitochondria have been successfully targeted with CPPs. The nucleus, the location of DNA, 
is an attractive target and the essential destination for agents used in gene therapy.
[84]
 The 
mitochondrion is a particularly appealing organelle for drug therapy given its role in the 
pathology of cancer, neurodegenerative diseases, and others where reactive oxygen species 
are linked with disease progression.
[85, 86]
 Kelley and co-workers have completed 
comparative studies on nuclear and mitochondria targeting peptide conjugates. Two peptide 
conjugates with specific cellular localization profiles were developed to separately address 
oxidative stress occurring in the nuclei and mitochondria of living HeLa cells (Figure 
1.17).
[82]
 Colocalisation studies confirmed the localisation profiles obtained. Their results 
indicated that different molecular charges of TO-FrFK and TO-RrRK were responsible for 
the distinct localisation profiles, where TO is thiazoleorange (TO), a chromophore that 
produces singlet oxygen (
1
O2) upon exposure to visible light. It is also noteworthy that both 
their compounds cross the plasma membrane with efficiencies that approach what has been 
previously observed for CPPs. 
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Figure 1.17 (A) Structure and fluorescence confocal microscopy images for TO-RrRK 
demonstrating localization of this compound within the nuclei of living, unfixed HeLa cells. 
Fluorescence image (left) is shown alongside corresponding DIC image (right). (B) Structure 
and fluorescence confocal microscopy images for TO-FrFK demonstrating localization of this 
compound within the mitochondria of living, unfixed HeLa cells. Fluorescence image (left) is 
shown alongside corresponding DIC image (right). The scale bars represent 10 µm.
[82]
 
 
 
Thus far the work done by our group has been with the cell penetrating peptide Arg8. 
This peptide sequence is capable of penetrating the cell membrane but do not localise 
preferentially in specific sub-cellular compartments. Although some cell penetrating 
peptides have entered clinical trials
[87]
, some weaknesses are still encountered, in particular 
due to the lack of specificity of unmodified CPPs toward targets. 
[47, 73, 88]
 Further localisation 
of these imaging agents within the cell will be useful in the study of mechanism(s) leading to 
membrane translocation and can also be useful in targeted therapy. This requires 
understanding of the interactions of these carrier peptides with the membrane components 
and the structural consequences of these interactions. These studies can then provide an 
insight into the ability of peptides to act as drug carriers. Several peptide sequences capable 
of permeating the plasma membrane of cells with various cargos have been reported.
[47]
 
These include a group of peptides called nuclear localisation signals (NLS) that can be 
targeted within the cell to the nucleus.  
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NLS peptides, particularly the NLS from simian virus 40 (SV40) large T antigen, 
have been used in several studies to drive uptake of DNA for non-viral gene therapy.
[84]
 Most 
studies have focused on the capability of the NLS sequences to drive localization of some 
exogenous DNA into the nucleus. Some studies use transfection agents or microinjection to 
assist with uptake efficiency and others exploits the cell-penetrating properties of the NLS 
peptides driving translocation in unaided uptake.
[49]
Nuclear localisation signals are mainly 
short cationic peptides that interact with receptors at the nucleus. These peptides can be 
exploited to introduce linked cargo into the cell and ultimately its nucleus.
[73] 
 
 
In the case of this thesis the NLS were used to target the novel chromophores to the 
nucleus. The first NLS chosen for our supramolecular assembly was the first NLS to be 
discovered from the SV40 large T antigen.
[89]
 It is imported into the nucleus by its 
interaction with importin α. [90]The NLS sequence of SV40 is PKKKRKV. 
 
The second sequence chosen for supramolecular assembly with the chromophores 
was a sequence derived from NF-κB. This peptide is derived from a transcription factor. 
Transcription is an important regulatory event in the pathway leading to gene expression. 
NF-κB has been the subject of intense study as it is implicated as a key mediator of a wide 
variety of cellular inflammatory responses.
[91]
 Although NF-κB activation has also been 
linked to the development of cancer, a cationic sequence limited to the protein transduction 
domain and mediating nuclear membrane translocation was employed. 
[92]
 These sequences 
have the added advantage of directing the attached molecule to the nucleus, which is the site 
of action for numerous chemotherapy agents.  NF-κB has been investigated for entry into 
various cancer cell lines. Its labelled version demonstrated rapid accumulation within cells 
and therefore shown the ability of this sequence to import linked cargo. 
[73]
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Ragin and co workers investigated a series of NLS sequence peptides (Figure 1.18, 
Table 1) for entry into different cancer cell lines by flow cytometry and confocal 
microscopy, which included SV-40 and NF-κB conjugated to fluorescein.[73] All NLS 
peptides demonstrated rapid accumulation within cells when added to the media of MCF-7 
(breast carcinoma) cells, as shown by flow cytometry in Figure 1.18A.  To determine if 
cellular uptake of the NLS peptides could be extended beyond the MCF-7 cell line, four 
other cancerous cell types (KB, nasopharengeal; HT29, colon; MIAPACA2, pancreatic; 
PC3, prostate) were evaluated. Cellular fluorescence was observed with all cell lines, 
demonstrating their broad capacity for cellular uptake (Figure 1.18 B). 
 
 
 
Figure 1.18 Table 1 Fluorescent nuclear localisation signal sequences used for cellular uptake 
experiments. (A) Uptake of fluorescently labelled NLS sequences (50 µM) with theMCF-7 
(breast carcinoma) cell line after 4 hr as measured by flow cytometry. (B) Uptake of the 
fluorescently labelled NLS sequences Fl-NF-κB, Fl-TFIIE-β, and Fl-Oct-6 (50 µM) with four 
other cancerous cell types—KB (nasopharengeal), HT29 (colon), MIAPACA2 (pancreatic), and 
PC3 (prostate)—after 4 hr as measured by flow cytometry.[73] 
 
The cellular location of a subset of the NLS peptides Fl-NF-κB, Fl-Oct-6, and Fl-
TFIIE-β, was evaluated by confocal microscopy, where Fl is fluorescein and the peptide 
sequences of NF-κB, Oct-6, and TFIIE-β are given in Figure 1.18. Fl-NF-κB was distributed 
in both the cytosol and the nucleus, showing greatest accumulation observed within nucleoli, 
whereas the other two sequences were located almost exclusively in the cytoplasm. Fl-Oct-6, 
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and Fl-TFIIE-β are highly cationic and they may tightly associate with negatively charged 
membrane lipids, preventing their release into the cytoplasm and subsequent routing to the 
nucleus. However, the NF-κB NLS sequence is able to escape from, or is never within, a 
similar endosomal compartment, possibly pointing to a unique mode of cellular uptake for 
NF-κB. 
 
Ragain et al also exploited the membrane-translocating property of the NLS of NF-
κB to deliver covalently linked cargoes across the plasma membrane of MCF-7 cells. A 
fluorescein labelled, 10-mer oligonucleotide (5’-GCCTCTAGCT-3) derived from the Kras 
oncogene was covalently linked to the NLS of NF-κB via a disulfide linkage. Without the 
attached NLS sequence, the oligonucleotide demonstrated no tendency to enter MCF-7 cells 
(Figure 1.19 B2), whereas cellular uptake of the Fl-DNA-NF-κB conjugate was observed 
and found to increase with increasing concentration of the conjugate as shown by flow 
cytometry analysis (Figure 1.19). Confocal microscopy images established the presence of 
the oligonucleotide within the cells, and revealed that the conjugate had accumulated in the 
cytoplasm (Figure 1.19 B4). The NF-κB sequence was also assessed for transduction of the 
protein lysozyme. Flow cytometry analysis revealed a 25-fold increase in cellular uptake of 
lysozyme when conjugated to the NF-κB NLS sequence. 
 
 
Figure 1.19 Cellular Uptake of the Fl-DNA-NF-κB Conjugate with MCF-7 Cells  
(A) Cellular uptake as a function of concentration of the Fl-DNA-NF-κB conjugate with MCF-7 
cells. (B) Cellular localization was determined by confocal microscopy: (1) transmitted light 
image and (2) fluorescence image for cells treated with Fl-DNA (50 µM) for 4 hr; (3) 
transmitted light image and (4) fluorescence image for cells treated with Fl-DNA-NF-κB (50 
µM) for 4 hr.
[73]
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Another important membrane enclosed organelle of a eukaryotic cell is the 
mitochondria. Certain disease are caused by mutations in mitochondrial DNA
[93]
 and it also 
has been reported that the mitochondria are key regulators of programmed cell death by 
apoptosis.
[94]
 There are multiple diseases including cancer, diabetes, some cardiovascular 
and neurodegernative diseases that have a considerable mitochondrial element. The design 
and development of drugs specifically targeting mitochondria is consequently on the 
increase.
[95]
 
 
Antimicrobial peptides (AMPs) are short cationic peptides that are strongly 
membrane active. Some of these AMP can penetrate a cell without permanent damage of the 
membrane. 
[96]
 This feature has made them attractive as transport vectors in the context of 
drug delivery and imaging agents. One such peptide is a well studied Magainin 2 (MG2), 
isolated from the skin of the African clawed frog Xenopus laevis.
[97]
 MG2 has been shown to 
accumulate fluorescent cargo probes in the mitochondria and nuclei.
[98]
 We used this peptide 
for our supramolecular assembly to target mitochondria organelle. The distinct membrane-
permeabilizing processes of magainin 2 in bacterial and mammalian cells were visualized 
and characterized in detail for the first time by Matsuzaki et al in 2008. 
[98]
 They wisely used 
unfixed cells as it has be noted that this process significantly alters the intracellular 
distribution of cationic peptides.
[99] 
Similarly the results presented in this thesis are on live 
cells. 
 
Matsuzaki et al successfully permeabilised bacteria membranes with Magainin 2 
attached to a fluorescent marker, TAMRA, a rhodamine based fluorophore Figure 1.20 (B). 
They also had Calcein, another fluorescent complex, present, however without the peptide 
present this did not penetrate the bacteria. When the peptide formed a pore in the bacteria 
membrane the Calcein entered also.  
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Figure 1.20 Permeabilization of membranes by Magainin 2 in B. megaterium. Cells in calcein 
solution before (A) and 68–70 s after (B) addition of Magainin 2-TAMRA at a final 
concentration of 10 μM (9.8/0.2 μM). [98] 
 
The permeabilization of plasma membranes of CHO-K1 cells by Magainin 2 was 
also examined, based on fluorescent molecules. Again before the addition of peptide, calcein 
was excluded from the cells (Figure 1.21(A)). The Magainin 2-TAMRA peptide also 
induced the influx of calcein through mammalian membranes. They also noted that the 
Magainin 2 peptide induced membrane budding during the process of membrane 
permeabilization, as shown by arrows in Figure 1.21. 
 
 
 
Figure 1.21 Permeabilization of membranes by Magainin-2 in CHO-K1 cells. Cells 
(105 cells/mL, 63×) in calcein solution before (A) and 68–70 s after (B) addition of Magainin-2-
TAMRA at a final concentration of 10 μM (9.8/0.2 μM). (B) Arrow indicates membrane 
budding. 
[98]
 
 
Matsuzaki et al then investigated the localisation of the Magainin-2 peptide within 
mammalian cells. To determine the intracellular localization of the peptide, cells labelled 
with the mitochondria marker Mitotracker Green FM were treated with the TAMRA-
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labelled peptide. The peptide was colocalized with the mitochondria marker (Figure 1.22). 
The TAMRA fluorescence was also observed in nuclei. Thus, the internalized peptide 
mainly accumulated in mitochondria and nuclei. 
 
 
 
Figure 1.22 Permeabilization of membranes by Magainin-2 in CHO-K1 cells. Cells with 
MitoTracker Green FM staining 70 s after addition of Magainin-2-TAMRA at a final 
concentration of 10 μM (9.8/0.2 μM). From left to right: MitoTracker, TAMRA, DIC, and 
merged images.
[98]
 
 
1.8.1 Targeting DNA 
 
In the last few decades, coordination complexes based on d
6 
metal centres and 
polypyridyl ligand architectures been developed as structure- and site-speciﬁc reversible 
DNA binding agents.
[100]
 The focus of this research is on ruthenium(II) centres due to their 
appealing photophysical properties. The attention has turned to the use of these complexes in 
biological contexts and numerous applications ranging from imaging to therapeutics are 
coming to light with the increase in understanding of the cellular uptake and cellular 
localisation of such systems. Ruthenium(II) polypyridyl complexes and DNA have been 
investigated heavily from structural probes to cellular imaging and therapeutics.
[100]
 
 
DNA, or deoxyribonucleic acid, is the hereditary material in all known living 
organisms. Most DNA is located in the cell nucleus (nuclear DNA), but a small amount of 
DNA can also be found in the mitochondria (mitochondrial DNA or mtDNA).The 
information in DNA is stored as a code made up of four chemical bases: adenine (A), 
guanine (G), cytosine (C), and thymine (T). DNA bases pair up with each other, A with T 
and C with G, to form units called base pairs. Each base is also attached by a glycosidic 
bond to a sugar molecule. The sugar molecule is attached to a phosphate molecule by a 
phosphodiester bond. Together, a base, sugar, and phosphate are called a nucleotide. 
Nucleotides are arranged in two long polymers that form a double helix.  
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Nuclear DNA (nDNA) exists as chromatin during non-replicative stages of the cell 
cycle and is compacted into combined structures known as chromosomes during cell 
division. DNA is highly compacted and wound up around bead-like proteins called histones 
during both states. DNA can be damaged by either normal metabolic processes inside the 
cell or environmental factors. DNA can repair itself through a set of processes by which the 
cell indentifies and corrects damage to DNA molecules.  
 
DNA damage can be subdivided into two main types, endogenous damage and 
exogenous damage. Endogenous damage can occur from normal metabolic pathways by-
products such as reactive oxygen species. Exogenous damage occurs from an external source 
such as radiation, ultraviolet, X- and gamma-rays, toxins and viruses.  
 
DNA damage plays a major role in mutagenesis, carcinogenesis and ageing. A 
detailed understanding of the types and frequency of endogenous DNA damage can be 
considered crucial for an understanding of the interaction of exogenous agents and 
influences with endogenous processes in the stimulation of cancer and other diseases.
[101]
 
Endogenous DNA damage occurs at a high occurrence compared with exogenous damage. 
The types of damage produced by normal cellular processes are related to those caused by 
some environmental agents.
[102]
 The frequency of cancer and other diseases might be 
significantly reduced if an approach could be developed leading to a decrease in endogenous 
DNA damage and endogenous mutations. Endogenous DNA damage occurs via numerous 
reactive oxygen species and products generated as a consequence of endogenous reactive 
chemicals and chemical DNA instability. 
 
 
1.8.1.1 Reactive Oxygen Species 
 
Reactive oxygen species (ROS) are chemically reactive molecules containing 
oxygen.  ROS are highly reactive due to the presence of unpaired valence shell electrons. 
ROS are generated in our body by various systems involving both endogenous and 
environmental factors as seen in Figure 1.23.  
 
During times of environmental stress (e.g., UV or heat exposure), ROS levels can 
increase dramatically. This may result in significant damage to cell structures, adversely 
alter lipids, proteins and DNA and have been implicated in aging and a number of human 
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diseases.
[103]
 Damage caused to DNA, can result in mutagenesis and carcinogenesis. 
Cumulatively, this is known as oxidative stress.  
 
 
Figure 1.23 Major sources of free radicals in the body and the consequences of free radical 
damage.
[103]
 
 
 
Oxidative stress is caused by an imbalance between the production of reactive 
oxygen species (ROS) and a biological system's capability to readily detoxify the reactive 
intermediates or to repair the consequential damage. Oxidative stress, arising as a result of 
an imbalance between free radical production and antioxidant defences, is associated with 
damage to a wide range of molecular species including lipids, proteins, and cellular 
macromolecules such as nucleic acids and  proteins.
[104]
 
 
The initial players in the defence against the destructive effects of ROS are a variety 
of antioxidants. Upon oxidative stress the ratio of oxidants to antioxidants rises. One of the 
most dramatic consequences of oxidative stress is the development of DNA lesions, which 
might result in genomic instability and can lead to various diseases.
[105-107]
 The cellular 
response to oxidative damage involves numerous processes, such as DNA repair, cell cycle 
arrest and apoptosis, while irreversible mutations contribute to oncogenesis. 
[108]
 
 
Cellular DNA is constantly in danger of oxidation from a host of sources.
[101, 102, 107]
 
Reactive oxygen species (ROS) constantly attack DNA. One of the best-characterized 
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oxidative DNA lesions is 7,8-dihydro-8-oxoguanine (8-oxo-G). Many human diseases, such 
as cancer and neurodegenerative disorders, have been correlated with oxidative DNA 
damage. 
[105]
 
 
It is essential to use a wide diversity of chemical and biological tools to advance our 
understanding of the chemical mechanisms underlying oxidative damage as well as the 
biological factors affecting the frequency, detection and repair of such damage. Optical 
probes for cellular imaging are important in understanding the structure and function of 
biological systems. Transition metal complexes have enormous potential as diagnostic and 
therapeutic agents. Ruthenium complexes are known to show environmental sensitivity. 
Their photophysical properties can exhibit a light switch effect, making them highly 
luminescent in hydrophobic surroundings such as inside stacks of DNA bases or lipid 
membrane bilayers, whereas in aqueous solutions the emission is strongly quenched.
[109, 110]
  
 
Their characteristic photophysical properties as outlined previously, including long 
lived excited metal to ligand charge transfer state and red emission wavelengths, make them 
ideal candidates for cellular imaging using confocal microscopy. Recently, the DNA binding 
properties of mono- and binuclear ruthenium complexes have been heavily investigated. 
[109-
112]
 In this thesis we target our ruthenium complexes to specific organelles with the aim to 
increase the understanding of the cellular uptake and cellular localisation of such systems.  
 
1.9 Apoptosis 
 
Cells die in reaction to a range of stimuli and they do so in a controlled, regulated 
fashion. These stimuli may originate either extracellularly or intracellularly. Necrosis, 
caused by external stimuli, occurs following a cell’s encounter with harmful events such as 
hypoxia, toxins, and bacterial or viral infection. Resulting damage ultimately causes the cell 
to swell and lyse, or rupture. Some extracellular signals, such as toxins,
[113]
 must cross the 
plasma membrane to effect a response.  
 
Intracellular apoptotic signalling can also occur in response to a stress from within 
the cell. Apoptosis is a normal cellular process and is essential for the proper development 
and maintenance of the organism; it is also often called programmed cell death. 
[114]
 
The apoptotic pathway is triggered that leads to the destruction of the cell by a characteristic 
set of reactions that require energy. The cascade of events that causes apoptosis is controlled 
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genetically by the cell, does not cause swelling, and completely removes the cell from the 
tissue or the body. Unique transformations occur in the cell once it has received precise 
signals instructing it to undergo apoptosis. The end result of apoptosis is cell death without 
inflammation of the surrounding tissue. Flawed apoptotic processes have been implicated in 
a widespread array of diseases. Excessive apoptosis causes atrophy, whereas an inadequate 
amount results in uncontrolled cell proliferation, such as cancer. 
 
Apoptosis is necessary for the elimination of cells deemed a threat, for example cells 
infected with viruses such as AIDS, cells with DNA damage and cancerous cells. Abnormal 
regulation of apoptosis has been implicated in a number of human diseases including cancer, 
autoimmune diseases, viral infections, neurodegenerative diseases, AIDS and cardiovascular 
diseases.
[115]
 Apoptotic failure has been associated with cancer’s resistance towards chemo- 
or radio-therapy.
[116]
 There has been recent discovery of molecular pathways that govern 
apoptosis and clinical studies now focus on connections among apoptosis, disease, and new 
therapeutic modalities. These have driven the design of peptides that in some cases can 
function as simplified versions of their parent pro- or anti-apoptotic proteins.
[117]
 These 
molecules are contributing to a better understanding of the activity and regulation of 
apoptotic proteins and setting the scene for the discovery of effective drugs to combat 
important diseases related to apoptosis.  
 
1.9.1 Caspase 
 
Since the idea of apoptosis was established in 1972
[114]
, research efforts have led to 
the recognition of hundreds of genes that control the initiation, execution and regulation of 
apoptosis. A family of proteins known as caspases are typically activated in the early stages 
of apoptosis. Caspases are the essential component of the apoptotic process and they 
irreversibly commit a cell to die. These proteins break down or cleave key cellular 
components that are required for normal cellular function. 
[114]
Three major pathways of 
apoptosis, associated with caspase activation, have been identified in mammals (Figure 
1.24): the extrinsic or death receptor pathway, the intrinsic or apoptosome pathway and the 
cytotoxic lymphocyte-initiated granzyme B pathway. 
[118]
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Figure 1.24 Caspase activation pathways. 1. The extrinsic or death receptor pathway, 2. The 
intrinsic or apoptosome pathway. 3. The cytotoxic lymphocyte-intiated granzyme B pathway
[118]
 
 
 
The intrinsic pathway is triggered in response to a broad range of death stimuli that 
are generated from within the cell, such as DNA damage. The inactivation of this pathway is 
normally regarded as a trademark of cancer.
[119]
  The intrinsic pathway is mediated by 
mitochondria, and, in reply to apoptotic stimuli, numerous proteins are released from the 
intermembrane space of mitochondria into the cytoplasm.
[120]
 One such protein and possibly 
the most fascinating one of these pro-apoptotic proteins is cytochrome c, which binds to and 
activates the protein APAF1 in the cytoplasm,  eventually leading to a cascade of caspase 
activation.
[121]
 The extrinsic pathway is initiated by the binding of an extracellular death 
ligand to its cell-surface death receptor. The extrinsic pathway can crosstalk to the intrinsic 
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pathway through the caspase- 8-mediated cleavage of BID (a BH3-ONLY member of the 
Bcl-2 family of proteins) which then triggers the release of mitochondrial proteins.
[122, 123]
 
 
1.9.2 Role of B-cell lymphoma-2 (Bcl-2) proteins 
 
The Bcl-2 family of proteins is involved in the response to apoptosis through their 
ability to regulate mitochondrial cytochrome c release. Bcl-2 proteins regulate the extrinsic 
and intrinsic pathway of apoptosis which converge at the mitochondria (Figure 1.24).
[124]
 
 
The Bcl-2 family comprises of both anti- and pro-apoptotic molecules and these are broken 
down into 3 sub-families based on their homology domains and function (Figure 1.25).  
 
The pro-apoptotic BAX-like subfamily share sequence homology at BH1, BH2 and 
BH3 but lacks BH4 domains and promotes apoptosis by forming pores at the mitochondrial 
outer membrane. When these members are activated the change from monomers to 
oligomers and these then disrupt the integrity of the outer mitochondrial membrane, a 
process called mitochondrial outer membrane permibilisation (MOMP), realising 
components such as cytochrome c, initiating apoptosis. 
 
The BH3-only sub-family of proteins, all of which are pro-apoptotic, contains 
structurally diverse members that only display homology within the BH3 domain. 
[118, 125, 126]
 
These proteins can sense cell damage and interact with pro-apoptotic members such as 
Bax/Bak causing them to oligermerise. The BH3-only proteins are either absent or inactive 
in a normal cell not undergoing stress. These proteins are involved in both the sensing and 
activation stages of apoptosis.  
 
The anti-apoptotic sub-family comprises proteins such as Bcl-2, Bcl-xL and Bcl-w, 
which share sequence homology particularly within four regions, BH1 through BH4 (Figure 
1.25).
[126]
  Most members of this subfamily also contain transmembrane domains (TM) and 
are therefore typically associated with cell membranes. These work by inhibiting the effects 
of the BH-3 only proteins after apoptosis is initiated as well as inhibiting the oligomerisation 
of activated pro–apoptotic members. 
 
Abnormal gene expression of some Bcl-2 family members that inhibits cell death 
contributes to the resistance of tumour cells to conventional therapies by interfering with a 
large variety of apoptotic stimuli, including chemotherapeutic agents.
[127-130]
 Recent studies 
have shown that the functional blockade of Bcl-2 or Bcl-XL restored the apoptotic process in 
39 
 
tumour cells
[131]
 and also reduced the resistance to chemo- and radiotherapies that some 
tumours possessed.
[132, 133]
 
 
 
 
Figure 1.25 The Bcl-2 family comprises of anti- and pro-apoptotic molecules and are broken 
down into 3 sub-families based on their homology and function.
[118]
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1.9.3 BH-3 only proteins 
 
The mammalian BH3-only protein family currently comprises eight members (BID, 
BAD, BIM, BIK, BMF, NOXA, PUMA and HRK), all of which have pro-apoptotic activity 
when over-expressed (Figure1.26 ).
[118]
 Apart from the BH3 homology domain, these 
proteins share little sequence similarity and are regulated in distinct ways. BH3  proteins use 
their BH3 domain to interact with other proteins when exerting their pro-apoptotic activity 
and because of this, the BH3 proteins are thought to be death ligands and their targets can be 
categorised as death receptors.
[134] 
 
 
Figure1.26  BH3 domain sequences of BH3 only proteins and their pro-survival protein binding 
targets.
 [135] 
 
1.9.4 BH3 interacting death agonist (BID) 
 
The BID protein is a pro-apoptotic member of the Bcl-2 family that contains only 
the BH3 homology domain (Figure1.27). BID is found in the cytosol of cell and at 
membrane locations. BID can stimulate apoptosis by activating BAX to trigger 
mitochondrial apoptosis.
[136]
 Activated BAX polymerises and induces permeabilization of 
the outer mitochondrial membrane, enabling released mitochondrial factors to activate 
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caspases, which in turn irreversibly implement the death program. 
[137]
 The amino acid 
sequence of BID is shown in Figure 1.27.
 
 
 
Figure 1.27 Amino acid sequences of BID and BCL-XL Aligned at the BH3 Domains (Shaded in 
Yellow)
[138]
 
 
1.9.5 Synthetic Peptides and Organic molecules as probes for the investigation of 
the structure and function of members of the Bcl-2 family- Targeted therapy 
 
The different domains found in the sequence of Bcl2 proteins have inspired the 
design and synthesis of a number of small organic molecules and active peptides. 
[135, 139]
Cell 
permeable synthetic peptides and small organic molecules targeted to a precise Bcl-2 family 
member can be utilised to control and modulate the function of that particular protein 
(Figure 1.28). They are also the preferred leads for development of tumour selective anti 
cancer drugs, one reason being, that patient tailored cancer cell directed therapeutic 
approaches offer the potential to have fewer side effects. 
[140, 141]
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Figure 1.28 Cell permeable synthetic peptides (BID) and small organic molecules (ABT-737) 
targeted to a precise Bcl-2 family member can be utilised to control and modulate the function 
of that particular protein and lead to cell death.
[142]
 
 
 
1.9.6 BID peptides 
 
One approach for studying and controlling the function of Bcl-2 family proteins is 
the use of synthetic peptides derived from the functional domains of pro-apoptotic and anti-
apoptotic Bcl-2 members. In comparison with full-length proteins that may contain other 
domains, these peptides offer simplified models for functional and structural studies in vitro 
or in cell free systems.
[139, 143]
 This is a means of testing and identifying the functional 
sequences in BID, which may lead to therapeutic targets. Modification with cell permeable 
moieties would allow these peptides to be exploited to investigate mechanisms of Bcl-2 
function in living cells.
[139, 144]
  
 
In this thesis, small fragments (overlapping peptides) of the BID protein will be 
synthesized to investigate the structure and function of this protein. These studies will 
include labelling of the peptide sequences with novel fluorescent probes, both metal 
complexes and by biotinylation as part of supramolecular assembly. As metal complexes can 
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photochemically generate active O2 species, these peptide-label conjugates will also have the 
potential to promote apoptosis in tumour cells and may be implemented in the development 
of anticancer drugs. 
 
Biotinylation is the procedure of covalently attaching biotin to a protein, nucleic acid 
or other molecule. Biotinylation is unlikely to disturb the natural function of the molecule 
due to the small size of biotin (MW = 244.31). Biotin binds to streptavidin and avidin with 
an extremely high affinity, fast on-rate, and high specificity, and these interactions are 
exploited in many areas of biotechnology to isolate biotinylated molecules of interest. 
Biotin-binding to streptavidin and avidin is resistant to extremes of heat, pH and proteolysis, 
making capture of biotinylated molecules possible in a wide variety of environments. Biotin 
binding proteins have the capacity to bind up to four biotin molecules, as shown in  Figure 
1.29, making this interaction ideal for both purification and detection strategies. For this 
thesis the BID sequence peptides were biotinaylated to be used in protein binding studies. 
 
Figure 1.29 Schematic of the avidin-biotin interaction.
[145]
 
 
1.9.7 ABT-263 
Small organic molecules can be used toward the investigation of the role of Bcl-2 in 
regulating apoptosis. These molecules offer advantages over peptide-based drugs in that they 
can easily be adapted for optimal stability, cell permeability, solubility and activity. Such 
low molecular weight compounds usually have high membrane permeability and thus can be 
used to study and control intracellular apoptotic signalling pathways. Such small organic 
molecules can either be discovered by random screening procedures of from natural 
products libraries or designed by computational methods that target certain functional sites 
of the Bcl-2 family. The three-dimensional structures of Bcl-XL and more recently Bcl-2, as 
determined by X-ray crystallography and/ or NMR spectroscopy, provides the structural 
basis for the prediction of new inhibitors of these anti-apoptotic proteins.
[146]
 
[147]
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These X-ray crystallography and NMR spectroscopy studies have resulted in the 
identification of natural products which induce apoptosis in cells over-expressing Bcl-2 or 
Bcl-XL.
[148, 149]
 Also by using these techniques other small molecule inhibitors such as 
HA14-1
[150]
 and the BH3I
[151]
 class of compounds, have been identified. 
 
By means of structure activity relationships studies (SAR), performed by nuclear 
magnetic resonance spectroscopy (NMR), ligands were found that had high binding 
affinities for the hydrophobic groove of Bcl-XL.
[152]
 From further studies of these lead 
compounds, a small organic molecule, ABT-737, was developed (Figure 1.30).
[153]
 This was 
shown to have a high affinity to Bcl-2 and Bcl-XL, however ABT-737 fails the classified 
rules of drug likeness when it comes to molecular mass, number of hetero-atoms, functional 
groups and rotational bonds. 
[154, 155]
 
 
 
 
 
Figure 1.30 (a) Structure of BCL-XL bound to fragments discovered by nuclear magnetic 
resonance. (b) BCL-XL bound to ABT-737. 
[135]
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Major differences are observed in both potency and selectivity of the various small 
molecule Bcl-2 inhibitors for the different anti-apoptotic Bcl-2 proteins.
[150, 151, 153, 156-162]
 By 
far the most potent small molecule inhibitors described to date are the BAD-like BH3 
mimetics, ABT-737 and its orally available analogue, ABT-263.
[163]
 These bind with very 
high affinity to Bcl-2, Bcl-XL and Bcl-w but with much lower affinity to Mcl-1 or 
Bcl2A1.
[161, 164]
 The majority of detailed mechanistic studies on Bcl-2 inhibitors have been 
carried out using ABT-737.
[165]
 The development of an orally bioavailable Bcl-2 inhibitor, 
such as ABT-263, with the ability to inhibit specifically BH3-Bcl-2 protein-protein 
interactions at low nanomolar concentrations, potentially marks a significant development in 
cancer therapy.  
 
Modifications to ABT-737 led to the discovery of ABT-263. ABT-263 retains its 
potency for Bcl-2 and BCL-XL and its oral availability properties made it a clinical 
candidate. The binding capabilities of ABT-263 is reminiscent of the BH-3 only protein 
BAD. ABT-263 has had positive results as an active agent in cell based assays. 
[161]
 
 
 
Figure 1.31 Structures of (a) ABT-737 and (b) ABT-263 
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With regards to this thesis, ABT-737 and ABT-263 (Figure1.31) can be used as 
probes complementing the peptide-based probes developed to investigate apoptotic 
pathways.  
 
1.10 Aims of the Project 
 
Over the past number of years research into the potential applications of photoactive 
supramolecular assemblies has extended to many areas including very recently therapeutics 
and diagnostics. The use of these assemblies in live cell imaging is enabled by optical 
imaging methods such as of confocal microscopy and fluorescent chromophores. Inorganic 
chromophores have many advantages over their organic counterparts and are looking 
increasingly viable as alternative molecular probes. Not only do they have good 
photophsical features such as long lived, polarised luminescence, good photostability, they 
also have the capacity to make their photophysical properties dependent on their 
environment.   
 
However in the past their weakness was their lack of uptake by the cell, but in recent 
times this has been overcome with cell penetrating peptides. As part of this research we 
looked at Ru (II) Chromophores and their conjugation to targeting peptides. Localisation of 
these chromophores can be used for diagnostic and therapeutic effects. A series of water 
soluble ruthenium (II) polypyridyl- peptide conjugates were synthesised and their 
spectroscopic and photophysical properties fully characterised and compared. Most of the 
assemblies detailed in this thesis are established by the supramolecular dyad system of A-L-
B, where the features or applications of the assembly outweigh that of the individual 
components. 
 
Successful conjugation of metal luminophores to peptides has been accomplished 
before by our group
[35, 39]
; however, their specific localisation using targeting peptides is yet 
to be reported. It was anticipated that the use of localising peptides would further enhance 
the applications of the chromophores compared to existing transition metal-polypeptide 
conjugates which tend to localise in the cytoplasm. In Chapters 3 and 6, conjugation of 
ruthenium (II) to biomolecules builds upon previously reported work by our group and 
facilitates the analysis of biological samples through targeted localisation within a cell, but 
most crucially without damaging the cell membrane in the process. The production of 
reactive oxygen species following absorption of light energy by the transition metal 
luminophores may also induce cell apoptosis and could potentially make these a powerful 
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diagnostic agents photo-therapeutic tools. We investigated conjugation of both nuclear and 
mitochondria targeting assemblies. 
  
Numerous reports highlight attempts to create targeted therapy for cancer 
treatment. Directed therapy blocks the growth of cancer cells by interfering with specific 
targeted molecules needed for carcinogenesis and tumour growth, rather than by simply 
interfering with rapidly dividing cells (e.g. traditional chemotherapy). Targeted cancer 
therapies are attractive as they may be more effective than current treatments and have less 
side-effects. The first step in targeted therapy is to identify and understand the protein-
protein interactions within cells. By understanding the apoptotic pathway to induce cell 
death would be an attractive strategy in developing targeted therapy. 
 
For this research we selected BH3 domain death agonist BID, a pro-apoptotic 
member of the Bcl2 family. BID can be fragmented into overlapping sequences of peptides 
for the investigation of the localisation and function properties of the parent protein by 
supramolecular assemblies. Conjugated to biotin allows for protein binding studies and 
conjugation to a Ru(II) chromophore could be used for cellular imaging. 
 
The Abbott molecule ABT 737 is a small molecule designed to react with anti-
apoptotic members. By attaching a chromophore to this molecule its cellular uptake and 
localisation can be investigated. This is in keeping with the general focus of research in 
constructing photoactive supramolecular assemblies based on biomolecules for applications 
in areas ranging from diagnostics to therapeutics. 
 
One of the main aims of this thesis is to apply suitable luminophores to demonstrate 
how their conjugation to cell membrane transporters enables their applications in cellular 
imaging. Furthermore, the inherent properties of the dyes may then be exploited to 
determine characteristics such as pH and oxygen levels within cellular structures. This thesis 
presents an insight into the production of supramolecular assemblies from its individual 
subunit synthesis to their collective functional applications. It also gives an idea of the work 
presently being undertaken across a range of disciplines and will add to the understanding of 
the basic principles on which these luminophores may be exploited for their potential uses in 
photoactive supramolecular assemblies, diagnostics and therapeutics. 
 
 
48 
 
References 
[1] Minsky, M., (1961) Microscopy apparatus, United States Patent 3013467. 
 
[2] Amos, W. B.; White, J. G., Biology of the cell / under the auspices of the European 
Cell Biology Organization, (2003) 95, 335. 
 
[3] van der Voort, H. T. M.; Brakenhoff, G. J.; Baarslag, M. W., Journal of Microscopy, 
(1989) 153, 123. 
 
[4] Fung, D. C.; Theriot, J. A., Curr Opin Microbiol, (1998) 1, 346. 
 
[5] Forster, R. J. K., T.E.  Vos In, J.G., Interfacial Supermolecular Assemblies,  Wiley: 
(2003). 
[6] LifeTechnologiesCorporation, Molecular Probes, In   (2012). 
 
[7] Lee, S.; Park, K.; Kim, K.; Choi, K.; Kwon, I. C., Chemical Communications, 
(2008), 4250. 
 
[8] Ghoroghchian, P. P.; Therien, M. J.; Hammer, D. A., Wiley Interdiscip Rev 
Nanomed Nanobiotechnol, (2009) 1, 156. 
 
[9] Tung, C. H., Biopolymers, (2004) 76, 391. 
 
[10] Zhong, W., Urayama, P. and  Mycek, M.A., Journal of Physics D: Applied Physics, 
(2003) 36, 1689. 
 
[11] Johnson, I., The Histochemical Journal, (1998) 30, 123. 
 
[12] Paul L, M.; Yu-Li Wang, D. L. T. a. K. W. J., (1988) Chapter 10 Incorporation of 
Macromolecules into Living Cells, in Methods in Cell Biology, Academic Press Vol. 
Volume 29,  153. 
 
[13] Juris, A.; Balzani, V.; Barigelletti, F.; Campagna, S.; Belser, P.; von Zelewsky, A., 
Coordination Chemistry Reviews, (1988) 84, 85. 
 
[14] Steed, J. W.; Atwood, J. L., Molecular Devices, In Supramolecular Chemistry,  John 
Wiley & Sons, Ltd: (2009); pp 707. 
 
[15] Balzani, V.; Bergamini, G.; Ceroni, P., Coordination Chemistry Reviews, (2008) 
252, 2456. 
 
[16] The Regents of the University of California, D., Electronic Spectroscopy: Theory, In   
(2011). 
 
[17] Suppan, P., Chapter 4 The Chemistry of Excited Molecules, In Chemistry and Light,  
The Royal Society of Chemistry: (1994); pp 87. 
 
[18] Steed, J. W.; Atwood, J. L., Supramolecular Polymers, Gels and Fibres, In 
Supramolecular Chemistry,  John Wiley & Sons, Ltd: (2009); pp 861. 
 
[19] Deiters, E.; Song, B.; Chauvin, A. S.; Vandevyver, C. D.; Gumy, F.; Bunzli, J. C., 
Chemistry, (2009) 15, 885. 
 
49 
 
[20] Bunzli, J. C., Acc Chem Res, (2006) 39, 53. 
 
[21] Pandya, S.; Yu, J.; Parker, D., Dalton Trans, (2006), 2757. 
 
[22] Keefe, M. H.; Benkstein, K. D.; Hupp, J. T., Coordination Chemistry Reviews, 
(2000) 205, 201. 
 
[23] Otsuki, J.; Akasaka, T.; Araki, K., Coordination Chemistry Reviews, (2008) 252, 32. 
 
[24] Yu, M.; Zhao, Q.; Shi, L.; Li, F.; Zhou, Z.; Yang, H.; Yi, T.; Huang, C., Chem 
Commun (Camb), (2008), 2115. 
 
[25] Bernhard, S.; Barron, J. A.; Houston, P. L.; Abruna, H. D.; Ruglovksy, J. L.; Gao, 
X.; Malliaras, G. G., J Am Chem Soc, (2002) 124, 13624. 
 
[26] Buda, M.; Kalyuzhny, G.; Bard, A. J., J Am Chem Soc, (2002) 124, 6090. 
 
[27] Payne, S. J.; Fiore, G. L.; Fraser, C. L.; Demas, J. N., Analytical chemistry, (2010) 
82, 917. 
 
[28] Hsu, N. M.; Li, C. Y.; Yang, C. M.; Lin, T. S.; Hu, B. H.; Tingare, Y. S.; Chang, W. 
C.; Srivastava, G. K.; Li, W. R., J Comb Chem, (2009) 11, 943. 
 
[29] Brooks, J.; Babayan, Y.; Lamansky, S.; Djurovich, P. I.; Tsyba, I.; Bau, R.; 
Thompson, M. E., Inorg Chem, (2002) 41, 3055. 
 
[30] Mullice, L. A.; Pope, S. J. A., Dalton Transactions, (2010) 39, 5908. 
 
[31] Lo, K. K.; Lee, T. K.; Lau, J. S.; Poon, W. L.; Cheng, S. H., Inorg Chem, (2008) 47, 
200. 
 
[32] Balzani, V.; Juris, A., Coordination Chemistry Reviews, (2001) 211, 97. 
 
[33] Zhang, K. Y.; Lo, K. K., Inorg Chem, (2009) 48, 6011. 
 
[34] Haas, K. L.; Franz, K. J., Chem Rev, (2009) 109, 4921. 
 
[35] Cosgrave, L.; Devocelle, M.; Forster, R. J.; Keyes, T. E., Chem Commun (Camb), 
(2010) 46, 103. 
 
[36] Steed, J. W.; Atwood, J. L., The Supramolecular Chemistry of Life, In 
Supramolecular Chemistry,  John Wiley & Sons, Ltd: (2009); pp 49. 
 
[37] Dixon, I. M.; Lebon, E.; Sutra, P.; Igau, A., Chemical Society Reviews, (2009) 38, 
1621. 
 
[38] Balzani, V.; Campagna, S.; Campagna, S.; Puntoriero, F.; Nastasi, F.; Bergamini, 
G.; Balzani, V., Photochemistry and Photophysics of Coordination Compounds: Ruthenium, 
In Photochemistry and Photophysics of Coordination Compounds I,  Springer Berlin 
Heidelberg: (2007); Vol. 280, pp 117. 
 
[39] Dolan, C., Dublin City University Dublin, (2011), p 382. 
 
[40] Durham, B.; Caspar, J. V.; Nagle, J. K.; Meyer, T. J., Journal of the American 
Chemical Society, (1982) 104, 4803. 
50 
 
 
[41] Adeloye, A. O. O., T.O.; Adebayo, A.I.; Ajibade, P.A., Int. J. Mol. Sci., (2012) 13, 
3511. 
 
[42] Terpetschnig, E.; Dattelbaum, J. D.; Szmacinski, H.; Lakowicz, J. R., Analytical 
Biochemistry, (1997) 251, 241. 
 
[43] Hu, W.-S.; Pathak, V. K., Pharmacological Rewiew, (2000) 52, 493. 
[44] Waehler, R.; Russell, S. J.; Curiel, D. T., Nat Rev Genet, (2007) 8, 573. 
 
[45] Chesnoy, S.; Huang, L., Annual Review of Biophysics and Biomolecular Structure, 
(2000) 29, 27. 
 
[46] Zaric, V.; Weltin, D.; Erbacher, P.; Remy, J.-S.; Behr, J.-P.; Stephan, D., The 
Journal of Gene Medicine, (2004) 6, 176. 
 
[47] Deshayes, S.; Morris, M. C.; Divita, G.; Heitz, F., Cellular and Molecular Life 
Sciences, (2005) 62, 1839. 
 
[48] Sebbage, V., Bioscience Horizon, (2009) 2, 64. 
 
[49] Stewart, K. M.; Horton, K. L.; Kelley, S. O., Organic & Biomolecular Chemistry, 
(2008) 6, 2242. 
 
[50] Sharma, A.; Sharma, U. S., International Journal of Pharmaceutics, (1997) 154, 
123. 
 
[51] National Institute of Cancer, Centre of Cancer Research (2012) Liposomes [online], 
available : http://ccr.cancer.gov/staff/gallery.aspprofileid=6797 [accessed 15 December 
2012] 
 
[52] Matthay, K. K.; Heath, T. D.; Papahadjopoulos, D., Cancer Research, (1984) 44, 
1880. 
 
[53] Kim JS, H. T., Arch Pharm Res., (2000) 23, 167. 
 
[54] Gabizon, A.; Tzemach, D.; Gorin, J.; Mak, L.; Amitay, Y.; Shmeeda, H.; Zalipsky, 
S., Cancer Chemotherapy and Pharmacology, (2012) 66, 43. 
 
[55] Shmeeda, H.; Amitay, Y.; Gorin, J.; Tzemach, D.; Mak, L.; Ogorka, J.; Kumar, S.; 
Zhang, J. A.; Gabizon, A., Journal of Controlled Release, (2010) 146, 76. 
 
[56] Lee, C. C.; Gillies, E. R.; Fox, M. E.; Guillaudeu, S. J.; Frachet, J. M. J.; Dy, E. E.; 
Szoka, F. C., Proceedings of the National Academy of Science, (2006) 103, 16649. 
 
[57] Wolinsky, J. B.; Grinstaff, M. W., Advanced Drug Delivery Reviews, (2008) 60, 
1037. 
 
[58] Goff, S. P.; Berg, P., Cell, (1976) 9, 695. 
 
[59] Thomas, C. E.; Ehrhardt, A.; Kay, M. A., Nat Rev Genet, (2003) 4, 346. 
 
[60] Muller, R. H.; Mader, K.; Gohla, S., European Journal of Pharmaceutics and 
Biopharmaceutics, (2000) 50, 161. 
 
51 
 
[61] Mukherjee S, R. S., Thakur R S Indian Journal of Pharmaceutical Sciences, (2009) 
71, 349. 
 
[62] Yang, S. C.; Lu, L. F.; Cai, Y.; Zhu, J. B.; Liang, B. W.; Yang, C. Z., Journal of 
Controlled Release, (1999) 59, 299. 
 
[63] A to Z Nanotechnology, Lipid Nanoparticles Used in Skin Care Cosmetics - 
Processes and Associated Benefits, (2012), available: 
http://www.azonano.com/article.aspxArticleID=1245 [accessed 15 December 2012]    . 
 
[64] Hauber, J., Perkins,A., Heimer, E.P., and Cullen, B.R., Proc Natl Acad Sci U S A, 
(1987) 84, 6364. 
 
[65] Frankel, A. D.; Pabo, C. O., Cell, (1988) 55, 1189. 
 
[66] Green, M.; Loewenstein, P. M., Cell, (1988) 55, 1179. 
 
[67] Joliot, A.; Prochiantz, A., Nat Cell Biol, (2004) 6, 189. 
 
[68] Madani, F.; Lindberg, S.; Langel, l.; Futaki, S.; Grslund, A., Journal of Biophysics, 
(2011)  
 
[69] Jarver, P.; Langel, U., Biochimica et Biophysica Acta (BBA) - Biomembranes, 
(2006) 1758, 260. 
 
[70] Flewelling, R. F.; Hubbell, W. L., Biophysical journal, (1986) 49, 541. 
 
[71] Liu, S.; Edwards, D. S., Chemical Reviews, (1999) 99, 2235. 
 
[72] Mitchell, D. J.; Steinman, L.; Kim, D. T.; Fathman, C. G.; Rothbard, J. B., The 
Journal of Peptide Research, (2000) 56, 318. 
 
[73] Ragin, A. D.; Morgan, R. A.; Chmielewski, J., Chem Biol, (2002) 9, 943. 
 
[74] Trehin, R.; Merkle, H. P., European Journal of Pharmaceutics and 
Biopharmaceutics, (2004) 58, 209. 
 
[75] Lebleu, B., Vives E., Brodin P., J Biol Chem, (1997) 272, 16010. 
 
[76] Derossi, D.; Joliot, A. H.; Chassaing, G.; Prochiantz, A., The Journal of Biological 
Chemistry, (1994) 269, 10444. 
 
[77] Jurek W, D., Journal of Photochemistry and Photobiology B: Biology, (2001) 65, 
136. 
 
[78] Neugebauer, U.; Pellegrin, Y.; Devocelle, M.; Forster, R. J.; Signac, W.; Moran, N.; 
Keyes, T. E., Chemical Communications, (2008), 5307. 
 
[79] Neugebauer, U.; Pellegrin, Y.; Devocelle, M.; Forster, R. J.; Signac, W.; Moran, N.; 
Keyes, T. E., Chem Commun (Camb), (2008), 5307. 
 
[80] Puckett, C. A.; Barton, J. K., Journal of the American Chemical Society, (2009) 131, 
8738. 
 
[81] Puckett, C. A.; Barton, J. K., Bioorganic & Medicinal Chemistry, (2010) 18, 3564. 
52 
 
 
[82] Mahon, K. P.; Potocky, T. B.; Blair, D.; Roy, M. D.; Stewart, K. M.; Chiles, T. C.; 
Kelley, S. O., Chemistry  Biology, (2007) 14, 923. 
 
[83] Strebhardt, K.; Ullrich, A., Nat Rev Cancer, (2008) 8, 473. 
 
[84] Cartier, R., Reszka R., Gene Therapy, (2002) 9, 157. 
 
[85] Dickinson, B. C.; Srikun, D.; Chang, C. J., Current Opinion in Chemical Biology, 
(2010) 14, 50. 
 
[86] Murphy, M. P.; Smith, R. A. J., Advanced Drug Delivery Reviews, (2000) 41, 235. 
 
[87] Milletti, F., Drug Discovery Today, (2012) 17, 850. 
 
[88] Shen, H.-M.; Tergaonkar, V., Apoptosis, (2009) 14, 348. 
 
[89] Kalderon, D.; Roberts, B. L.; Richardson, W. D.; Smith, A. E., Cell, (1984) 39, 499. 
 
[90] Fontes, M. R. M.; Teh, T.; Kobe, B., Journal of Molecular Biology, (2000) 297, 
1183. 
 
[91] Chen, L. F. G., W.C., Nat Rev Mol Cell Biol, (2004) 5, 392. 
 
[92] Garg, A.; Aggarwal, B., Leukemia, (2002) 16,  
 
[93] Wallace, D. C.; Singh, G.; Lott, M. T.; Hodge, J. A.; Schurr, T. G.; Lezza, A. M.; 
Elsas, L. J.; Nikoskelainen, E. K., Science, (1988) 242, 1427. 
 
[94] Liu, X.; Kim, C. N.; Yang, J.; Jemmerson, R.; Wang, X., Cell, (1996) 86, 147. 
 
[95] Armstrong, J. S., British Journal of Pharmacology, (2007) 151, 1154. 
 
[96] Splith, K.; Neundorf, I., European Biophysics Journal, (2011) 40, 387. 
 
[97] Zasloff, M., Proc Natl Acad Sci U S A, (1987) 84, 5449. 
 
[98] Imura, Y.; Choda, N.; Matsuzaki, K., Biophysical journal, (2008) 95, 5757. 
 
[99] Lundberg, M.; Johansson, M., Biochem Biophys Res Commun, (2002) 291, 367. 
 
[100] Gill, M. R.; Thomas, J. A., Chemical Society Reviews, (2011) 41, 3179. 
 
[101] De Bont, R.; van Larebeke, N., Mutagenesis, (2004) 19, 169. 
 
[102] Jackson, A. L.; Loeb, L. A., Mutation Research/Fundamental and Molecular 
Mechanisms of Mutagenesis, (2001) 477, 7. 
 
[103] Young, I. S.; Woodside, J. V., Journal of clinical pathology, (2001) 54, 176. 
 
[104] McCord, J. M., The American journal of medicine, (2000) 108, 652. 
 
[105] van Loon, B.; Markkanen, E.; Hubscher, U., DNA Repair, (2010) 9, 604. 
 
53 
 
[106] Maynard, S.; Schurman, S. H.; Harboe, C.; de Souza-Pinto, N. C.; Bohr, V. A., 
Carcinogenesis, (2009) 30, 2. 
 
[107] Valko, M.; Rhodes, C. J.; Moncol, J.; Izakovic, M.; Mazur, M., Chemico-Biological 
Interactions, (2006) 160, 1. 
 
[108] Khanna, K. K.; Jackson, S. P., Nat Genet, (2001) 27, 247. 
 
[109] Friedman, A. E.; Chambron, J. C.; Sauvage, J. P.; Turro, N. J.; Barton, J. K., Journal 
of the American Chemical Society, (1990) 112, 4960. 
 
[110] Matson, M.; Svensson, F. R.; Norden, B.; Lincoln, P., The Journal of Physical 
Chemistry B, (2011) 115, 1706. 
 
[111] Ardhammar, M.; Lincoln, P.; Nordan, B., The Journal of Physical Chemistry B, 
(2001) 105, 11363. 
 
[112] Svensson, F. R.; Abrahamsson, M.; Stroimberg, N.; Ewing, A. G.; Lincoln, P., The 
Journal of Physical Chemistry Letters, (2012) 2, 397. 
 
[113] Popov, S. G.; Villasmil, R.; Bernardi, J.; Grene, E.; Cardwell, J.; Wu, A.; Alibek, 
D.; Bailey, C.; Alibek, K., Biochemical and Biophysical Research Communications, (2002) 
293, 349. 
 
[114] Kerr, J. F.; Wyllie, A. H.; Currie, A. R., Br J Cancer, (1972) 26, 239. 
 
[115] Thompson, C. B., Apoptosis in the pathogenesis and treatment of disease, In   
(1995); Vol. 267, pp 1456. 
 
[116] Mendoza, F. J., Espino, P. S., Cann, K. L., Bristow, N., McCrea, K. and Los, M., 
Arch Immunol Ther Exp, (2005) 53, 47. 
 
[117] Salgado, J.; García-Sáez, A. J.; Malet, G.; Mingarro, I.; Pérez-Payá, E., Journal of 
Peptide Science, (2002) 8, 543. 
 
[118] Taylor, R. C.; Cullen, S. P.; Martin, S. J., Nat Rev Mol Cell Biol, (2008) 9, 231. 
 
[119] Hanahan, D.; Weinberg, R. A., Cell, (2000) 100, 57. 
 
[120] Wang, X., Genes and Development, (2001) 15, 2922. 
 
[121] Li, P.; Nijhawan, D.; Budihardjo, I.; Srinivasula, S. M.; Ahmad, M.; Alnemri, E. S.; 
Wang, X., Cell, (1997) 91, 479. 
 
[122] Luo, X.; Budihardjo, I.; Zou, H.; Slaughter, C.; Wang, X., Cell, (1998) 94, 481. 
 
[123] Li, H.; Zhu, H.; Xu, C.-j.; Yuan, J., Cell, (1998) 94, 491. 
 
[124] Kutuk, O.; Basaga, H., Apoptosis, (2006) 11, 1661. 
 
[125] Salgado, J.; Garcia-Saez, A. J.; Malet, G.; Mingarro, I.; Perez-Paya, E., J Pept Sci, 
(2002) 8, 543. 
 
[126] Tsujimoto, Y., Genes to Cells, (1998) 3, 697. 
 
54 
 
[127] Lotem, J.; Sachs, L., Cell Growth Differ, (1993) 4, 41. 
 
[128] Miyashita, T.; Reed, J. C., Blood, (1993) 81, 151. 
 
[129] Reed, J. C.; Miyashita, T.; Takayama, S.; Wang, H. G.; Sato, T.; Krajewski, S.; 
Aime-Sempe, C.; Bodrug, S.; Kitada, S.; Hanada, M., J Cell Biochem, (1996) 60, 23. 
 
[130] Walton, M. I.; Whysong, D.; O'Connor, P. M.; Hockenbery, D.; Korsmeyer, S. J.; 
Kohn, K. W., Cancer Research, (1993) 53, 1853. 
 
[131] Webb, A.; Cunningham, D.; Cotter, F.; Clarke, P. A.; di Stefano, F.; Ross, P.; 
Corbo, M.; Dziewanowska, Z., Lancet, (1997) 349, 1137. 
 
[132] Piche, A.; Grim, J.; Rancourt, C.; Gomez-Navarro, J.; Reed, J. C.; Curiel, D. T., 
Cancer Research, (1998) 58, 2134. 
 
[133] Jansen, B.; Schlagbauer-Wadl, H.; Brown, B. D.; Bryan, R. N.; van Elsas, A.; 
Muller, M.; Wolff, K.; Eichler, H. G.; Pehamberger, H., Nature medicine, (1998) 4, 232. 
 
[134] Tsujimoto, Y., Genes Cells, (1998) 3, 697. 
 
[135] Lessene, G.; Czabotar, P. E.; Colman, P. M., Nat Rev Drug Discov, (2008) 7, 989. 
 
[136] Wang, K.; Yin, X. M.; Chao, D. T.; Milliman, C. L.; Korsmeyer, S. J., Genes Dev, 
(1996) 10, 2859. 
 
[137] Walensky, L. D.; Pitter, K.; Morash, J.; Oh, K. J.; Barbuto, S.; Fisher, J.; Smith, E.; 
Verdine, G. L.; Korsmeyer, S. J., Mol Cell, (2006) 24, 199. 
 
[138] Chou, J. J.; Li, H.; Salvesen, G. S.; Yuan, J.; Wagner, G., Cell, (1999) 96, 615. 
 
[139] Liu, D.; Huang, Z., Apoptosis, (2001) 6, 453. 
 
[140] Mendoza, F. J.; Espino, P. S.; Cann, K. L.; Bristow, N.; McCrea, K.; Los, M., Arch 
Immunol Ther Exp (Warsz), (2005) 53, 47. 
 
[141] Johar, D.; Roth, J. C.; Bay, G. H.; Walker, J. N.; Kroczak, T. J.; Los, M., Rocz Akad 
Med Bialymst, (2004) 49, 31. 
 
[142] Wagner, G., Nat Chem Biol, (2005) 1, 8. 
 
[143] Shangary, S.; Johnson, D. E., Biochemistry, (2002) 41, 9485. 
 
[144] Huang, Z., Oncogene, (2000) 19, 6627. 
 
[145] Thermo Scintific, (2012) Avidin-Biotin Interactions, [online], available: 
http://www.piercenet.com/browse.cfm?fldID=4A957146-5056-8A76-4E97-81995432210B 
[accessed 15 December 2012]      
 
[146] Petros, A. M.; Medek, A.; Nettesheim, D. G.; Kim, D. H.; Yoon, H. S.; Swift, K.; 
Matayoshi, E. D.; Oltersdorf, T.; Fesik, S. W., Proc Natl Acad Sci U S A, (2001) 98, 3012. 
 
[147] Muchmore, S. W.; Sattler, M.; Liang, H.; Meadows, R. P.; Harlan, J. E.; Yoon, H. 
S.; Nettesheim, D.; Chang, B. S.; Thompson, C. B.; Wong, S. L.; Ng, S. L.; Fesik, S. W., 
Nature, (1996) 381, 335. 
55 
 
 
[148] Nakashima, T.; Miura, M.; Hara, M., Cancer Res, (2000) 60, 1229. 
 
[149] Tokutake, N.; Miyoshi, H.; Satoh, T.; Hatano, T.; Iwamura, H., Biochim Biophys 
Acta, (1994) 1185, 271. 
 
[150] Wang, G.; Nikolovska-Coleska, Z.; Yang, C. Y.; Wang, R.; Tang, G.; Guo, J.; 
Shangary, S.; Qiu, S.; Gao, W.; Yang, D.; Meagher, J.; Stuckey, J.; Krajewski, K.; Jiang, S.; 
Roller, P. P.; Abaan, H. O.; Tomita, Y.; Wang, S., J Med Chem, (2006) 49, 6139. 
 
[151] Degterev, A.; Lugovskoy, A.; Cardone, M.; Mulley, B.; Wagner, G.; Mitchison, T.; 
Yuan, J., Nat Cell Biol, (2001) 3, 173. 
 
[152] Petros, A. M.; Dinges, J.; Augeri, D. J.; Baumeister, S. A.; Betebenner, D. A.; 
Bures, M. G.; Elmore, S. W.; Hajduk, P. J.; Joseph, M. K.; Landis, S. K.; Nettesheim, D. G.; 
Rosenberg, S. H.; Shen, W.; Thomas, S.; Wang, X.; Zanze, I.; Zhang, H.; Fesik, S. W., J 
Med Chem, (2006) 49, 656. 
 
[153] Oltersdorf, T.; Elmore, S. W.; Shoemaker, A. R.; Armstrong, R. C.; Augeri, D. J.; 
Belli, B. A.; Bruncko, M.; Deckwerth, T. L.; Dinges, J.; Hajduk, P. J.; Joseph, M. K.; 
Kitada, S.; Korsmeyer, S. J.; Kunzer, A. R.; Letai, A.; Li, C.; Mitten, M. J.; Nettesheim, D. 
G.; Ng, S.; Nimmer, P. M.; O'Connor, J. M.; Oleksijew, A.; Petros, A. M.; Reed, J. C.; Shen, 
W.; Tahir, S. K.; Thompson, C. B.; Tomaselli, K. J.; Wang, B.; Wendt, M. D.; Zhang, H.; 
Fesik, S. W.; Rosenberg, S. H., Nature, (2005) 435, 677. 
[154] Veber, D. F.; Johnson, S. R.; Cheng, H. Y.; Smith, B. R.; Ward, K. W.; Kopple, K. 
D., J Med Chem, (2002) 45, 2615. 
 
[155] Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J., Adv Drug Deliv Rev, 
(2001) 46, 3. 
 
[156] Chan, S. L.; Lee, M. C.; Tan, K. O.; Yang, L. K.; Lee, A. S.; Flotow, H.; Fu, N. Y.; 
Butler, M. S.; Soejarto, D. D.; Buss, A. D.; Yu, V. C., J Biol Chem, (2003) 278, 20453. 
 
[157] Becattini, B.; Kitada, S.; Leone, M.; Monosov, E.; Chandler, S.; Zhai, D.; Kipps, T. 
J.; Reed, J. C.; Pellecchia, M., Chem Biol, (2004) 11, 389. 
 
[158] Kitada, S.; Leone, M.; Sareth, S.; Zhai, D.; Reed, J. C.; Pellecchia, M., J Med Chem, 
(2003) 46, 4259. 
 
[159] Mohammad, R.; Giri, A.; Goustin, A. S., Recent Pat Anticancer Drug Discov, 
(2008) 3, 20. 
 
[160] Nguyen, M.; Marcellus, R. C.; Roulston, A.; Watson, M.; Serfass, L.; Murthy 
Madiraju, S. R.; Goulet, D.; Viallet, J.; Belec, L.; Billot, X.; Acoca, S.; Purisima, E.; 
Wiegmans, A.; Cluse, L.; Johnstone, R. W.; Beauparlant, P.; Shore, G. C., Proc Natl Acad 
Sci U S A, (2007) 104, 19512. 
 
[161] Tse, C.; Shoemaker, A. R.; Adickes, J.; Anderson, M. G.; Chen, J.; Jin, S.; Johnson, 
E. F.; Marsh, K. C.; Mitten, M. J.; Nimmer, P.; Roberts, L.; Tahir, S. K.; Xiao, Y.; Yang, X.; 
Zhang, H.; Fesik, S.; Rosenberg, S. H.; Elmore, S. W., Cancer Res, (2008) 68, 3421. 
 
[162] Tang, G.; Yang, C. Y.; Nikolovska-Coleska, Z.; Guo, J.; Qiu, S.; Wang, R.; Gao, 
W.; Wang, G.; Stuckey, J.; Krajewski, K.; Jiang, S.; Roller, P. P.; Wang, S., J Med Chem, 
(2007) 50, 1723. 
 
56 
 
[163] Zhang, L.; Ming, L.; Yu, J., Drug Resist Updat, (2007) 10, 207. 
 
[164] Zhai, D.; Jin, C.; Satterthwait, A. C.; Reed, J. C., Cell Death Differ, (2006) 13, 1419. 
 
[165] Vogler, M.; Dinsdale, D.; Dyer, M. J.; Cohen, G. M., Cell Death Differ, (2009) 16, 
360. 
 
 
  
Chapter 2: 
Experimental Methods and 
Instrumentation 
 
 58 
 
2.0 Peptide Synthesis 
Peptides are synthesized by coupling the carboxyl group of one amino acid or C-
terminus of a peptide chain to the amino group of another amino acid or N-terminus of a 
peptide chain. Protecting groups for either the -amino or -carboxyl group and for 
functional side-chains are generally required due to the risk of side-reactions. Historically, a 
liquid phase approach has been used in peptide synthesis, but this has been replaced by the 
solid phase technique. The latter is now the preferred method for the synthesis of peptides, 
both for small scale (research) and large scale (manufacturing) synthesis. 
 
Solid Phase Peptide Synthesis (SPPS) was pioneered by Robert Bruce Merrifield.
[1]
 
Small insoluble solid polymer beads known as resin are modified with functional units on 
which peptide chains can be immobilised and elongated. The polymer remains insoluble but 
is solvated, allowing the reaction of the resin-bound amino acid / peptide with other reagents 
dissolved in the solution. The peptide will stay covalently bonded to the resin until cleaved 
from it by a reagent such as anhydrous hydrogen fluoride or trifluoroacetic acid. The peptide 
is retained on the solid-phase during a filtration process, allowing liquid-phase reagents and 
by-products of synthesis to be rinsed away. This is illustrated in Figure 2. 1 where alpha-
amino acid group is deprotected before coupling the next amino acid. 
 
The general principle of SPPS is one of recurring cycles of coupling-wash-
deprotection-wash. The free N-terminal amine of the resin is coupled to a single N-protected 
amino acid unit. This unit is then deprotected, revealing a new N-terminal amine to which 
another amino acid may be connected. The advantage of the SPPS partially lies in the ability 
of removing excess reagent by wash cycles after each reaction, with the growing peptide 
remaining covalently attached to the insoluble resin. 
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Figure 2. 1 General Scheme of SPPS 
 
There are two commonly used strategies of SPPS, Fmoc and Boc, depending on the 
temporary protection used for the -amino group (X in Figure 2. 1). For this thesis the 
Fmoc/t-Bu strategy was applied. The Fmoc strategy was applied for the following reasons; 
the repetitive TFA acidolysis required for Boc group deprotection may lead to alteration of 
sensitive peptide bonds as well as acid catalysed side-reactions. In the Fmoc strategy, the 
growing peptide chain is exposed to mild base conditions during Fmoc-group deprotection 
and TFA is only required for the final cleavage. In Figure 2. 2 the general orthogonal 
temporary and semi-permanent protections and cleavage strategy for Fmoc/t-Bu strategy is 
shown, where the side-chain deprotection of t-butyl-based groups and final cleavage from 
the resin is completed by acidic treatment (TFA) while the Fmoc group is removed by basic 
treatment (piperidine). In contrast the Boc strategy cleavage requires the use of highly 
corrosive HF and specialised laboratory apparatus that was not available.  An automated 
peptide synthesizer was available and was used in conjunction with manual synthesis. 
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Figure 2. 2 General protecting group and cleavage strategy of Fmoc chemistry 
 
2.1 Resins for solid phase synthesis 
 
Solid phase synthesis has many advantages over solution phase. Reactions can be 
driven to completion through the use of excess reagents, which can be conveniently 
eliminated after reaction by simple filtration and wash of the resin beads. The synthesis is 
highly amenable to automation. Combinatorial chemistry methods, enabling large numbers 
of compounds to be prepared simultaneously, are generally based on solid phase techniques, 
where single resin beads can function as mini reactors. A large variety of resins for solid 
phase synthesis is commercially available. The choice of the resin is dictated by the C-
terminus required (acid or amide) and the difficulty to assemble the sequence. For this thesis 
Rink amide MBHA resin, Nova PEG Rink Amide resin and a pre-loaded Wang resin were 
used, discussed further in Chapter 3. 
 
2.2 Protecting groups 
 
Amino acids have reactive moieties at the N- and C-termini, which facilitate amino 
acid coupling during synthesis. Several amino acids also have reactive side-chain functional 
groups, which can interact with free termini or other side-chain groups during peptide 
elongation and their reaction would negatively influence yield and purity. To prevent side-
chain reactivity, chemical groups have been developed to bind to specific amino acid 
functional groups and block, or protect, these groups from non-specific reactions. Amino 
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acids are purchased with these protecting groups prior to synthesis and then selectively 
removed during specific steps of peptide synthesis. 
 
The N-terminal protecting group used throughout this thesis is Fmoc. Cleavage of 
the Fmoc requires ~20% piperidine in DMF or NMP as shown in the scheme of Figure 2. 3.  
Because the liberated dibenzofulvene group is a chromophore, deprotection of Fmoc can be 
monitored by UV absorbance of the runoff, a strategy which is employed in automated 
synthesizers. Amino acids are added in excess to guarantee complete coupling during each 
synthesis step, and without N-terminal protection, polymerization of unprotected amino 
acids would occur, resulting in low peptide yield or synthetic failure.  
 
 
Figure 2. 3 Fmoc Cleavage 
 
Amino acid side-chains are a diverse range of functional groups and are potential 
sites of non-specific reactivity during peptide synthesis. Therefore various protecting groups 
are necessary that are usually based on the benzyl (Bzl) or tert-butyl (t-Bu) group. Side-
chain protecting groups are semi-permanent protecting groups, because they can endure the 
multiple cycles of chemical treatment during synthesis and are only removed during 
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treatment with strong acids after peptide synthesis is completed. This occurs during the 
cleavage step. 
 
2.3 Coupling Methods 
 
For the peptide bond formation, the carboxyl group of the N-protected amino acid 
requires activation for reaction with the amino group of another amino acid or of a peptide 
chain. In situ activating agents are widely accepted because they are easy to use, give fast 
reactions and are generally free of side-reactions. For this thesis, the coupling reagents used 
were phosphonium or uronium agents. In the presence of a tertiary base they convert 
protected amino acids into a variety of activated species.  
 
2.4 Microwave assisted peptide synthesis 
 
Since the first reports of microwave heating in the laboratory, more than 3500 
articles have been published in this fast moving and exciting field. However, there have been 
only very few reports on the use of microwave irradiation in combination with solid phase 
peptide synthesis. In 1991, Wang et al. described the use of microwave irradiation to 
increase coupling efficiency and reduce reaction time in SPPS.
[2] 
Several groups have since 
reported the synthesis of difficult peptide sequences using this technique, showing better 
results in term of yields and purities.
[3]
 In peptide synthesis, microwave irradiation has been 
used to complete long peptide sequences in high yields. It has also shown low degrees of 
racemisation and reduced aspartimide formation.
[4]
 The technique uses microwave 
irradiation and cooling simultaneously to keep the overall bulk temperature of the solution 
low, while allowing for maximum microwave energy input. Aggregation, a process of β-
sheet formation between resin-bound protected peptides which compromises the reactions 
required for sequence elongation, is lessened by microwave energy allowing for the 
possibility of longer peptide sequences assembly. 
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2.5 Instrumentation and Reagents 
2.5.1 Reagents and Solvents 
Material and reagents were of reagent grade purchased from commercial suppliers 
and were used without purification unless otherwise stated. Protected amino acids, HBTU, 
PyBOP and Rink-amide MBHA resin were obtained from Novabiochem (Merck 
Biosciences). HOBt was purchased from Iris Biotech GmbH. Synthesizer filters (in-line and 
reactor) and solvents (DCM, NMP) were obtained from Applied Biosystems. Other reagents 
and solvents were supplied by Sigma- Aldrich. 
 
2.5.2 Microwave Synthesis 
 
Microwave experiments were performed in a Biotage Initiator microwave equipped 
with pressure vessels and temperature and pressure controls.  
 
2.5.3 Nuclear Magnetic Resonance (NMR) Spectroscopy 
 
1
H NMR spectra were determined at 400MHz with a BRUKER NMR spectrometer. 
The chemical shift values are expressed in δ values (parts per million). Coupling constants 
(J) are in Hertz and are corrected to the nearest 0.5 Hz. Multiplicities are reported as follows: 
s, singlet, d, doublet, dd, double doublet, t, triplet, q quartet, m, multiplet and br broad. 
1
H 
NMR spectral assignments are supported by 
13
C-
1
H COSY. Samples were prepared in 
CDCl3 (referenced to 7.26ppm for 
1
H and 77.0 for 
13
C) and DMSO-d6 (referenced to 
2.50ppm for 
1
H and 40.45 for 
13
C) All NMR spectra were processed and analysed using 
Topspin NMR software. 
 
2.5.4 Thin Layer Chromatography 
 
Thin layer chromatography (TLC) was performed on glass silica gel (Merck, 250 
μm thickness) plates. These were then immersed in a beaker containing mobile phase of 
interest and analysed under UV light (254 and 365 nm). 
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2.5.5 Mass Spectrometry Analysis 
2.5.5.1 Matrix Assisted Laser Desorption Ionisation-time of flight 
 
The mass spectrometry analyses were performed on a LaserToF by Matrix Assisted 
Laser Desorption Ionisation-time of flight (MALDI-TOF). α-cyano-4-hydroxy cinnamic 
acid matrix, dissolved in 1:1 H2O containing 0.1% TFA : CH3CN containing 0.1% TFA, at a 
concentration of 10mg/ml, was used. Two microliters of 1:1 solution of peptide to matrix 
were applied to the MALDI plate.  
 
2.5.5.2 Electrospray ionization (ESI) 
 
Mass spectrometry experiments were carried out using a Bruker Esquire LC_00050 
electron spray interface (ESI) with a positive ion polarity. Samples were dissolved in HPLC 
grade methanol/ acetonitrile or de-ionised water. 
 
2.5.6 Elemental Analysis  
 
Elemental analyses were carried out on an CE440 Elemental Analyser at the School 
of Pharmacy in RCSI. (Conducted by Senior Technician, Ms. Suzanne Donnelly). 
 
2.5.7 Absorption Spectroscopy 
 
UV-Vis spectra were recorded on a Varian Cary 50 spectrophotometer. Samples 
were analysed in a quartz cuvette with a path length of 1 cm with a spectral range of 200-
800 nm unless otherwise stated. The background was corrected for the absorption of the 
buffer prior to every measurement and was performed at room temperature.  
 
2.5.8 Fluorescence Spectroscopy 
 
Emission spectra were recorded on a Varian Cary Eclipse fluorescence 
spectrophotometer with an excitation slit width of 5 nm and an emission slit width of 5 nm 
unless otherwise stated. All experiments were performed using a 1 cm path length quartz 
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cuvette. The background was corrected for blank solvent fluorescence prior to each 
measurement and was performed at room temperature. 
 
2.5.9 Lifetime Measurements 
 
Luminescent lifetimes were obtained using a Picoquant Fluotime 100 TCSPC (Time 
Correlated Single Photon Counting) system exciting at 450 nm and using a 510 nm narrow 
band pass dielectric filter for ruthenium complexes.  5,000 counts were collected for each 
lifetime measurement and all measurements were performed in triplicate using Nanoharp 
software to confirm results. Typical pulse rates of the excitation source were 1x10
5
 s
-1
 with 
typical pulse widths of 300 ps. Degassed samples were degassed with nitrogen for 20 
minutes prior to analysis.  
 
The calculation of the luminescent lifetimes was performed by fitting an exponential 
decay function to each decay plot to extract the lifetime information using FluoFit software. 
Due to the inherently long lifetimes of inorganic complexes all data were fitted to mono 
exponential decay functions to the baseline of the decay curve using tail-fit with an x2 value 
of between 0.9-1.1. 
 
2.5.10 Freeze Drier 
 
The freeze drier used was an EC Modulyo system. Prior to placement on the freeze 
drier, all samples were dissolved or dispersed in deionised water and fully frozen in liquid 
nitrogen. The samples were then left on the freeze drier overnight.  
 
2.5.11 Confocal Fluorescence Microscopy 
 
Confocal fluorescence microscopy is an imaging technique that performs a point-by-
point image construction by focusing a point of light sequentially across a specimen to 
eliminate out of focus light in samples that are thicker than the focal plane as outlined in 
chapter 1. Luminescent images were recorded using with a Zeiss LSM510 Meta confocal 
microscope using a 63x oil immersion objective lens (NA 1.4). The 458 nm argon ion laser 
excitation was used for ruthenium samples. The luminescence from ruthenium was collected 
using 560 nm long pass filters. (Conducted by Research Engineer, Dr. Roisin Moriarty) 
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2.5.12 Cell Culture 
 
Chinese hamster ovarian (CHO) (CHO-K1, ATCC no. CCL-61) were purchased 
from ATCC Cell Biology Collection (UK). The adherent cell line CHO were grown in 
DMEM/Hams F-12 supplemented with 10% foetal calf serum (Biosera) at 37 °C with 5% 
CO2. Cells were harvested or split when they reached 90% confluency for CHO cells.  
 
The SK-N-AS and Kelly neuroblastoma cell line were a kind gift from Prof. Ray 
Stallings.  (Conducted by Dr. Roisin Moriarty, Research Engineer, DCU) 
 
2.5.13 Cellular Uptake of Complexes 
 
In order to assess and compare the ability of the compounds to transport across the 
cell membrane, CHO cells were cultured on 35 mm glass bottom culture dishes. CHO cells 
were harvested after trypsinisation (0.25% trypsin for 5 mins at 37 °C) and seeded at 8 x 10
4
 
cells in 2 ml media. Cells were grown for 24 hours before imaging. For confocal 
measurements the growth medium was removed by washing with PBS buffer (pH 7.4) and 
dye-peptide (40 μM final concentration) in PBS (pH 7.4, with MgCl2 and CaCl2) was added.  
 
The cell lines used throughout this thesis are CHO cell line and Kelly neuroblastoma 
cell line. Chinese hamster ovary (CHO) cells are epithelial cells which grow as an adherent 
monolayer in culture in many academic research laboratories. Furthermore, they are the most 
widely used mammalian cells for transfection, expression and protein production.  
 
The Kelly neuroblastoma cell line is predominantly neuroblastic and therefore a 
good model of neuroblastoma. The SK-N-AS neuroblastoma cell line is derived from a 
female patient with neuroblastoma from the metastasis of the bone marrow. (Conducted by 
research engineer, Dr. Roisin Moriarty) 
 
 67 
 
2.5.14 Cytotoxicity Assay 
 
Cells were seeded in a 96-well plate in 100 μl of media for 24 hours at 37 °C with 
5% CO2 before addition of compounds. CHO cells at 1 x 10
4
 cells per well. 10 μl of 
resazurin reagents (PromoKine) were added and incubated for 7 hours for resazurin at 37 °C. 
The resazurin converted to resorufin in viable cells was detected at absorbance 570 nm with 
background subtracted at 600 nm. Absorbance readings were performed using a Tecan 96-
well plate reader. All cytotoxicity experiments are reported in terms of % cytotoxicity, e.g. 
100% cytotoxicity = 100% of cells non-viable and carried out in triplicate (n=3 ± SD). 
(Conducted by research engineer, Dr. Roisin Moriarty) 
2.6 Peptide Synthesis 
2.6.1 Automatic Peptide Synthesis 
   
Syntheses were carried out by automated Standard Solid Phase Peptide Synthesis 
(SPPS), performed on an Applied Biosystem ABI 433A Synthesizer (Warrington, UK). 1 
mmol (10 fold molar excess) quantities of each protected amino acids were used. The amine 
group on the resin is Fmoc protected initially but is available for amino acid coupling at the 
start of the synthesis, as a result of piperidine (20% in NMP) deprotection.  The peptide was 
elongated from the C-terminus (amide functional group) to the N-terminus (amino group). 
The sequence was assembled with monitoring of the Fmoc deprotection by UV absorption at 
301nm.  
 
2.6.2 Manual Coupling 
 
Manual peptide synthesis is used to elongate difficult sequences and to reduce the 
quantities of valuable reagents required for the labelling of peptides. The resin was placed 
into a 5ml syringe fitted with a Teflon filter and a stopcock. The resin was swelled for 1hour 
in NMP. Coupling reagents HBTU and HOBt, or PyBOP, and HOBt were used in 4.5 molar 
equivalents to the resin. The molecule to be coupled is used in 4.5 molar equivalents to the 
resin and DIEA is used in 10 molar equivalents. The coupling reagents and the protected 
amino acid are dissolved in 4ml of DMF and then DIEA is added. The solution is then added 
to the syringe and placed on the shaker for 4 hours. The resin is filtered and then washed 
consecutively twice with NMP and then a third time with DCM (3 x 5 ml aliquots for each 
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solvent, with 2 minutes agitation).  An aliquot of the resin was then analysed to confirm that 
the coupling was complete using the qualitative Kaiser test.  The Kaiser test is a colorimetric 
test for the presence of a primary N-terminal amino group on the peptide. It is based on the 
reaction of ninhydrin with amino groups to form an adduct characterised by a blue colour.  
Therefore, an incomplete coupling cycle will lead to a positive Kaiser test, confirmed by the 
development of a blue colour, while complete coupling will produce a negative 
(yellow/clear) coloured test.   
 
 
2.6.3 Microwave Coupling 
 
The microwave synthesizer (Biotage Initiator 2.5) was used to couple amino acids in 
a difficult sequence. This technique is used when other coupling techniques have been 
exhausted. The resin is swelled for 1 hour in NMP prior to using the microwave synthesizer. 
Coupling reagents HBTU and HOBt, or PyBOP and HOBt are used together in 5 molar 
equivalents to the resin. The protected amino acid is used in 5 molar equivalents to the resin 
and DIEA is used in 10 molar equivalents. The coupling reagents and the protected amino 
acid are dissolved in 4ml of NMP and then DIEA is added. The resin is placed in the 
microwave vial 2-5ml with the corresponding stirrer. The coupling reagents are then added 
to the vial and the vial is then sealed. The vial is placed in the port in the synthesizer using 
the correct adapter for the vial size used. 
Coupling reactions took place for 5 minutes at 50°C with pre-stirring for 30 seconds and 
with fix hold time on. Absorption level was set to high as NMP was the solvent used. 
 
2.6.4 Manual Deprotection 
 
Manual deprotection was used after manual coupling to remove the Fmoc group. If 
the resin is not already swelled, then it should be swelled for 1hour in DMF before 
deprotection. Manual deprotection took place in the syringe fitted with the filter. 20% 
piperidine in DMF (v/v) is added to the syringe and placed on the shaker for 10-15 minutes. 
The syringe is then drained and 20% piperidine in DMF (v/v) is added again and shaken for 
a further 10 minutes. This step is repeated and monitored by a positive Kaiser test as 
described above. 
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2.6.5 Microwave deprotection 
 
The microwave synthesizer (Biotage Initiator 2.5) was used to deprotect the Fmoc 
group when vortexing at room temperature had been attempted without success for the 
deprotection reaction. The resin and the stirring bar is added to a 2-5ml vial and placed in 
the synthesizer port. 
Deprotection reactions took place for 2 minutes at 50°C with pre-stirring for 30 seconds; fix 
hold time on and absorption were set to high.  
 
2.6.6 Cleavage 
 
The cleavage procedure was used to remove the peptide form the resin and deprotect 
the amino acid side-chains once assembly of the sequence is complete. The resin (188mgs, 
substitution 0.53mmol/g) was placed in a test tube with a magnetic stirrer and the cleavage 
cocktail was added. A cleavage cocktail consisting of 4 ml of trifluoroacetic acid (TFA 80%) 
was used, while scavenging of the cationic species formed from the protecting groups was 
achieved by using the following reagents – 250 l of water (5%), 250 l of triisopropylsilane 
(TIS or TIPS, 5%), 250 l of thioanisole (TA, 5%), 250 l of 1,2-ethanedithiol (EDT, 5%). 
The cleavage cocktail is made up freshly in a separate centrifuge tube and added altogether 
to the test tube. The mixture is let stir for 2 hours with an additional half an hour for each 
arginine residue present in the sequence (with a maximum of 4 hours).   
 
After stirring the solution was filtered into a plastic centrifuge tube using a teflon 
tube fitted with a filter. To the centrifuge tube, diethyl ether (~10ml) is added (to precipitate 
the peptide). The centrifuge tube can then be placed in the freezer for 5-10 minutes to aid the 
precipitation process. The product is centrifuged for five minutes at 2.8  103 rpm.   The 
acidic liquid was drained off and disposed of carefully. The peptide was then washed twice 
using 15 ml of ether each time before being air dried for 1hr. The product was lyophilised 
overnight using a Thermo Electron Corporation, Modulyop-230 Freeze Dryer. 
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2.6.7 HPLC Analysis of Peptides 
 
Chromatographic analyses were carried out on a Varian HPLC Chromatography 
Workstation using Gemini (C-18) reverse-phase chromatography column obtained from 
Phenomenex. The Gemini C 18 (250mm x 2.5 mm) was used at 1ml.min
-1
 with linear 
gradient programs. UV was monitored at 214nm unless otherwise indicated and for dye-
peptide conjugates at dual wavelength of 214nm and 452nm. Solvent A consisted of H2O 
containing 0.1% TFA and solvent B of CH3CN containing 0.1% TFA. The gradient ran over 
30 min going from 5% to 65% of buffer A. 
 
 
2.6.8 HPLC Purification of Peptides 
 
Reverse Phase Purifications were carried out on a PerSeptive Biosystems BioCAD 
SPRINT using a semi preparative column Gemini (C-18) reverse-phase chromatography 
column obtained from Phenomenex. The Gemini C 18 (250mm x 10 mm) column was used 
at 4ml.min
-1
 with linear gradient programs. UV was monitored at 214nm unless other wise 
indicated and for dye-peptide conjugates at dual wavelength of 214nm and 452nm. Solvents 
were degassed using Helium for 20 minutes. Solvent A consisted of H2O containing 0.1% 
TFA and solvent B of CH3CN containing 0.1% TFA. The gradient ran over 30 min going 
from 5% to 65% of buffer A. 
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3.1 Introduction 
A major barrier to the application of inorganic chromophores in cell imaging to date 
has been the inability of such materials to passively diffuse across a cell membrane without 
membrane permeabilisation. The comparatively low cationic charge associated with many of 
these metal complexes means that they are unable to successfully use the cell’s membrane 
potential as means for cellular entry. Reported methods for permeabilisation include 
electroporation, the use of organic solvents and detergents; all of them potentially affect the 
cell viability.
[1]
  
 
However, research published by our group 
[2, 3]
 established that conjugation of a 
metal complex to a CPP can assist in the efficient translocation of the luminescent probe 
across mammalian cell membranes without destroying the lipid bilayer and without the need 
for permeabilisation. Additionally, once inside the cytoplasm, the environmentally sensitive 
photophysics and spectroscopic properties of the dye-peptide may be exploited to report on 
the intracellular environment. Chapter 1 reviewed examples where localising peptides have 
been used for the internalisation of inorganic luminophores into cellular structures for live 
cellular imaging and the processes by which these biomolecules are uptaken by the cell. 
 
The aim of this chapter was first the synthesis of a range of peptide-probe conjugates 
and then to evaluate their application in delivery of the Ru centre to the nucleus. The 
environmentally sensitive ruthenium polypyridyl peptide conjugates, were investigated as a 
membrane permeable, oxygen sensitive, probe in myeloma cells, and the labelling of the 
peptide sequences preferentially localising to the nucleus was also investigated. 
 
This chapter details the synthesis of ruthenium (II) inorganic metal luminophores 
conjugated to nuclear localisation peptides and the preliminary studies on cell imaging. As 
discussed in Chapter 1, metallo dye-peptide conjugates hold significant potential for use as 
molecular probes in multimodal cellular imaging. Due to their large Stokes shifts, 
photostability, long aqueous lifetimes and pH / oxygen sensitivity, these conjugates can label 
cells / sub-cellular structures. As outlined in Chapter 1, the interaction of Ru chromophores 
with DNA needs to be targeted to the nucleus if used for a therapeutic context. This may 
prove very valuable as they can sensitize photodamage to DNA and can have potential 
therapeutic use if delivered to the nucleus of, for example, cancer cells. Additionally, the 
intrinsic photophysical properties of these metal complexes, with their triplet excited states 
allowing for the generation of singlet oxygen and other reactive oxygen species may lead to 
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induced apoptosis in cells, thus, making these dye-peptides potentially valuable in the area 
of photodynamic therapy. 
 
The  supramolecular assemblies synthesized were prepared in a similar way to 
previously reported methods developed by Cosgrave et al. 
[3]
 The precursor  Ru(II) 
polypyridal complexes were supplied by Ciaran Dolan and Kellie Adamson (Dublin City 
University). The peptide N-terminally modified with a β-alanine spacer was then prepared 
by Merrifield’s Solid Phase Peptide Synthesis.[4] The novel complex [Ru(dpp)2PIC]ClO4 is 
based on the related ruthenium complex [Ru(bpy)2(pic)]
2+
 where pic is 2-(4-
carboxyphenyl)imidazo[4,5-f][1,10]phenanthroline, bpy is 2,2-bipyridine, dpp is 4,7-
diphenyl-1,10-phenanthroline. Conjugation to the peptide occurs through the aromatic 
carboxyl group. The coupling reaction was performed on the side-chain protected resin-
bound peptide.  
 
3.2 Experimental Details for the Synthesis of targeting peptides-dye 
conjugates 
3.2.1 Preparation of Ru (dpp)2PIC- βAla- NF-κB (-VQRKRQKLMP-NH2) 
conjugate. 
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Synthesis of βAla- NF-κB (-βAla -VQRKRQKLMP-NH2) took place on an 
automated synthesizer by standard SPPS using 0.1mmol of Rink Amide Resin (substitution 
0.7mmol/g). Manual coupling of [Ru(dpp)2PIC]ClO4 (supplied by DCU) took place by solid 
phase synthesis using PyBOP/HOBt (3eq) / DIEA (6eq) coupling chemistry overnight.  The 
peptide was cleaved by standard methods and then purified as usual by RP-HPLC. Fractions 
collected by semi-preparative HPLC were analysed by mass spectrometry and analytical 
HPLC.  
 
Purity 97% (Appendix Figure 1). 
MALDI-MS 2440.46 [M+1]
+
 calculated for C126H150N30O14RuS 2439.95 (Appendix Figure 
2). 
Experiment Number: LB-3-05 
 
 
3.2.2 Preparation of Ru(bpy)2PIC-βAla-NF-κB (-VQRKRQKLMP-NH2) 
conjugate. 
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The βAla-NF-κB (βAla -VQRKRQKLMP-NH2) peptide was assembled using 
0.1mmol of Rink Amide Resin (substitution 0.7mmol/g) on the automated synthesizer as 
previously described. Manual coupling of [Ru(bpy)2PIC] ClO4 (supplied by DCU) to the 
resin-bound peptide took place overnight using PyBOP/HOBt (3eq) / DIEA (6eq) coupling 
chemistry.  The peptide was cleaved by standard methods and then purified as usual by RP-
HPLC. Fractions collected by semi-preparative HPLC were analysed by mass spectrometry 
and analytical HPLC.  
 
Purity 98% (Figure 3.1). 
m/z=1044.64  (100%, [M +2 H]
2+
) calculated for C98H134N30O14RuS 2088.95 (Appendix 
Figure 3). 
Experiment Number: LB-1-05 
 
 
Figure 3. 1: Purity of Ru(bpy)2PIC-βA-NF-κB (-VQRKRQKLMP-NH2) conjugate 
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3.2.3 Preparation of Ru(dpp)2PIC-Ahx-NF-κB (-VQRKRQKLMP-NH2) conjugate. 
 
 
The peptide NF-κB (Ahx-VQRKRQKLMP-NH2) was assembled using 0.1mmol of 
Rink Amide Resin (substitution 0.7mmol/g) by automated synthesis as previously described. 
Manual coupling of [Ru(dpp)2PIC]ClO4 (supplied by DCU) took place on the resin using 
PyBOP/HOBt (3eq) / DIEA (6eq) coupling chemistry with overnight shaking.  The peptide 
was cleaved by standard methods and then purified as usual by RP-HPLC. Fractions 
collected by semi-preparative HPLC were analysed by mass spectrometry and analytical 
HPLC.  
 
Purity 96% (Appendix Figure 4) 
HRMS m/z: found 833.70[M + 3H]
3+
, calculated for C129H156N30O14RuS 2493.94  (Figure 3. 
2). 
Experiment Number: LB-2-72  
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Figure 3. 2: Mass Spectra of the [Ru(dpp)2PIC] ClO4 - NF-κB (Ahx-VQRKRQKLMP-NH2) 
conjugate 
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3.2.4 Preparation of Ru(bpy)2PIC-Ahx-NF-κB (-VQRKRQKLMP-NH2) conjugate. 
 
 
 
The peptide βAla NF-κB (βAla -VQRKRQKLMP-NH2)  was assembled using 
0.1mmol of Rink Amide Resin (substitution 0.7mmol/g) on an automated synthesizer as 
previously described. Manual coupling of [Ru(bpy)2PIC]ClO4 (supplied by DCU) took place 
by solid phase synthesis, using PyBOP/HOBt (3eq) / DIEA (6eq) coupling chemistry with 
overnight shaking.  The peptide was cleaved by standard methods and then purified as usual 
by RP-HPLC. Fractions collected by semi-preparative HPLC were analysed by mass 
spectrometry and analytical HPLC.  
 
Purity 85% (Appendix Figure 5) 
MALDI-MS 2130.99 [M+1]
+
 calculated for C101H140N30O14RuS 2129.714 (Appendix Figure 
6). 
Experiment Number: LB-2-71 
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3.2.5 Preparation of Ru(dpp)2PIC –Ahx- Sv-40 (-PKKKRKV-NH2) conjugate. 
 
 
The Ahx- Sv-40 (Ahx -PKKKRKV-NH2) peptide  was assembled from a Rink 
Amide Resin (0.1 mmol scale, substitution 0.7mmol/g) by automated synthesis as previously 
described. Manual coupling of [Ru(dpp)2PIC]ClO4 (supplied by DCU) to the resin-bound 
peptide using PyBOP/HOBt (3eq) / DIEA (6eq) coupling chemistry was performed by 
overnight reaction.  The peptide was cleaved by standard methods and then purified as usual 
by RP-HPLC. Fractions collected by semi-preparative HPLC were analysed by mass 
spectrometry and analytical HPLC.  
 
Purity 89% (Appendix Figure 7) 
HRMS m/z: found 1041.48 [M + 2H]
2+
, calculated for C114H132N24O9Ru 2083.96 (Figure 3. 
3). 
Experiment Number: LB-2-83 
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Figure 3. 3: Mass Spectra of Ru(dpp)2PIC –Ahx- Sv-40 (-PKKKRKV-NH2) conjugate 
 
3.2.6 Preparation of Ru(bpy)2PIC –Ahx- Sv-40 (-PKKKRKV-NH2) conjugate. 
 
 
 The Ahx- Sv-40 (Ahx -PKKKRKV-NH2) peptide was assembled using 0.1mmol of 
Rink Amide Resin (substitution 0.7mmol/g) and took place on the AB 433A synthesizer as 
previously described. Manual coupling of [Ru(bpy)2PIC]ClO4 (supplied by DCU) took place 
on the resin using PyBOP/HOBt (3eq) / DIEA (6eq) coupling chemistry with overnight 
shaking.  The peptide was cleaved by standard methods and then purified as usual by RP-
HPLC. Fractions collected by semi-preparative HPLC were analysed by mass spectrometry 
and analytical HPLC.  
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Purity 96% (Figure 3. 4) 
HRMS m/z: found 865.422 [M + 2H]
 2+
, calculated for C86H116N24O94Ru 1730.84 (Appendix 
Figure 8). 
Experiment Number: LB-2-82 
 
Figure 3. 4 Purity of Ru (bpy)2 PIC –Ahx- Sv-40 (-PKKKRKV-NH2) conjugate 
 
 
 
3.3 Results and Discussion 
 
Synthesis 
 
Six novel Ru II polypyridyl peptide conjugates were synthesised by standard SPPS. 
Rink amide MBHA resin, a common cross-linked polystyrene support for the synthesis of 
peptide amides was chosen for several reasons. NLS sequences do not require a C-terminal 
carboxyl group and can be prepared as peptide amides. The latter are more conveniently 
synthesised than peptide acids and are moreover more resistant to proteolytic degradation 
mediated by exopeptidases. The peptide was elongated from the C-terminus to the N-
terminus, as traditionally performed in solid phase synthesis to prevent racemisation and was 
therefore modified at its N-terminus with the ruthenium label. Assembly of the peptide 
sequence and elongation with a (2 or 5 carbon) linker was performed by automated 
synthesis, with final N-terminal deprotection. The resin-bound peptide was then transferred 
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to a fritted funnel for manual coupling of the Ru II polypyridal complex. The latter 
contained a PIC ligand which had a carboxy functional group, allowing therefore its 
conjugation to the peptide through a stable amide bond. The conjugation of the chromophore 
to the peptide was performed by solid phase synthesis as shown in  
Figure 3. 5. PyBOP was chosen as the coupling reagent over HBTU as previous in-
house labelling studies had shown the superiority of the phosphonium reagent over the 
uronium reagent for the amidation of peptides with a chromophore. Due to the limited 
amount of Ru (II) complexes available, only 3 equivalents of the Ru (II) complexes to the 
resin were used in comparison to the 10 equivalents of each amino acid used by the 
synthesizer.  
 
 
Figure 3. 5 Schematic of Ru (II) polypyridyl complex conjugation to a peptide 
 
 
Cleavage of the Ru (II) polypyridal peptide conjugates from the resin took place by 
treatment with TFA in the presence of scavengers. High concentrations of TFA are used for 
Rink Amide resins. Optimum cleavage conditions are very much dependent on the 
individual amino acid residues present in the peptide sequence, the side-chain protecting 
groups and the type of linker attached to the resin. Small scale cleavages, between 30-50mg 
of resin were carried out to determine the optimum cleavage conditions and to assess the 
integrity of the conjugate by mass spectrometry. TFA/TIS/Water/TA/EDT (80:5:5:5:5) was 
generally used as the cleavage cocktail. The benzhydryl linkage of the Rink Amide resin is 
acid sensitive and can be broken, resulting in coloured bi-products which are not easily 
removed from the product by simple washes. This can be overcome by using silane 
scavengers such as triisopropylsilane (TIS). Methionine, cysteine and tryptophan are 
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extremely susceptible to alkylation by cations produced during the cleavage process. 
Reaction of these amino acids with t-butyl cations results in modification of the product 
peptide. By adding scavengers to the cleavage mixture these side-reactions can be largely 
suppressed. The most commonly used scavenger is EDT. It is an extremely good scavenger 
of t-butyl cations; it assists in the removal of the trityl protecting group from cysteine and 
can effective in preventing the acid-catalysed oxidation of methionine and cysteine residues.  
Thioanisole (TA) can also help with suppressing acid-catalysed oxidation of methionine. 
The oxidation of methionine can also be minimized by carrying out the reaction cleavage 
under nitrogen; this procedure was used for peptides containing a methionine residue. The 
cleavage times varied from 2-4 hours depending on of the number of arginine residues in the 
sequence. The Pbf group used to protect the guanidino group of arginine requires extended 
deprotection times. Therefore if the sequence contained no Arg residues, the cleavage times 
were 2 hours and increased by 30 mins for every Arg residue with a maximum cleavage time 
of 4 hours. After this time the TFA could potentially break down the peptide chain.  The 
polypyridyl peptide conjugate was precipitated by addition of diethyl ether and then 
lyophilised before purification.  
 
Semi-preparative HPLC on a reverse phase polymeric support was used to achieve 
purities of the metal complex metal conjugates >85%. The selection of the stationary phase 
for the column was guided by the length of the peptide and the hydrophobicity of its 
conjugate. In the case of the Ru (II) polypyridal peptide conjugates, C18 packings were 
suitable. A water/ACN gradient with TFA as the acidic ion pairing reagent was used. 
Monitoring was performed using UV-VIS detector at wavelengths of 214nm for the amide 
bond and 452nm for the Ru (II) polypyridal complex.  The pure Ru (II) polypyridal peptide 
conjugates were then re-lyophilized and stored in the freezer until use. The Ru (II) 
polypyridal peptide conjugates were characterised by mass spectroscopy. The isotopic 
distribution of Ru is shown in the mass spectrums in Figure 3.2 and Figure 3.3. 
 
  The NF-κB sequence, VQRKRQKLMP, was chosen first as this had shown ability 
to import conjugated fluorescein to the nucleus in previous reports.
[5, 6]
 However, this peptide 
was prone to oxidation as seen in Figure 3. 6. A minor signal at 2090.6522 represents the 
non-oxidised peptide whereas the larger signal at 2105.447 represent the oxidised peptide 
with an increased mass of 16. It is likely that this oxidation occurred at the methionine (M) 
residue in the sequence, either during a post-synthetic (cleavage and/or purification) step. 
Methionine oxidation is discussed further in Chapter 4. This NF-κB conjugate was 
synthesised again with the cleavage taking place under nitrogen and with careful 
purification. The non-oxidised peptide was successfully isolated under these conditions and 
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used for testing. This led us to seek out an NLS sequence that did not have a residue prone to 
oxidation, such as methionine or cysteine, and with the SV-40 sequence was therefore 
selected. The synthesis and purification of the SV-40 peptide and its conjugates led to no 
difficulties. 
 
 
 
Figure 3. 6 MALDI-TOF of NF-κB (βAla-VQRKRQKLMP-NH2) [Ru (bpy)2 PIC] ClO4 
conjugate using α-cyano-4-hydroxycinnamic acid matrix. 
 
 
Mass spectrometry and HPLC analysis were used routinely to confirm the purity of 
the chromophore peptide conjugates. The ruthenium (II) polypyridyl chromophores used 
were conjugated through a single reactive carboxyl group on the hetero ligand with the 
amino functionality on the protected peptide while on the resin. As a consequence of the 
selective coupling reactivity they normally do not contain isomers or other competing 
functional groups that may in turn lower the synthetic yields. 
 
Mass spectra of the chromophore-peptide conjugates are reported in Section 3.2 and 
the Appendix. The purity of these conjugates was confirmed by HPLC analysis, their 
chromatograms showing a single peak. Their retention times, obtained under HPLC 
conditions as set out in the Chapter 2, are reported in Table 3.1. It is noted that the more 
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hydrophobic [Ru (dpp)2 PIC] 
2+
 polypyridyl peptide conjugates have longer retention times 
than the [Ru (bpy)2 PIC]
2+
 polypyridyl peptide conjugates as expected by RP-HPLC. As seen 
in Table 3.1 the retention times of Ru (dpp)2 PIC polypyridyl peptide conjugates are 
approximately 30 minutes whereas the Ru (bpy)2 PIC polypyridyl peptide conjugates are 
approximately 19 minutes. On a reverse phase C18 column the more hydrophobic 
conjugates would have a stronger affinity for the hydrophobic stationary phase and remain 
on the column for longer until the gradient has a high enough concentration of the organic 
solvent to elute the molecule.  
 
The integrity of these supramolecular assemblies was investigated with 2 different 
bridging linkers. There was no significant difference in photophysical or localising 
properties of the conjugates, between β-Ala, the 2 carbon linker or 6-amino-hexanoic acid, 
the 5 carbon linker, consistent with supramolecular linkers which do not influence extra 
electronic communication between A and B. Conjugation of the ruthenium (II) dye to the 
peptide did not cause any significant alterations to the wavelength of absorbance and 
emission of the conjugate when compared to the parent chromophores. There was an 
increase of the absorbance between 250-300nm due to the peptide conjugation system. 
 
 
Table 3.1 Synthesised peptide-linker-chromophores with % purities and retention times 
Experiment 
number 
Peptide Linker Chromophore 
Retention 
Time 
% 
Purity 
Experimental 
Mass (Da) 
LB-2-71 NF-κB Ahx [Ru(bpy)2PIC]ClO4  19.8 83 2130.99 
LB-2-72 NF-κB Ahx [Ru(dpp)2PIC]ClO4  29.2 96 2497.11 
LB-2-82 SV-40 Ahx [Ru(bpy)2PIC]ClO4  18.4 96 1728.84 
LB-2-83 SV-40 Ahx [Ru(dpp)2PIC]ClO4  29.1 89 2082.96 
LB-1-05 NF-κB β-Ala [Ru(bpy)2PIC]ClO4  18.1 98 2089.28 
LB-3-05 NF-κB β-Ala [Ru(dpp)2PIC]ClO4  32.1 97 2440.46 
 
3.4 Photophysical Characterisation of Peptide-Chromophore 
Conjugates 
 
The spectroscopic and photophysical data of all ruthenium complexes synthesised 
are presented in Table 3.2. The UV-VIS wavelengths in Table 3.2 are for the MLCT and the 
emission is the phosphorescence when excited at this wavelength. The luminescent decays 
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are monoexponential kinetics, recorded in aqueous solution at room temperature. The 
deaerated samples were bubbled with nitrogen for ~20 minutes before lifetime 
measurements were recorded. The deaerated lifetimes are longer than the aerated, and also 
noted is that the [Ru (dpp)2 PIC]
2+
 polypyridyl peptide conjugates lifetimes are longer than 
those for [Ru (bpy)2 PIC]
2+
 polypyridyl peptide conjugates. This is due to the collision 
quenching of the triplet MLCT interaction with the triplet oxygen state. [Ru (bpy)2 PIC]ClO4 
is less rigid than [Ru (dpp) 2 PIC]ClO4 making it less oxygen sensitive and therefore with a 
shorter lifetime than [Ru(dpp)2PIC]ClO4. The increase in lifetime in absence of oxygen is 
also indication of the triplet MLCT character of the emission.
[7]
  
 
 
Table 3.2 The spectroscopic and photophysical data of all ruthenium complexes synthesised 
Peptide Linker Dye 
UV-VIS 
(nm) 
Emission 
(nm) 
Lifetimes 
Deaerated 
(µs) 
Lifetimes 
Aerated 
(µs) 
NF-κB Hex-acid [Ru(bpy)2PIC]ClO4 455 607 0.89±0.02 0.47±0.03 
NF-κB Hex-acid [Ru(dpp)2PIC]ClO4 456 613 3.63±0.04 0.73±0.02 
SV-40 Hex-acid [Ru(bpy)2PIC]ClO4 458 608 0.81±0.03 0.70±0.04 
SV-40 Hex-acid [Ru(dpp)2PIC]ClO4 457 618 5.33±0.02 0.24±0.03 
NF-κB β-Ala [Ru(bpy)2PIC]ClO4 462 607 0.94±0.02 0.80±0.03 
NF-κB β-Ala [Ru(dpp)2PIC]ClO4 460 614 3.72±0.04 0.49±0.02 
Parent - [Ru(bpy)2PIC]ClO4 455 606 1.02±0.02 0.16±0.03 
Parent - [Ru(dpp)2PIC]ClO4 466 614 2.40±0.03 0.20±0.04 
 
 
3.4.1 Absorbance 
 
Below in Figure 3. 7, the overlaid UV-VIS absorbance spectra are shown for the 
ruthenium (II) polypyridal peptide conjugates synthesised. The electronic spectra of all six 
complexes are distinguished by a ruthenium π to ligand π* MLCT transition at ~460 nm 
(individual values shown in Table 3.2). There is also evidence of a further MLCT transition 
within the [Ru(bpy)2PIC]ClO4 conjugates at approximately 245nm. The strong absorbance 
band at approximately 285 nm may be assigned to π-π* transitions within the polypyridal 
ligands, whereas the shoulder at approximately 330 nm is attributed to the π-π* transitions of 
the carboxy-phenylphenatroline ligands containing the two ionisable protons on the 
imidazole ring. The carbon spacers have little effect on the absorbance spectra of the 
complex. There is an increase in the absorbance of the conjugates compared to the parent 
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complexes between 270-300nm due to the conjugation in the peptide. The absorbance 
profile of these conjugates are almost identical to those of their parent complexes 
[Ru(bpy)2PIC]ClO4 and [Ru(dpp)2PIC]ClO4 indicating little electronic contribution induced 
by the peptide or the linker. 
 
 
 
Figure 3. 7 Overlaid absorbance of the synthesised chromophore-peptide conjugates and parent 
complexes in water (a) [Ru(bpy)2PIC]ClO4 parent complex and corresponding chromophore-
peptide conjugates (b) [Ru(dpp)2PIC]ClO4 parent complex and corresponding chromophore-
peptide conjugates. 
(a) 
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3.4.2 Emission 
 
The emission spectra of the conjugates are shown in Figure 3.8. Ru(bpy)2PIC 
polypyridyl peptide conjugates exhibits a maximum emission at approximately 608 nm when 
excited into the MLCT absorbance bands outlined in Table 3.2 which is consistent with the 
emission of the parent complex [Ru(bpy)2PIC]ClO4. Ru(dpp)2PIC polypyridyl peptide 
conjugates exhibits a maximum emission at approximately 615nm, also consistent with the 
[Ru(dpp)2PIC]ClO4 polypyridyl parent complex. All emission decays follow 
monoexponential kinetics with a lifetime in aerated samples being shorter than in degassed 
solutions. The length of the linker has no apparent effect on the lifetimes of the polypyridyl 
peptide conjugates. The lifetimes are comparable to those of the parent complexes.  
 
 
Figure 3.8 Overlaid emission of the synthesised chromophore-peptide conjugates and parent 
complexes in water. 
 
3.5 Cellular Uptake of Chromophores-Peptide Conjugates  
 
A key objective in preparing the complex conjugates was their targeting and 
membrane transport in mammalian cells. Their incubation with cells was therefore 
examined. In order to assess and compare the ability of the compounds to transport across 
the cell membrane of CHO cells, the latter were cultured separately on 35 mm glass bottom 
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culture dishes. CHO cells were seeded at 5 x 10
5 
cells in 2 ml media and were grown for 24 
hours before imaging. Incubation of the ruthenium complexes (40 μM) was at 37 oC 
overnight following its addition to the cells. Images were acquired using a Zeiss LSM510 
Confocal microscope, with a 63x oil immersion lens and a 458nm laser line for Ru. Cell 
imaging and cytotoxicity experiments presented throughout this chapter were performed by 
Dr. Róisín Moriarty. These were performed with co-localisation studies to confirm nuclear 
penetration and localisation. 
 
Figure 3.9 shows evidence of [Ru(bpy)2PIC]
2+
 chromophore  being cargoed into the 
cell by the NF-κB peptide and most importantly under goes strong evidence of transported to 
the nucleus. It shows the luminescent cross-section of the Ru(bpy)2PIC- βAla-
VQRKRQKLMP-NH2 peptide (red) and nuclear stain DAPI (blue) in live CHO cells after 
overnight incubation at 37oC in PBS buffer. DAPI or 4',6-diamidino-2-phenylindole is 
a fluorescent stain that binds strongly to A-T rich regions in DNA. It is used extensively in 
fluorescence microscopy as a nuclear stain. 
 
Influence of the counter ligand 
 
Figure 3.9 shows a merged image of [Ru(bpy)2 PIC-βAla-NFκB]
6+
, DAPI; the 
backscatter reflection is shown on the bottom right and the yellow line represents the 
fluorescence intensity profile in the graph on the left, generated using ImageJ image analysis 
software. DAPI alone is shown on the top left with [Ru(bpy)2 PIC-βAla-NFκB]
6+
shown 
alone on the top right. DAPI (300nM) was added for 30 mins at 37
 o
C and excited by the 
375nm laser line. This image shows clear nuclear staining with [Ru(bpy)2 PIC-βAla-
NFκB]6+conjugate, as confirmed by co-localisation and profile matching with the nuclear 
stain DAPI within the cell. Overall the images of [Ru(bpy)2 PIC-βAla-NFκB]
6+
show clear 
localisation in the nucleus confirmed by co-staining and fluorescent intensity profile. 
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Figure 3.9 A merged image (Ru(bpy)2PIC- βAla-VQRKRQKLMP-NH2) 10
-6
 M), DAPI;. λex = 
458 nm in PBS Buffer (Images collected by Dr. Róisín Moriarty) 
 
 
Figure 3.10 shows [Ru(dpp)2PIC]
2+
 crosses the cellular membrane when conjugated 
to NF-κB peptide and again it is transported to the nucleus. It shows the luminescent cross-
section of the [Ru(dpp)2 PIC-βAla-NFκB]
6+
conjugate in live CHO cells. Whereas the 
probe does penetrate the nucleus, the dye intensity is comparable in the cytoplasm and 
the nucleus, it is not deemed therefore to specifically localise in the nucleus. There is 
evidence for localisation of the dpp probe in the cell membrane.  
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Figure 3.10 Luminescent confocal image (λex = 458 nm) showing luminescent cross-section of a 
live CHO cell incubated with NF-κB (Ru(dpp)2PIC- βAla-VQRKRQKLMP-NH2) 10
-6
 M) for 90 
minutes at 37
o
C in PBS buffer. (Images collected by Dr. Róisín Moriarty) 
 
The vesicles observed in the CHO cells after 90 minutes (Figure 3.10) are an 
indication of cell death discussed in Section 3.7. The [Ru(dpp)2 PIC-βAla-NFκB]
6+ 
exhibits 
high cytotoxicity in comparison to the Ru(bpy)2PIC- peptide conjugates which does not 
display any signs of vesicle formation in CHO cells after several hours incubation.  
 
Figure 3.11 shows a merged image of  [Ru(dpp)2 PIC-βAla-NFκB]
6+
 (red) alone and 
a merged image of [Ru(dpp)2 PIC-βAla-NFκB]
6+
 and DAPI; the backscatter reflection is on 
the bottom right and the yellow line represents the fluorescence intensity profile in the graph 
on the left, generated using ImageJ image analysis software. This image shows clear nuclear 
staining with [Ru(dpp)2 PIC-βAla-NFκB]
6+
complex as confirmed by co-localisation and 
profile matching with the nuclear stain DAPI within the cell.  
 
The image also illustrates the pre-concentration of the dye inside a small spherical 
area within the nucleus that is likely to be the nucleolus which is particularly brightly 
luminescent. The nucleolus is a non-membrane bound structure composed of proteins and 
nucleic acids found within the nucleus of cells.  Ribosomal RNA (rRNA) is transcribed and 
assembled within the nucleolus. Malfunction of nucleoli can be the cause for several human 
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diseases.
[8, 9]
 DAPI is not seen concentrated in this region of the cell in Figure 3.11 and this 
is supported by the relative intensity profile of DAPI and [Ru(dpp)2 PIC-βAla-NFκB]
6+
. 
DAPI targets DNA which is not found in the nucleolus. Further imaging is required to 
confirm this. 
 
Overall the images of [Ru(dpp)2 PIC-βAla-NFκB]
6+
show clear penetration of the 
complex in the nucleus confirmed by co-staining and fluorescent intensity profile. However 
compared to the corresponding [Ru(bpy)2 PIC-βAla-NFκB]
6+
, [Ru(dpp)2 PIC-βAla-NFκB]
6+ 
does not only  localise inside the nucleus, but tends to co-localise at the membrane. This is 
due to [Ru(dpp)2 PIC-βAla-NFκB]
6+ 
hydrophobicity, arising from the dpp ligand. In addition 
[Ru(dpp)2 PIC-βAla-NFκB]
6+
, again, exhibits vesicle formation associated with its higher 
cytotoxicity  
 
 
 
Figure 3.11 A merged image NF-κB (Ru(dpp)2PIC- βAla-VQRKRQKLMP-NH2) 10
-6
 M), 
DAPI; the backscatter reflection is on the bottom right and the yellow line represents the 
fluorescence intensity profile in the graph on the left generated using ImageJ image analysis 
software λex = 458 nm in PBS in buffer. (Images collected by Dr. Róisín Moriarty) 
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Influence of the Linker 
 
Figure 3.12 shows the confocal images of CHO cells with evidence of 
[Ru(bpy)2PIC]
2+
 chromophore  being cargoed into the cell by the NF-κB peptide and 
transported to the nucleus with a 6-amino-hexanoic acid (Ahx) linker. Figure 3.12(a) shows 
a cluster of cells with an area within the cell being targeted by the Ru(II) polypyridyl peptide 
conjugate. Figure 3.12 (b) & (c) are focused on two cells, showing the targeted organelle 
within each cell which is believed to be the nucleus.  These results are very similar to those 
of [Ru(bpy)2 PIC-βAla-NFκB]
6+
, indicating the linker has little effect on the uptake 
properties of the peptide. This indicates these components are good for supramolecular 
chemistry and suggesting that the length of the linker is benign. Figure 3.13 supports this 
statement for the [Ru(dpp)2PIC]
2+
 chromophore as the NF-κB peptide with an amino-
hexanoic acid (Ahx) linker gives similar results to those of  [Ru(dpp)2 PIC-βAla-NFκB]
6+
, 
that contains the 2 carbon linker.   
 
 
Figure 3.12 Luminescent confocal images (λex = 458nm) of live CHO cells incubated with NF-κB 
(Ru(bpy)2PIC- Ahx-VQRKRQKLMP-NH2) 10
-6
 M) overnight at 37
o
C with 5% CO2 in PBS 
buffer. (Images collected by Dr. Róisín Moriarty) 
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Figure 3.13 Luminescent confocal images (λex = 458nm) of live CHO cells incubated with NF-κB 
(Ru(dpp)2PIC-Ahx-VQRKRQKLMP-NH2) 10
-6
 M) overnight at 37
o
C with 5% CO2 in PBS in 
buffer. (Images courtesy of Dr. Róisín Moriarty) 
 
SV-40 as another NLS 
  
The next peptide to be investigated for its localisation properties was SV-40, another 
well known nuclear localising peptide as described in Chapter 1, section 1.8. 6-Amino-
hexanoic acid was chosen as the linker. This peptide was not as successful as the NF-κB in 
term of cellular uptake of the conjugated complex. The Ru(bpy)2PIC-Ahx-SV40 peptide 
conjugate did not cross the cell membrane under the incubation conditions used for NF-κB. 
There was no evidence of dye within the cells. It may be necessary for the SV40 peptide to 
be conjugated to a CPP to cross the cell membrane when conjugated to a cargo, at least in 
the case of a ruthenium bpy complex. Surprisingly, the corresponding Ru(dpp)2PIC-Ahx-
SV40 did cross the cell membrane as seen in Figure 3.14. However, there was no specific 
localisation to the nucleus. We believe the [Ru(dpp)2PIC]
2+
 disrupts the integrity of the cell 
membrane and therefore gains entry, eventually inducing cell death. This is supported by the 
cytotoxic results in section 3.7, collected by Dr. Róisín Moriarty. There are many examples 
of hydrophobic compounds used to induce cell death in the literature. 
[10-12]
 There is a 
concentrated area within a cell organelle as seen in Figure 3.14, again this may be the 
nucleolus as seen previously with Ru(dpp)2PIC polypyridyl peptide conjugates. Ragin et al 
showed slightly less uptake of their SV-40 fluorescently labelled conjugate than that of their 
corresponding NF-κB fluorescently labelled conjugate by flow cytometry, which is 
consistent with our findings that the SV-40 peptide did not show as good uptake as the NF-
κB peptide. Also Ragin et al found for two other NLS sequences Fl-Oct-6, and Fl-TFIIE-β 
(Fl-fluorescein) which are highly cationic, more cationic than Fl-NF-κB, did not localise to 
the nucleus. It was suggested that Fl-Oct-6, and Fl-TFIIE-β may tightly associate with 
negatively charged membrane lipids, preventing their release into the cytoplasm and 
subsequent routing to the nucleus.
[5]
 As our Ru(dpp)2PIC-Ahx-SV40 conjugates are more 
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cationic than our Ru(dpp)2PIC-Ahx- NF-κB analogues, this also may be the reason why they 
did not reach the nucleus.  
 
Figure 3.14 Luminescent confocal images (λex = 458nm) of live CHO cells incubated with SV-40 
(Ru(dpp)2PIC- Ahx- PKKKRKV -NH2) 10
-6
 M) overnight at 37
o
C with 5% CO2. (a) 
Luminescent confocal image (b) Rainbow image(c) backscatter (Images collected by Dr. Róisín 
Moriarty) 
 
3.6 Cytotoxicity 
 
Resazurin is a colorimetric assay performed in cytotoxicity studies. Resazurin (7-
hydroxy-3H-phenoxazin-3-one-10-oxide) is a non-fluorescent blue coloured dye. It is used 
mainly as an oxidation-reduction indicator in cell viability assays for bacteria and 
mammalian cells. As shown in Figure 3.15 upon reduction of the dye to form resorufin (red 
in colour) the dye is brightly fluorescent. The resazurin assay is based on the ability of 
viable, active cells to reduce resazurin to resorufin and dihydroresorufin, and can be readily 
applied to live cell cultures. This redox conversion is intracellular and is facilitated by 
mitochondrial, microsomal and cytosolic oxidoreductases. The rate of dye reduction is 
directly proportional to the amount of viable cells present in a given assay.
[13]
 An advantage 
of the resazurin assay over other cell viability assays include its low toxicity to living cells 
allowing for the study of cells over longer time periods.  
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Figure 3. 15 Schematic diagram illustrating the conversion of resazurin to resorufin following 
reduction by active cell enzymes. 
 
Given the evidence of vesicle formation following incubation with the 
[Ru(dpp)2PIC]
2+
  peptide conjugates, it is important to assess the potential toxic effects of the 
chromophore peptide conjugates on the cell line selected. The effect of these complexes on 
the viability of the cells was tested using the resazurin cytotoxicity assay (also known as the 
alamar blue assay) which is explained in detail above and in Figure 3. 15. As seen in Figure 
3. 16 which is a plot of the percentage cytotoxicity against concentration (µg/ml), it is 
evident from the results that the [Ru(dpp)2PIC]
 2+
  peptide conjugates exhibits a toxic effect 
on the cells well above that of the [Ru(bpy)2PIC]
 2+
  peptide conjugates. The [Ru(dpp)2PIC
2+
] 
peptide conjugates show cyctotoxicity greater than 60% at 300 µg/ml, whereas the 
[Ru(bpy)2PIC]
2+
 peptide conjugates at the same concentration shown less than 10% 
cytotoxicity. 
 
The [Ru(dpp)2PIC]
 2+
 peptide conjugates induces cellular toxicity (in CHO cells) at 
concentrations above 10μM when incubated overnight at 37°C. The most likely origin of this 
cytotoxicity is due to the more hydrophobic structure of [Ru(dpp)2 PIC]
 2+
  compared to 
[Ru(bpy)2 PIC]
 2+
. The [Ru(bpy)2 PIC]
 2+
 does not induce significant cytotoxicity up to doses 
of 150μM, as previously shown by our group. Ru(bpy)2 PIC-peptide conjugates did not 
induce cytotoxicity in CHO cells, this is consistent with Ru(bpy)2PIC-octaarginine which 
also induced no cytotoxicity up to 140μM. Furthermore the parent complexes of each 
conjugate act in a similarly toxic or non-toxic fashion to the chromophore peptide conjugates 
indicating that the toxicity is not due to the peptide moiety. Further cytotoxicity testing is 
ongoing and will give us insightful relationships with apoptosis vs necrosis pathways. The 
relatively low cytotoxicity of the [Ru(bpy)2 PIC]
2+
 complex further supports its value for use 
as a molecular probe for multimodal imaging purposes, where as the [Ru(dpp)2 PIC]
2+
 
complex is less likely to valid as a probe but further investigated as a therapeutic agent. 
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Figure 3. 16 Cytotoxicity assay with CHO cells treated with Chromophore-peptide conjugates 
(Data collected by Dr. Róisín Moriarty) 
 
3.7 Conclusions 
 
Chapter 3 detailed the preparation, purification and characterisation of nuclear 
localisation peptides, NF-κB and SV-40, and their conjugation to ruthenium (II) polypyridyl 
chromophores using techniques of solid phase peptide synthesis. The effect of the linker 
between the metal complex and the peptide was also investigated with β-alanine, a 2 carbon 
linker and 6-amino-hexanoic acid, a 5 carbon linker when the nuclear localisation signal 
peptide is NF-κB. The synthesis of the chromophore-peptides proceeded with good yields. 
Their purification induced minor complications in some cases with oxidation of methionine 
residues but was overcome by performing the cleavage under nitrogen and purifications 
under controlled conditions. Purifications took place on a C18 column on HPLC with 
purities > 85%. The hydrophobicity of the [Ru(dpp)2PIC]
 2+
  peptide conjugates was reflected 
in the longer retention times of these complexes compared to the [Ru(bpy)2PIC]
 2+
 peptide 
conjugates as expected for this HPLC system. Characterisation was conducted using 
MALDI-TOF and High Resolution Mass Spectroscopy and all values conformed very well 
to expected values. 
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The photophysics of the conjugates were similar to those of the parent 
chromophores. The wavelength of the MLCT of all the Ru(II) polypyridyl peptide 
conjugates was ~ 458nm. The emission wavelength of the [Ru(dpp)2PIC]
 2+
 peptide 
conjugates was centred at 615nm and [Ru(bpy)2PIC]
 2+
 peptide conjugates was centred at 
607nm. The lifetimes for the [Ru(dpp)2PIC]
 2+
 peptide conjugates were longer than the 
corresponding Ru[Ru(bpy)2PIC]
 2+
 peptide conjugates and the de-aerated lifetimes were 
longer for all Ru(II) polypyridyl peptide conjugates than the aerated samples. 
 
Prior to peptide conjugation, neither parent complex was capable of sufficient 
transport across the cell membrane of CHO cells. However once both Ru(II) chromophores 
were coupled to the NF-κB sequence, the complex conjugates underwent diffusion across 
the cell membrane of CHO cells and their uptake were not affected by the length of the 
linker. For NF-κB this led to the localisation of the dyes within the cells’ nucleus. Confocal 
fluorescence microscopy was used to determine the distribution of the dyes throughout the 
cells. Co-staining with a nuclear stain and fluorescent profiling confirmed nuclear 
localisation.  
 
The Ru(bpy)2 PIC-SV-40 conjugate did not exhibit efficient transport across the 
membrane. This indicates that SV-40 is not a good carrier for such complexes. However it 
still may be a nuclear localising peptide and further studies would be required, such as 
attaching a CPP or permeabilising the cells. Its corresponding Ru(dpp)2 PIC-SV-40 did 
penetrate the cell membrane however we believe that this occurred through its disruption of 
the membrane , eventually leading to cell death. This is supported by the preliminary 
cytotoxicity studies which showed the [Ru(dpp)2PIC]
 2+
 peptide conjugates have higher  
cytotoxicity than the corresponding [Ru(bpy)2PIC]
 2+
 peptide conjugates. 
 
The [Ru(bpy)2PIC]
 2+
 peptide conjugates show promise as imaging agents. They also 
exhibit efficient nuclear localisation and low cytotoxicity. The [Ru(dpp)2PIC]
 2+
 peptide 
conjugates do not appear to be as useful as imaging agents as the Ru(bpy)2PIC polypyridyl 
peptide conjugates due to their higher toxicity. The [Ru(dpp)2PIC]
 2+
 peptide conjugates also 
remain mainly associated with the cell membrane. This suggests that the toxic nature of the 
dye occurs through its interference with the cell membrane. The ability of its conjugates to 
impart nuclear localization is affected by the nature of the cargo, with larger and more 
positively charged ruthenium complex being more difficult to direct than smaller ones. The 
[Ru(dpp)2 PIC]
 2+
 peptide conjugates may be useful in therapeutics if their effects on the cell 
membrane could be alleviated and if their accumulation in the nucleus result in the apoptosis 
of cancer cells. The specific localisation of the [Ru(dpp)2 PIC]
 2+
 requires further 
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investigation as it appears to be concentrated within the nucleus. NF-κB proved to be a 
highly efficient NLS and was independent of its cargo. SV-40 was inefficient as a universal 
carrier peptide. The worked would also need to be completed on a range of cell lines. 
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Chapter 4:  
Preparation and Characterisation of 
overlapping peptides of BH3 
Interacting Domain Death Agonist 
(BID) 
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4.1 Introduction  
 
Different from other pro-apoptotic Bcl-2 family members, BH3 interacting domain 
death agonist (BID) has evolved unique functions both in apoptosis signalling 
[1, 2]
 and in the 
control of cell cycle progression. 
[3, 4]
 BID is a 22-kDa pro-apoptotic member of the Bcl-2 
family containing only the BH3 domain. BID protein usually exists in an inactive form in 
the cytoplasm and is inhibited by Bcl-2, but upon cleavage by activated caspase-8, truncated 
Bid (tBid) translocates to the mitochondria.
[5, 6]
 In response to apoptotic signalling, BID 
interacts with another pro-apoptotic protein (Bax), leading activated Bax and/or Bak to form 
pores that disrupt mitochondrial membrane integrity. These events precede the activation of 
two distinct apoptotic pathways: caspase-dependent and caspase-independent cell death 
pathways.
[7]
 This results in the release of cytochrome c 
[8]
and other pro-apoptotic factors 
from the mitochondria, often referred to as mitochondrial outer membrane permeabilization, 
leading to activation of caspases and ultimately causing cell death.
[9, 10]
 The translocation of 
apoptosis-inducing factor (AIF) from the mitochondria to the nucleus triggers the caspase-
independent cell death pathway. At the nucleus DNA fragmentation and apoptosis occurs by 
an unknown, caspase-independent mechanism.
[11, 12]
 Therefore BID is a key factor in 
apoptosis as shown in Chapter 1. 
 
For this work peptides from the BID protein were selected as targets. The long term 
objective of this study was to identify if any peptide sequence fulfilled the BID function 
outside of the protein. They were prepared for study by the group Prof. Jochen Prehn in the 
Department of Physiology and Medical Physics at the Royal College of Surgeons in Ireland.  
The protein sequence is shown in Figure 4. 1. Studies have shown that the interaction of 
BH3 peptides derived from BAD with Bcl-XL depend dramatically on the length of the 
peptide. Results show that the 25 residue long BH3 (BAD) forms additional interactions 
with Bcl-XL compared with the 16-mer BH3 (Bak) peptide.
[6]
 It has also been shown that 
the length of the peptide affects its helix propensity.
[13]
 Therefore in preparing overlapping 
peptides, the sequence of the protein was broken down into peptides of around 20-25 amino 
acids long, depending on the anticipated difficulty of synthesis of the sequence (Table 4. 
1).The cysteine (C) residues were replaced with serine (S) to avoid disulphide bridge 
formation and oxidation. 
 
Figure 4. 1 BH3-interacting domain death agonist amino acid sequence. 
[14]
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Table 4. 1 Overlapping sequences of truncated BID that was synthesized 
BID 1-20 MDSEVNNGSSLRDESITNLL 
BID 18-36 TNLLVFGFLQSSSDNSFRR 
BID 29-48 SDNSFRRELDALGHELPVLA 
BID 46-64 VLAPQWEGYDELQTDGNRS 
BID 62-82 NRSSHSRLGRIEADSESQEDI 
BID 78-101 SQEDIIRNIARHLAQVGDSMDRSI 
BID 97-117 MDRSIPPGLVNGLALQLRNTS 
BID 116-137 TSRSEEDRNRDLATALEQLLQA 
BID 137-157 AYPRDMEKEKTMLVLALLLAK 
BID 155-177 LAKKVASHTPSLLRDVFHTTVNF 
BID 175-195 VNFINQNLRTYVRSLARNGMD 
 
4.2 Experimental Details for the synthesis of BID peptides 
  
4.2.1 Preparation of biotinylated BID 01-20 
 
Biotin-βAla -MDSEVNNGSSLRDESITNLL -NH2 
 
Synthesis of biotinylated BID 01-20 took place on the ABI 433A synthesizer by 
standard SPPS as far as V
17
, from a Nova Peg Rink Amide Resin (scale 0.25mmol, 
substitution 0.5mmol/g). Fmoc-Ser(tBu)-OH, Fmoc-Gly-OH, Fmoc-Asn(Trt)-OH, Fmoc-
Val-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Met-OH and Fmoc-βAla-OH 
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were then manually assembled by HATU (5eq) / DIEA (10eq) coupling chemistry. The 
synthesis was monitored by the qualitative Kaiser test and double coupling procedures 
applied when required. The coupling times were 3 hrs.  Usual conditions of manual Fmoc 
deprotection and washes were performed as outlined in Chapter 2. Manually coupling of 
biotin took place using PyBOP/HOBt (3eq) / DIEA (6eq) coupling chemistry.  The peptide 
was finally cleaved by standard methods and then purified by RP-HPLC. Fractions were 
collected by semi-preparative HPLC, C18 column with gradient H2O:ACN mobile phase and 
were analysed by mass spectrometry.  
 
MALDI-MS 2489.54 [M+1]
+
 calculated for C101H170N30O40S2 2490.766 (Appendix Figure 9) 
Purity: 83% (Appendix Figure 10) 
 
4.2.2 Preparation of biotinylated BID 18-36 
 
Biotin-βAla- TNLLVFGFLQSSSDNSFRR -NH2 
 
The biotinylated BID 18-36 peptide was assembled as far as G
23
 on the synthesizer, 
0.25mmol of Rink Amide MBHA Resin (substitution 0.7mmol/g) was used.  Fmoc-Phe-OH, 
Fmoc-Val-OH, Fmoc-Leu-OH, Fmoc-Asn(Trt)-OH, Fmoc-Thr(tBu)-OH and Fmoc-βAla-
OH were manually assembled by HBTU/HOBt (5eq) / DIEA (10eq) coupling chemistry. 
The synthesis was followed by Kaiser test and double coupling procedures applied when 
required. The coupling times were 3hrs.  Usual conditions of manual Fmoc deprotection and 
washes were performed as outlined in Chapter 2. Manually coupling of biotin took place 
using PyBOP/HOBt (3eq) / DIEA (6eq) coupling chemistry.  The peptide is cleaved by 
normal methods and then purified as usual by RP-HPLC. Fractions were collected by semi-
preparative HPLC, C18 column with gradient H2O:ACN mobile phase and were analysed by 
mass spectrometry.  
 
MALDI-MS 2486.1 [M+1]
+
 calculated for C119H192N38O36S2 2484.833 (Appendix Figure 
11). 
Purity: 72%(Appendix Figure 12) 
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4.2.3 Preparation of biotinylated BID 29-48 
 
Biotin-βAla -SDNSFRRELDALGHELPVLA -NH2 
 
Synthesis of biotinylated BID 29-48 took place on the ABI 433A synthesizer by 
standard SPPS as far as A
39
, 0.1mmol of PEG Fmoc Rink Amide (substitution 0.5mmol/g) 
was used. Fmoc-Asp(OtBu)-OH, Fmoc-Leu-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Arg(Pbf)-
OH, Fmoc-Phe-OH, Fmoc-Ser(tBu)-OH, Fmoc-Asn(trt)-OH and Fmoc-βAla-OH were 
manually assembled by HBTU/HOBt (5eq) / DIEA (10eq) coupling chemistry. The 
synthesis was followed by Kaiser Test and double coupling procedures applied when 
required. The coupling times were 3hrs.  Usual conditions of manual Fmoc deprotection and 
washes were performed as outlined in Chapter 2. Manually coupling of biotin took place 
using PyBOP/HOBt (3eq) / DIEA (6eq) coupling chemistry.  The peptide is cleaved by 
normal methods and then purified as usual by RP-HPLC. Fractions were collected by semi-
preparative HPLC, C18 column with gradient H2O:ACN mobile phase and were analysed by 
mass spectrometry.  
 
MALDI-MS 2535.30 [M+1]
+
 calculated for C110H177N33O35S 2535.88 (Appendix Figure 13). 
Purity: 74 %( Appendix Figure 14) 
 
4.2.4 Preparation of biotinylated BID 46-64 
 
Biotin-βAla -VLAPQWEGYDELQTDGNRS -NH2 
 
Synthesis of biotinylated BID 46-64 took place on the ABI 433A synthesizer by 
standard SPPS as far as G
61
; 0.1mmol of Nova Peg Rink Amide Resin (substitution 
0.5mmol/g) was used. Fmoc-Asp(OMpe)-OH (D
60
), Fmoc-Thr(tBu)-OH, Fmoc-Gln(trt)-OH, 
Fmoc-Leu-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Tyr(tBu)-OH, Fmoc-
Gly-OH, Fmoc-Trp(tBu)-OH, Fmoc-Pro-OH, Fmoc-Ala-OH, Fmoc-Val-OH and Fmoc-
βAla-OH were manually assembled by HBTU/HOBt (5eq) / DIEA (10eq) coupling 
chemistry. The synthesis was followed by Kaiser Test and double coupling procedures 
applied when required. The coupling times were 3hrs.  Usual conditions of manual Fmoc 
deprotection and washes were performed as outlined in Chapter 2. Manually coupling of 
biotin took place using PyBOP/HOBt (3eq) / DIEA (6eq) coupling chemistry.  The peptide 
is cleaved by normal methods and then purified as usual by RP-HPLC. Fractions were 
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collected by semi-preparative HPLC, C18 column with gradient H2O:ACN mobile phase and 
were analysed by mass spectrometry.  
 
MALDI-MS 2476.1 [M+1]
+
 calculated for C107H162N30O37S2 2474.705 (Appendix Figure 
15). 
Purity: 90% (Appendix Figure 16) 
 
 
4.2.5 Preparation of biotinylated BID 62-82 
 
Biotin-βAla -NRSSHSRLGRIEADSESQEDI -NH2 
 
Synthesis of biotinylated BID 62-82 took place on the ABI 433A synthesizer by 
standard SPPS as far as R
68
, 0.1mmol of Nova Peg Rink Amide Resin (substitution 
0.5mmol/g) was used. Fmoc-Ser(tBu)-OH, Fmoc-His(trt)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-
Asn(trt)-OH and Fmoc-βAla-OH were manually assembled by HBTU/HOBt (5eq) / DIEA 
(10eq) coupling chemistry. The synthesis was followed by Kaiser test and double coupling 
procedures applied when required. The coupling times were 3hrs.  Usual conditions of 
manual Fmoc deprotection and washes were performed as outlined in Chapter 2. Manually 
coupling of biotin took place using PyBOP/HOBt (3eq) / DIEA (6eq) coupling chemistry.  
The peptide is cleaved by normal methods and then purified as usual by RP-HPLC. 
Fractions were collected by semi-preparative HPLC, C18 column with gradient H2O:ACN 
mobile phase and were analysed by mass spectrometry.  
 
MALDI-MS 2683.79 [M+1]
+
 calculated for C107H172N38O42S 2682.882 (Appendix Figure 
17). 
Purity: 72% (Appendix Figure 18) 
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4.2.6 Preparation of biotinylated BID 78-101 
 
Biotin-βAla - SQEDIIRNIARHLAQVGDSMDRSI-NH2 
 
 
Biotinylated BID 78-101 was fully assembled by automated synthesis (ABI 433A) 
using 0.1mmol of Nova PEG Rink Amide Resin (substitution 0.7mmol/g). All amino acids 
were standard, however for D
95
 Fmoc-Asp (OMpe)-OH was used to prevent aspartimide 
formation. Manually coupling of biotin took place on the resin using PyBOP/HOBt (3eq) / 
DIEA (6eq) coupling chemistry.  The peptide is cleaved by standard methods and the crude 
peptide was purified by HPLC, C18 column with gradient H2O:ACN mobile phase and 
analysed by mass spectrometry. 
 
MALDI-MS 3021.16 [M+1]
+
 calculated for C125H210N42O41S2 3021.44 (Appendix Figure 
19). 
Purity: 95% (Appendix figure 20)  
 
4.2.7 Preparation of biotinylated BID 97-117 
 
Biotin-βAla -MDRSIPPGLVNGLALQLRNTS -NH2 
 
Synthesis of biotinylated BID 97-117 took place on the ABI 433A synthesizer by 
standard SPPS as far as A
104
, 0.1mmol of Nova Peg Rink Amide Resin (substitution 
0.5mmol/g) was used. Fmoc-Pro-OH, Fmoc-Ile-OH, Fmoc-Ser (tBu)-OH, Fmoc-Arg (Pbf)-
OH, Fmoc-Asp (OtBu)-OH, Fmoc-Met-OH and Fmoc-βAla-OH were manually assembled 
by HBTU/HOBt (5eq) / DIEA (10eq) coupling chemistry. The synthesis was followed by 
Kaiser Test and double coupling procedures applied when required. The coupling times were 
3hrs.  Usual conditions of manual Fmoc deprotection and washes were performed as 
outlined in Chapter 2. Manually coupling of biotin took place using PyBOP/HOBt (3eq) / 
DIEA (6eq) coupling chemistry.  The peptide is cleaved by normal methods and then 
purified as usual by RP-HPLC. Fractions collected by semi-preparative HPLC, C18 column 
with gradient H2O:ACN mobile phase, were analysed by mass spectrometry.  
 
MALDI-MS 2550.32 [M+1]
+
 calculated for C109H188N34O33S2 2549.03(Appendix Figure 21). 
Purity: 91% (Appendix Figure 22) 
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4.2.8 Preparation of biotinylated BID 116-137 
 
Biotin-βAla -TSRSEEDRNRDLATALEQLLQA -NH2 
 
Synthesis of biotinylated BID 116-137 took place on the ABI 433A synthesizer by 
standard SPPS as far as A
128
, 0.1mmol of Nova Peg Rink Amide Resin (substitution 
0.5mmol/g) was used. Fmoc-Leu-OH, Fmoc-Asp(OtBu)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-
Asn(trt)-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Thr(tBu)-OH, and Fmoc-
βAla-OH were manually assembled by HBTU/HOBt (5eq) / DIEA (10eq) coupling 
chemistry. The synthesis was followed by Kaiser Test and double coupling procedures 
applied when required. The coupling times were 3hrs.  Usual conditions of manual Fmoc 
deprotection and washes were performed as outlined in Chapter 2. Manually coupling of 
biotin took place using PyBOP/HOBt (3eq) / DIEA (6eq) coupling chemistry.  The peptide 
is cleaved by normal methods and then purified as usual by RP-HPLC. Fractions were 
collected by semi-preparative HPLC, C18 column with gradient H2O:ACN mobile phase and 
were analysed by mass spectrometry.  
 
MALDI-MS 2812.44 [M-1]
-
 calculated for C115H196N38O43S 2814.42 (Appendix Figure 23) 
Purity: 73 %( Appendix Figure 24) 
 
4.2.9 Preparation of biotinylated BID 137-157 
 
Biotin-βAla - AYPRDMEKEKTMLVLALLLAK-NH2 
 
Synthesis of biotinylated BID 137-157 took place on the ABI 433A synthesizer by 
standard SPPS as far as K
146
, 0.1mmol of PS PEG 600 Fmoc Rink Amide MBHA resin 
(substitution 0.62mmol/g) was used. Fmoc-Glu (OtBu)-OH, Fmoc-Lys (Boc)-OH, Fmoc-
Met-OH, Fmoc-Asp (OtBu)-OH, Fmoc-Arg (Pbf)-OH, Fmoc-Pro-OH, Fmoc-Tyr-OH, 
Fmoc-Ala-OH and Fmoc-βAla-OH were manually assembled by HBTU/HOBt (5eq) / DIEA 
(10eq) coupling chemistry. The synthesis was followed by Kaiser Test and double coupling 
procedures applied when required. The coupling times were 3hrs.  E
143
 was coupled by 
microwave activation using the same coupling chemistry and Fmoc-Glu (OtBu)-OH. 
Coupling reactions took place for 5 minutes at 50°C with pre-stirring for 30 seconds and 
with fix hold time on. Absorption level was set to high as NMP was the solvent used. Usual 
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conditions of manual Fmoc deprotection and washes were performed as outlined in Chapter 
2. Manually coupling of biotin took place using PyBOP/HOBt (3eq) / DIEA (6eq) coupling 
chemistry.  The peptide is cleaved by normal methods and then purified as usual by RP-
HPLC, C18 column with gradient H2O:ACN mobile phase. Fractions collected by semi-
preparative HPLC were analysed by mass spectrometry.  
 
MALDI-MS 2732.35 [M+2]
+
 calculated for C123H211N31O33S3 2730.41 (Appendix Figure 
25). 
Purity: 97.8 %( Appendix Figure 26) 
4.2.10 Preparation of biotinylated BID 155-177 
 
Biotin-βAla- LAKKVASHTPSLLRDVFHTTVNF-NH2 
 
Synthesis of biotinylated BID 155-177 took place on the ABI 433A synthesizer by 
standard SPPS; 0.1mmol of Rink Amide MBHA Resin (substitution 0.7mmol/g) was used. 
Manual coupling of biotin took place on the resin using PyBOP/HOBt (3eq) / DIEA (6eq) 
coupling chemistry.  The peptide is cleaved by usual methods and then purified as usual by 
RP-HPLC, C18 column with gradient H2O:ACN mobile phase. Fractions collected by semi-
preparative HPLC were analysed by mass spectrometry.  
 
MALDI-MS 2878.69 [M+1]
+
 calculated for C131H209N37O34S 2878.31 (Appendix Figure 27). 
Purity: 71 %( Appendix Figure 28) 
 
4.2.11 Preparation of biotinylated BID 175-195 
 
Biotin-βAla-VNFINQNLRTYVRSLARNGMD-COOH 
 
Biotinylated BID 175-195 was assembled as far as L
182
 on the synthesizer, 0.1mmol 
of preloaded (Asp) Wang Resin (substitution 0.7mmol/g) was used.  Fmoc-Asn(Trt)-OH, 
Fmoc-Gln-OH, Fmoc-Ile-OH, Fmoc-Phe-OH, Fmoc-Val-OH and Fmoc-βAla-OH were 
manually assembled by HBTU/HOBt (5eq) / DIEA (10eq) coupling chemistry. The 
synthesis was followed by Kaiser Test and double coupling procedures applied when 
required. The coupling times were 3hrs.  N
181
 was coupled by microwave activation using 
the same coupling chemistry and Fmoc-Asn (Trt)-OH. Coupling reactions took place for 5 
minutes at 50°C with pre-stirring for 30 seconds and with fix hold time on. Usual conditions 
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of manual Fmoc deprotection and washes were performed and Fmoc deprotection of F and 
V took place by microwave activation as outlined in Chapter 2. Deprotection reactions took 
place for 2 minutes at 50°C with pre-stirring for 30 seconds; fix hold time on and absorption 
were set to high.  
  
Manually coupling of biotin took place using PyBOP/HOBt (3eq) / DIEA (6eq) 
coupling chemistry.  The peptide is cleaved by normal methods and then purified as usual by 
RP-HPLC. Fractions were collected by semi-preparative HPLC, C18 column with gradient 
H2O:ACN mobile phase and were analysed by mass spectrometry.  
 
MALDI-MS 2782.7 [M+2]
2+
 calculated for C119H192N38O36S2 2779.21 (Appendix Figure 29). 
Purity: 81.6 %( Appendix Figure 30) 
 
4.2.12 Preparation of BID 137-157 conjugated to Ru (dppz)2PIC 
 
 
 
Synthesis of the peptide took place on the ABI 433A synthesizer by standard SPPS 
as far as K
146
; 0.1mmol of Nova Peg Rink Amide Resin (substitution 0.62mmol/g) was used. 
Fmoc-Glu (OtBu)-OH, Fmoc-Lys (Boc)-OH, Fmoc-Met-OH, Fmoc-Asp (OtBu)-OH, Fmoc-
Arg (Pbf)-OH, Fmoc-Pro-OH, Fmoc-Tyr-OH, Fmoc-Ala-OH and Fmoc-βAla-OH were 
manually assembled by HBTU/HOBt (5eq) / DIEA (10eq) coupling chemistry. The 
synthesis was followed by Kaiser Test and double coupling procedures applied when 
required. The coupling times were 3hrs.  E
143
 was coupled by microwave activation using 
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the same coupling chemistry and Fmoc-Glu (OtBu)-OH. Usual conditions of manual Fmoc 
deprotection and washes were performed. Manually coupling of [Ru (dppz) 2PIC]
2+
took 
place using PyBOP (3eq) / DIEA (6eq) coupling chemistry, with [Ru (dppz) 2PIC]
2+
, PyBOP 
and DIEA allowed to react for 3 minutes before adding the peptide on resin.  The peptide is 
cleaved by normal methods and then purified as usual by RP-HPLC. Fractions collected by 
semi-preparative HPLC were analysed by mass spectrometry MALDI-TOF.  
  
MALDI-MS 3492.4609[M+1]
+
 calculated for C169H227N41O32SRu 3492.1035 (Figure 4.9). 
4.2.13 Preparation of BID 155-177 conjugated to Ru (dppz)2PIC 
 
 
 
 
Synthesis of the peptide took place on the ABI 433A synthesizer by standard SPPS; 
0.1mmol of Rink Amide MBHA Resin (substitution 0.7mmol/g) was used. Manual coupling 
of [Ru (dppz) 2PIC]
2+
 took place on the resin using PyBOP/HOBt (3eq) / DIEA (6eq) 
coupling chemistry.  The peptide is cleaved by usual methods and then purified as usual by 
RP-HPLC. Fractions collected by semi-preparative HPLC were analysed by mass 
spectrometry, MALDI-TOF.  
 
MALDI-MS 3640.4919 [M+1]
+
 calculated for C177H227N47O34Ru 3640.0985(Appendix 
Figure 31). 
Purity: 85% (Appendix Figure 32). 
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4.3 Results and Discussion 
4.3.1 Synthesis 
 
Synthesis of BID peptides was first attempted by automated standard solid phase 
peptide synthesis using the common amino acid precursors presented in appendix unless 
otherwise stated. This stepwise elongation, in which the amino acids are connected 
iteratively, was successful for 2 sequences, BID 155-177 and BID 78-101, the integrity of 
these peptides was confirmed by mass spectrometry (Appendix: Figure 31 and Figure 23 
respectively). For the other BID sequences with a higher content of hydrophobic residues 
this method failed. This can be seen by the deprotection traces on the automated peptide 
synthesizer. As mentioned in Chapter 2, the peptide sequences were assembled with 
monitoring of the Fmoc deprotection by UV absorption at 301nm. The synthesizer removes 
the Fmoc and monitors the amount of dibenzofulvene-piperidine adduct form by UV as seen 
in Figure 4. 2. It then performs a second deprotection step of the Fmoc. The Fmoc quantity 
removed in the second deprotection should be less than 3.5% of the first peak. If this level is 
reached, the synthesiser will move on to the next amino acid and coupling step. This is seen 
in Figure 4. 2 for amino acids X1 to X6. However if the quantity of dibenzofulvene formed 
is not sufficiently low the automated synthesizer will repeat the deprotection step, up to a 
maximum of 5 deprotections, as shown in Figure 4. 2 for amino acids X7 to X10. After this 
the synthesizer will move on to the next amino acid in the sequence to be coupled regardless 
of the final deprotection trace. From these traces we can see where a break down occurred in 
the synthesis of the peptides. In the case of Figure 4. 2 this was X7 and that is where the 
manual coupling would begin on the second synthetic attempt. 
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Figure 4. 2 Representation of Fmoc removal trace from an Applied Biosystem ABI 
433A Synthesizer monitored by UV at 301nm. Amino acids X1-X6 have a successful 
deprotection trace whereas for amino acids X7-X10 the deprotection becomes sluggish with the 
last two amino acids receiving maximum deprotection. 
  
 As the peptide is elongated, it can form secondary structures such as β-sheets and 
aggregates either with other peptide chains or with the polymer support, which can result in 
turn in lower reaction rates. The effects can range from just a subtle slowing down to a 
complete failure of both deprotection and coupling reactions. The ease of assembly of a 
particular sequence is generally hard to predict, although peptides containing stretches of 
continuous hydrophobic and/or branched amino acids like Ala, Val, Ile, as well as those 
containing residues which can form intra-chain hydrogen bonding such as Gln, Ser and Thr 
are frequently difficult to make.  When automated synthesis proves to be unsuitable for the 
assembly of difficult sequences, other methods were examined, such as manual synthesis, 
microwave-assisted synthesis and more efficient coupling reagents and resins. 
 
Manual synthesis was performed when a sequence could not be fully elongated on 
the synthesizer. The sequence was assembled on the synthesiser up to the longest stretch of 
hydrophobic amino acid routinely assembled by automated synthesis and then transferred to 
a syringe for completion by manual synthesis as described in 2.2. This method allowed the 
use of longer reaction times and higher equivalents of amino acids and coupling reagents to 
force the reaction to completion. Both the coupling and deprotection reactions were 
monitored by Kaiser test, based on the formation of a blue adduct by reaction of ninhydrin 
(2,2-dihydroxyindane-1,3-dione) with a primary amino group.
[15]
  A Kaiser test is used to 
monitor reactions in peptide synthesis and can be performed on a resin for solid phase 
synthesis. A deprotected amino acid yields a positive Kaiser test indicated by the blue 
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coloration of the resin. Conversely, a negative Kaiser test (colourless or yellow resin) 
indicates the successful coupling of a N-protected amino acid or an unsuccessful 
deprotection of a Fmoc group. 
 
When this elongation of the peptide sequence became difficult, as shown by mixed 
results from a Kaiser test, coupling and deprotection reactions were completed in the 
Biotage Initiator 2.5 microwave synthesizer. This was carried out for BID 175-195, residue 
176 (N) and BID137-157, residue 143 (E). The parameters of the coupling reaction were 
based on the recommendations of the manufacturer of the microwave synthesizer. Pre-
stirring between 30 seconds and 1 minute was found to improve the outcomes of the 
reactions. This is consistent with results reported by Coantic et al., who demonstrated the 
importance of maintaining stirring during Microwave-assisted Solid Phase Peptide Synthesis 
(MW-SPPS) on high loaded resins.
[16]
 Fixed hold time, which means that the time duration 
of the reaction did not start until the reaction temperature was reached, was also selected. 
Microwave coupling was successful for the amino acids that could not be coupled otherwise 
as outlined in Section 4.2. It was used in a similar fashion for deprotection reactions. Peptide 
synthesis was completed using the general methods outlined in Chapter 2.6 and the general 
methods outlined below. 
 
 
 
4.3.2 Coupling Reagents 
 
When the reactions remained unsuccessful, despite microwave activation, the resin 
or the coupling reagents had to be changed. Initially 2-(1H-benzotriazole-1-yl)-1, 1, 3, 3-
tetramethyl-uronium-hexafluoro-phosphate (HBTU) (Figure 4. 3a) was used as the coupling 
reagent for both automated and manual syntheses, including microwave-assisted couplings 
(Figure 4. 4). The next amino acid to be added in the sequence is deprotonated by the base 
introduced with the coupling reagent and can then react with the latter to form an active ester 
as seen in Figure 4.4. This ester intermediate reacts with a polymer-bound amino 
deprotected residue. This is one of the most common coupling reagents that form an active 
hydroxybenzotriazole (HOBt) ester.  
 
Other uronium couplings reagents, such as 2-(1H-7-azabenzotriazol-1-yl)--1,1,3,3-
tetramethyl uronium hexafluorophosphate (HATU) (Figure 4. 3b), are also available that  
that can facilitate the reaction of the active ester, through the hypothetical formation of 
116 
 
hydrogen bonds between the HATU’s aza group and the amino group of the incoming amino 
acid.
[17, 18]
  The coupling reagent HATU is a highly efficient coupling reagent for solid- and 
solution-phase peptide synthesis. In comparative studies HATU has been found to give 
better coupling yields with less racemisation that HBTU, TBTU, or PyBOP. HATU in the 
presence of a base convert carboxylic acids to the corresponding HOAt esters. Such esters 
are also more reactive than their HOBt counterparts owing to the lower pKa of HOAt as 
compared to HOBt. However owing to its cost, its use is generally only recommended for 
difficult and hindered couplings and the synthesis of long peptides.  
 
 
 
Figure 4. 3: (a) HBTU (b) HATU (uronium) coupling reagents 
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Figure 4. 4: Mechanism of HBTU/HOBt mediated coupling reaction 
 
 
 
4.3.3 Resin 
 
The common solid support for the synthesis of peptide amides is the Rink Amide 
MBHA resin. It contained a modified Rink amide linker that incorporated an acetic acid 
spacer that is not degraded by TFA and therefore compatibable with the standard 95% TFA 
cleavage reaction. Rink amide MBHA resin is a polystyrene resin cross-linked with 1-2% 
divinylbenzene and can therefore promote aggregation of hydrophobic sequences. Nova 
PEG Rink Amide resin was used for these difficult sequences. Nova PEG Rink Amide resin 
contains the same linker but is based on PEG which provides excellent swelling, including in 
protic solvents, and mechanical properties to the polymeric support. Nova PEG resins have 
excellent chemical stability, particularly towards strong acids and bases. The amphiphilic 
nature of this resin makes it an excellent support for the synthesis of difficult, aggregated 
peptides and of long peptides.
[19]
 It has also been shown to increase in general the yield and 
purity of peptides prepared by SPPS, compared to polystyrene-based resins. 
[19] 
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4.3.4 Aspartimide Formation 
 
The most frequently encountered side-reaction affecting aspartic acid residues 
during solid phase synthesis is aspartimide formation, resulting from ring closure between 
the nitrogen of the amide bond and the β- carboxy side chain with loss of the ester protecting 
group. This problem is particularly significant in SPPS according to the Fmoc strategy, as 
cyclisation is promoted by bases, such as piperidine, used to remove the Fmoc group. The 
Asp-Gly sequence is particularly prone to aspartimide formation, which is estimated to occur 
to the extent of approximately 0.5% per Fmoc deprotection cycle (Figure 4. 5). 
[20]
 The 
problem is most serious in long peptides, as the degree of aspartimide formation is 
dependent on the total exposure time to piperidine but can be reduced by using Fmoc-Asp 
(OMpe)-OH. By substituting OtBu for the more bulky OMpe group in the synthesis of a 
model Asp-Gly containing peptide, formation of aspartimide related by-products (β-
branched and diastereoisomeric peptides) can be reduced considerably.  This was adopted 
for the BID BH3 domain (78-101) which had an Asp-Gly motif near the C-terminus and 
therefore exposed to repetitive deprotection procedures.  
 
Figure 4. 5 Mechanism for aspartimide-related by-products formation 
119 
 
 
4.3.5 Selecting BID sequences for studies with oxygen-sensitive probes 
 
Two of the BID sequences were selected for initial investigation of the chemistry 
required for their conjugation to a Ru (II) polypyridal probe. The two sequences chosen were 
BID 137-157 and BID 155-177, as they had the highest content of hydrophobic amino acids. 
BID 137-157 and BID 155-177 had 57% and 50% of hydrophobic residues, respectively.  To 
ensure consistency in the linker selected for the future labelling of all the BID sequences, 
these least soluble sequences were chosen to determine if a hydrocarbon-based linker could 
be introduced between the peptide sequence and the probe, while maintaining the solubility 
of the conjugate in aqueous buffers. A PEG-based linker would otherwise be required to 
enhance this solubility.  
 
 
Guidelines for hydrophobicity and solubility of peptides were taken from 
GenScript
[21]
:  
1. Peptides that are shorter than 5 residues are generally soluble in aqueous media, 
except where all the residues are very hydrophobic. 
2. Hydrophilic peptides containing >25% charged residues and <25% hydrophobic 
residues also generally dissolve in aqueous media, provided that the charged 
residues are fairly evenly distributed throughout the sequence.  
3. Hydrophobic peptides containing 50% to 75% hydrophobic residues may be 
insoluble or only partially soluble in aqueous solutions, even if the sequence 
contains 25% charged residues. 
4. Very hydrophobic peptides containing 75% hydrophobic residues will generally 
not dissolve in aqueous solutions. 
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Table 4. 2 Table of BID sequences with acidic basic and hydrophobic residues identified. The % 
hydrophobicity is also reported. Red: acidic residues, like D and E Blue: basic residues, like R, 
K and H Green: hydrophobic uncharged residues, like F I L M V W A and P Black: other 
residues, like G S T C N Q and Y 
 
Name Peptide Sequence % Hydrophobicity 
BID 1-20 AMDSEVNNGSSLRDESITNLL 33.3 
BID 18-36 ATNLLVFGFLQSSSDNSFRR 40.0 
BID 29-48 ASDNSFRRELDALGHELPVLA 47.6 
BID 46-64 AVLAPQWEGYDELQTDGNRS 35.0 
BID 62-82 ANRSSHSRLGRIEADSESQEDI 23.8 
BID 78-101 ASQEDIIRNIARHLAQVGDSMDRSI 41.7 
BID 97-117 AMDRSIPPGLVNGLALQLRNTS 50.0 
BID 116-137 ATSRSEEDRNRDLATALEQLLQA 34.8 
BID 137-157 AAYPRDMEKEKTMLVLALLLAK 59.1 
BID 155-177 ALAKKVASHTPSLLRDVFHTTVNF 50.0 
BID 175-195 AVNFINQNLRTYVRSLARNGMD 40.9 
 
 
 
 
4.3.6 [Ru(dppz)2PIC]ClO4 conjugation 
 
As described in Chapter 1, ruthenium-based probes have many favourable 
photophysical properties that make them ideal as probes for cellular imaging.  Another key 
advantage of Ru (II) complexes is the capacity to make their photophysical properties 
dependent on their environment. For example, the sensitivity of the excited state lifetime and 
hence the phosphorescent intensity to O2 is well known for many ruthenium complexes.
[22]
  
The probe chosen for studies with BID sequences was Ru(dppz)2PIC. Ru-dppz has been 
widely investigated as a probe for nucleic acid structure.
[23]
 Ruthenium dipyridophenazine 
(dppz) complexes were developed as luminescent probes due to their high affinity for DNA, 
and the “light switch effect” that makes them brightly luminescent in hydrophobic 
environments and virtually non-luminescent in aqueous solutions.
[24]
 In aqueous conditions, 
water quenches this excited state by hydrogen bonding with the phenazine nitrogen atoms 
but when the dppz is shielded from water the luminescence is activated and the complex 
eﬀectively acts as if dissolved in an organic solvent.[25] 
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Ruthenium (II) complexes have shown potential as luminescent probes for other 
interactions with biological molecules and structures, such as RNA 
[26, 27]
 and lipid 
membranes.
[28-30]
 Since the photoluminescence lifetime is independent of fluorophore 
concentration, light intensity and photo-bleaching,
[24]
it is an ideal parameter to remotely 
monitor the local environment of the probe. Ruthenium polypyridyl complexes have been 
used as oxygen sensing probes,
[31-33]
 and their ability to monitor the microenvironment may 
enable probing of cellular events and biomolecular interactions. 
[34]
 In this study they are 
intended to be used to investigate the localisation and function of the BID protein. 
Biotinylated sequences can be used in protein arrays to identify interacting partners and 
consequently functional regions of the BID protein, while their ruthenium-labelled 
counterparts would be used to confirm the localisation of these peptides at the mitochondrial 
membrane, where the (predicted) interacting partners are located. 
 
 
4.3.7 Method of Synthesis of Ruthenium polypyridyl BID peptide conjugates 
 
Initially coupling took place using the HATU coupling chemistry. This caused the 
peptide to be capped by the coupling reagent as confirmed by an increased mass of 97 on the 
mass spectra (Figure 4. 6). It is likely that the steric hindrance of the large Ru complex along 
with the high reactivity of HATU led to the coupling reagent reacting with the peptide only 
and terminating the sequence by guanidination (Figure 4.7) without conjugation to the metal 
complex. 
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Figure 4. 6: MALDI-TOF of BID 137-157 capped by HATU coupling reagent, using α-cyano-4-
hydroxycinnamic acid matrix 
 
122 
 
 
 
Figure 4.7 Mechanism of HATU termination 
 
The HATU based amide coupling is mediated in two steps; activation and coupling. 
In the activation step HATU reacts with the deprotonated carboxylic group forming an 
active intermediate. In the coupling step the created intermediate reacts with the amino 
component to form the amide. The rate of the first step is regulated by the structural feature 
of the carboxylic component. In the second step the rate is regulated of characteristics of the 
amino group and of the coupling reagent. 
 
During the activation of hindered carboxylic components, the aminium salts can 
react with the amino component, leading to a guanidine derivative, a process that terminates 
the peptide chain. HATU should not be used in excess because it can react with the 
unprotected N-terminal and block further chain elongation. 
 
The reaction was attempted by benzotriazol-1-yl-oxytripyrrolidinophosphonium 
hexafluorophosphate PyBOP coupling chemistry. This resulted in a good yield of pure BID 
155-177 coupled to [Ru (dppz) 2PIC]
2+
. The BID 137-157 peptide after conjugation to [Ru 
(dppz) 2PIC]
2+
 was poorly soluble in water and made the purification by reverse-phase 
chromatography more difficult resulting in a lower yield.  
 
4.3.8 Oxidation of Methionine 
 
Methionine, cysteine, tryptophan, tyrosine and histidine residues are vulnerable to 
oxidation. The oxidation of methionine to the sulfoxide form is of particular concern as it 
has been shown to occur in a wide variety of peptides and often reduces or eliminates 
biological activity.
[35]
 Methionine oxidation is of serious concern when proteins are used as 
pharmaceuticals because of the potential effects on activity and the likelihood of oxidation 
during processing or storage.
[36-39]
 It is acknowledged that side chain substitution can have 
profound effects on protein stability and structure. In effect oxidation can be regarded as a 
chemical `mutagenesis' which substitutes the methionine side chain with methionine 
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sulfoxide, a larger and more polar side chain (Figure 4. 8). It can significantly disrupt protein 
structure and stability. 
[40]
 
 
 
Figure 4. 8 Methionine can be oxidized to methionine sulfoxide and further to 
methionine sulfone. 
 
A potential approach for protecting a protein against the effects of methionine 
oxidation is to substitute methionine residues with amino acids which are resistant to 
oxidation. Although, this may alter the properties of the peptide or protein in question. 
Oxidation of the methionine residues (M
46
 and M
52
) in BID 137-157 coupled to Ru (dppz) 
2PIC occurred, as shown by mass spectrometry by an increase of 16 in the mass/charge 
signal of the molecular ion in Figure 4.9. Figure 4.9 shows the isotopic distribution of Ru. 
The desired Ruthenium polypyridal peptide conjugate has a relative molecular mass of 3,493 
and the corresponding signal is seen on the spectrum. The signal at m/z = 3,509 indicates 
one oxidized methionine and at 3,525 suggests the oxidation of the 2 methionines as 
sulfoxides or of 1 methionine as a sulfone.  For future work the replacement of these 
residues should be considered. The most appealing alternatives for a replacement side chain 
resistant to oxidation are norvaline and norleucine which are isomers of valine and leucine 
respectively. Substitution with norvaline removes the sulphur and prevents oxidation, but 
reduces side chain hydrophobicity and the potential for favourable van der Waals 
interactions. Norleucine maintains most of the side chain hydrophobicity and steric 
properties of methionine, but modifies its electronic properties and could therefore 
potentially affect the structure and activity of the parent sequence. 
[40, 41]
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Figure 4. 9: MALDI-TOF of BID 137-157 coupled to [Ru(dppz)2PIC]
2+
  using α-cyano-4-
hydrxycinnamic acid matrix showing oxidation of the methionine residues. 
 
4.3.9 Results from chromophore conjugation 
 
BID 137-157 contained the highest quantity of hydrophobic regions out of all the 
BID sequences synthesized and it also contained two methionine residues. For these reasons 
the yields were so low that only an analytical sample was obtained for this labelled peptide. 
Due to time and resources constraints, the synthesis of Ru (dppz) 2PIC-BID 155-177 was 
prioritised. 
 
The UV-VIS spectrum of Ru (dppz) 2PIC BID 155-177 recorded in an aqueous 
solution is shown in Figure 4.10. The same solution did not give an emission spectrum 
presumably due to the H-bond interactions between the dppz ligands and water.  This 
confirmed that the BID peptide did not confer any protection on the Ru centre from aqueous 
environment. The UV-VIS spectra is distinguished by a ruthenium π to ligand π* MLCT 
transition at 470 nm. The strong absorbance band at approximately 285 nm may be assigned 
to π-π* transitions within the polypyridal ligands, whereas the shoulder at approximately 340 
nm is attributed to the π-π* transitions of the carboxy-phenanthroline ligands containing the 
two ionisable protons on the imidazole ring. The absorbance profile of this conjugate is 
almost identical to that of the parent complex [Ru(dppz)2PIC]ClO4 seen by our group 
previously.  
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Figure 4.10 Absorbance of the synthesised Ru(dppz)2PIC-BID 155-177 (aqueous solvent) 
chromophore-peptide conjugate and the parent complex Ru(dppz)2PIC (acetonitrile solvent) 
 
The emission spectrum of Ru(dppz)2PIC-BID 155-177 is shown Figure 4. 11. 
Ru(dppz)2PIC-BID 155-177 exhibits a maximum emission at approximately 610 nm when 
excited into the MLCT absorbance band 470nm which is consistent with the emission of the 
parent complex [Ru(dppz)2PIC]ClO4. The emission decays follow biexponential kinetics 
with lifetimes for the emission decays of 0.2717 μs and 0.06795 μs. These lifetimes are 
comparable to those of the parent complexes [Ru(dppz)2PIC]ClO4 which also follow 
biexponential kinetics with lifetimes of 0.22361 μs and 0.06855 μs for the emission decays.  
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Figure 4. 11 Overlaid emission of the synthesised Ru(dppz)2PIC-BID 155-177 and parent 
complex in ACN. 
 
 
4.3.10 Preliminary Cell Imaging Studies 
 
Preliminary cell imaging was conducted on Ru(dppz)2PIC-BID 155-177 in SK-N-
AS neuroblastoma cells. In order to assess the ability of the BID compounds for cell 
imaging, cells were cultured separately on 35 mm glass bottom culture dishes. Kelly 
neuroblastoma cells were seeded at 5 x 10
5 
cells in 2 ml media and were grown for 24 hours 
before imaging. Addition of the ruthenium complexes (40 μM) was performed at 37 oC and 
incubated overnight. Images were acquired using a Zeiss LSM510 Confocal microscope, 
63x oil immersion lens, 458nm laser line for Ru.  
 
The parent complex was used as a control and as seen from Figure 4. 12, without the 
peptide the parent complex, [Ru(dppz)2PIC]ClO4, did not penetrate the cell. Under the same 
conditions the Ru (dppz)2PIC-BID 155-177 showed signs of cell penetration. 
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Figure 4. 12 [Ru(dppz)2PIC]ClO4 parent complex (200μM) in Kelly neuroblastoma cells 
incubated overnight. (Images collected by Dr. Róisín Moriarty) 
 
Figure 4. 13 Ru(dppz)2PIC-BID 155-177 (200μM) in Kelly neuroblastoma cells 
incubated over night. (Images collected by Dr. Róisín Moriarty) 
 
Figure 4. 14 shows the luminescent cross-section of the Ru(dppz)2PIC-BID 155-177  
peptide (red) and nuclear stain DAPI (blue) in fixed Kelly neuroblastoma cells after 
overnight incubation at 37
o
C in PBS buffer. It is evident that the Ru(dppz)2PIC-BID 155-177  
peptide does not localise in the nucleus as expected. Preliminary cytotoxicity data suggests 
that the Ru(dppz)2PIC-BID 155-177 peptide (~70% toxicity at 100µm concentration) is far 
more toxic than the parent complex [Ru(dppz)2PIC]ClO4 (~10% toxicity at 100µm 
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concentration). Thus the imaging and preliminary cytotoxicity results provide evidences that 
the Ru(dppz)2PIC-BID 155-177  peptide does penetrate Kelly neuroblastoma cells while the 
parent complex [Ru(dppz)2PIC]ClO4 which does not penetrate this cell line at all. However 
we cannot conclude toxicity following intracellular access or if cell penetration occurs 
because of toxic effects. 
 
 
Figure 4. 14 Ru(dppz)-Bid and DAPI in SK-N-AS fixed neuroblastoma cells. (Images 
collected by Dr. Róisín Moriarty) 
 
 
4.10 Conclusion 
 
 This chapter described the synthesis of 11 overlapping BID peptide 
sequences spanning the complete protein (tBid). Most of these peptides could not be 
prepared by routine techniques. Only two BID sequences, BID 155-177 and BID 78-101, 
were successfully made by automated synthesis. The remaining 9 were partly assembled on 
the synthesizer and fully elongated by manual with microwave activation when required. 
Some sequences also required a change in the coupling chemistry and the polymeric support. 
Sequence assembly was carefully monitored by carrying out both a mass spectrometry 
analysis of the sequence resulting from the automated synthesis and a Kaiser test after each 
step performed manually, to ensure the integrity of the 11 BID sequences upon completion 
of the synthesis. Purifications took place on a C18 column on HPLC with purities > 85%. 
Characterisation was conducted using MALDI-TOF or High Resolution mass spectroscopy.  
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The 11 BID sequences were successfully coupled to biotin for protein binding 
studies. The latter will be conducted through an independent collaborative project. Two of 
the BID sequences, BID 137-157 and BID 155-177, were chosen for conjugation with 
[Ru(dppz)2PIC]ClO4 on the basis of their high hydrophobic amino acid contents. The 
synthesis and purification of these proved to be more difficult than the biotin-labelled 
analogues, requiring a change in the coupling chemistry to overcome the low reactivity of 
the carboxyl group from the ruthenium complex. The latter may also promote the oxidation 
of sensitive residues when conjugated to a peptide sequence. The optimal conditions for 
[Ru(dppz)2PIC]ClO4 conjugation were identified and should be successfully applied to any 
of the other BID sequences which would show promising results from the protein binding 
studies. These studies addressed in particular the choice of the linker between the label and 
the peptide to ensure sufficient solubility in aqueous media of the conjugates. Photophysical 
and imaging studies were conducted with BID 155-177 and showed that the properties of the 
parent complex are not significantly modified by the conjugation of the peptide sequence. 
 
Unlike its unconjugated complex, Ru(dppz)2PIC BID 155-177  underwent diffusion 
across the cell membrane of Kelly neuroblastoma cells, with no accumulation in the nucleus, 
but also showed significant toxicity which could result from its interaction with the cell 
membrane or uptake in the cytoplasm. 
 
Protein binding studies with the 11 BID-Biotin peptide conjugates will be performed 
by the group Prof. Jochen Prehn in the Department of Physiology and Medical Physics at the 
Royal College of Surgeons in Ireland.  Further studies with Ru(dppz)2PIC-BID 155-177 by 
confocal microscopy, to determine its sub-cellular localisation, and by the cytotoxicity 
assay, to elucidate the chronology of the uptake and toxicity events are currently performed 
by Dr. Róisín Moriarty, research engineer, within the Prof. Tia Keyes group in Dublin City 
University. 
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Chapter 5: Targeting Mitochondria 
with Luminescent Chromophores 
134 
 
5.1 Introduction 
 As outlined in Chapter 3 the localisation of chromophores within cells 
has important applications in life science research. After successfully targeting two Ru 
(II) chromophores to the nucleus with NF-κB, confirming thereby that the presence of 
the ruthenium label did not modify the natural distribution of its conjugated peptide 
sequence, we then aimed to target them to the mitochondria, the organelle to be studied 
ultimately with the Bid peptides described in chapter 4. Prior to this application, the aim 
of the present study was to synthesize, purify and characterise mitochondrial targeting 
peptides conjugated to Ru(II) luminophores and then to carry out preliminary evaluation 
of their ability the to enter and localise in myeloma and bacterial cells lines. 
 
Mitochondrial DNA (mtDNA) located inside mitochondria organelles, exists in 
multiple copies. Inside mitochondria, reactive oxygen species (ROS) or free radicals, by-
products of the constant production of adenosine triphosphate (ATP), create a highly 
oxidative environment that is known to damage mtDNA.[1] Targeting the mitochondria 
with Ru(II) Chromophores has potential for imaging and therapeutic applications. The 
peptide chosen for supramolecular assembly to target the mitochondria is Magainin 2. 
Magainin 2 is an antimicrobial peptide (AMP), belonging to a class of short cationic 
peptides that are strongly membrane active.[2] Magainin 2 has previously been shown to 
accumulate fluorescent cargo probes in the mitochondria and nuclei.[3]  
 
This chapter details the synthesis of ruthenium (II) inorganic metal luminophores 
conjugated to Magainin 2 (GIGKKLHSAKKFGKAFVGEIMNS-NH2) and the 
preliminary cell imaging studies with these conjugates. Conjugation of the 
chromophores to Magainin 2 allows for their passive entry, without the need for 
permeabilisation, into living mammalian cells for cellular imaging studies. As 
previously outlined in Chapter 1, Magainin 2 has antimicrobial properties. It is an 
amphipathic peptide with potent, broad-spectrum antibiotic activity which has been 
investigated as a potential novel therapeutic agent for anti-infective but also anticancer 
applications. Additionally, the intrinsic photophysical properties of these metal 
complexes, with their triplet excited states can lead to generation of singlet oxygen and 
other reactive oxygen species which in turn may lead to induced apoptosis in cells, thus, 
making these dye-peptides potentially valuable in the area of photodynamic therapy. In a 
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therapeutic context, the peptide and the chromophore may prove to have a very valuable 
synergistic effect in the detection and treatment of certain diseases. 
 
The supramolecular assemblies synthesized were prepared as described 
previously in Chapter 3. The peptide, N-terminally modified with a 6-amino-hexanoic 
acid spacer, was prepared by Merrifield’s Solid Phase Peptide Synthesis.[4] Conjugation 
of the Ru polypyridal complexes to the peptide occurs through a stable amide bond with 
the aromatic carboxyl group of the former entity. The coupling reaction was performed 
on a side-chain protected resin-bound peptide.  
 
 
5.2 Experimental Details for the Synthesis of targeting peptides-dye 
conjugates 
 
The conjugates were synthesized according to methods previously reported in 
Chapter 3. The Ru(II) polypyridal complexes were supplied and characterised by Dr. 
Ciaran Dolan[5] and Kellie Adamson (Dublin City University). General experimental 
details of peptide synthesis itself are outlined in chapter 2 and specific details are 
outlined below. 
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5.2.1 Preparation of Ru(dpp)2PIC- Magainin 2 (Ahx-
GIGKKLHSAKKFGKAFVGEIMNS-NH2) conjugate. 
 
 
The Magainin 2 (Ahx-GIGKKLHSAKKFGKAFVGEIMNS-NH2) was 
assembled from a Rink Amide MBHA Resin (0.1mmol, substitution 0.7mmol/g) by 
automated synthesis as previously described. Manual coupling of [Ru(dpp)2PIC] ClO4 
(supplied by DCU) took place by solid phase synthesis, using PyBOP/HOBt (3eq) / 
DIEA (6eq) coupling chemistry with overnight shaking.  The peptide was cleaved by 
standard methods and then purified by RP-HPLC. Fractions collected on the semi-
preparative HPLC were analysed by mass spectrometry.  
 
Purity 84% (Appendix Figure 33) 
HRMS m/z: found 3667.68 [M + H]1+, calculated for C188H234N40O30RuS 3667.11 
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Figure 5. 1 Mass Spectra of Ru(dpp)2PIC- Magainin 2 (Ahx-
GIGKKLHSAKKFGKAFVGEIMNS-NH2) conjugate 
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5.2.2 Preparation of Ru(bpy)2PIC- Magainin 2 (Ahx-
GIGKKLHSAKKFGKAFVGEIMNS-NH2) conjugate. 
. 
 
 
The Magainin 2 (Ahx-GIGKKLHSAKKFGKAFVGEIMNS-NH2) was 
assembled from a Rink Amide MBHA Resin (0.1mmol, substitution 0.7mmol/g) by 
automated synthesis as previously described. Manual coupling of [Ru(dpp)2PIC] ClO4 
(supplied by DCU) took place by solid phase synthesis, using PyBOP/HOBt (3eq) / 
DIEA (6eq) coupling chemistry with overnight shaking.  The peptide was cleaved by 
standard methods and then purified by RP-HPLC. Fractions collected on the semi-
preparative HPLC were analysed by mass spectrometry.  
 
Purity 87% (Appendix Figure 34) 
MALDI-MS 3315.857 [M+1]+ calculated for C160H218N40O30RuS 3315.25(Figure 5.2) 
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5.3 Results and Discussion 
 
 The synthesis of these two novel Ru(II) polypyridal peptide conjugates 
was conducted in a similar manner to that outlined in section 3.2.  The peptide was 
synthesized on the Applied Biosystem ABI 433A Synthesizer.  The bio-conjugation of 
chromophore to peptide took place on the resin with PyBOP as the coupling reagent. 
Cleavage of the Ru(II) polypyridal peptide conjugates from the resin took place in TFA 
in the presence of scavengers and optimisation of the cleavage was completed as 
outlined in Section 3.2. Semi-preparative HPLC on reverse phase silica, C18 column was 
used to achieve purities >83%. A water/ACN gradient with TFA as the acidic ion pairing 
reagent was used. Monitoring was performed using UV-VIS detector at wavelengths of 
214nm and 452nm. The Ru(II) polypyridal peptide conjugates were characterised by 
mass spectroscopy, with the isotopic distribution pattern of Ru evident in Figure 5.1. 
 
Mass spectrometry and HPLC analysis were used routinely to confirm the purity 
of these chromophore peptide conjugates.  The HPLC chromatograms showed a single 
peak in both cases and the retention times of these signals are reported in Table 5. 1, 
using HPLC conditions as set out in the Chapter 2. Again, it is noted that the more 
hydrophobic Ru(dpp)2PIC- Magainin 2 conjugate has a retention time which is longer by 
approximately 8 minutes than the Ru(bpy)2PIC- Magainin 2 conjugate.  This is 
expected, as in reverse phase HPLC as hydrophobic-hydrophobic interactions are 
responsible for retention.   
 
The mass spectra of these novel chromophore-peptide conjugates are presented 
in Table 5.1. As already observed with the NF-κB peptides presented in Chapter 3, 
oxidation of one residue occurred in the conjugate of the [Ru(bpy)2PIC]
2+ complex, as 
evidenced by the mass spectral results (Figure 5. 2). The correct relative molecular mass 
of the Ru(bpy)2PIC- Magainin 2 conjugate  is 3315.25 and is seen by the m/z signal in 
the spectrum. However m/z signal at 3330.55 has an increased mass of 16 and suggests 
oxidation has occurred. Again, it is believed that this oxidation occurred at the 
methionine (M) residue in the sequence. The reason why this occurs for 
[Ru(bpy)2PIC]
2+ and not for [Ru(dpp)2PIC]
2+ is unclear.  The latter is expected to be 
more electron rich with an oxidation potential which is slightly lower than the bpy 
analogue. If it is the increased electron density on the dpp complex which is responsible 
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for oxidation of the M residue, this suggest that there is electronic communication within 
the assembly which is surprising given the M is so far from the conjugation point. It is 
more likely to be the time differences of the [Ru(bpy)2PIC]
2+ peptide conjugate spent in 
air during the cleave conditions.  
 
Table 5. 1 Synthesised peptide-linker-chromophores with % purities, retention times and 
experimental mass 
Peptide Linker Chromophore 
Retention Time 
(mins) 
% 
Purity 
Mass (Da) 
Magainin 2 Ahx-acid [Ru(bpy)2PIC]ClO4 24.2 84 3667.68 
Magainin 2 Ahx-acid [Ru(dpp)2PIC]ClO4 32.4 87 3315.857 
 
 
 
Figure 5. 2 Mass Spectra of Ru(bpy)2PIC- Magainin 2 (Ahx-
GIGKKLHSAKKFGKAFVGEIMNS-NH2) conjugate 
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5.4 Photophysical Characterisation of the Peptide-Chromophore 
Conjugates 
 
The spectroscopic and photophysical data of these ruthenium complexes 
peptides are presented in Table 5.2.  Similar to the other peptide conjugates reported in 
chapter 3, conjugation of the ruthenium (II) dye to the peptide did not cause any 
significant alterations to the wavelength of absorbance and emission of the conjugate 
when compared to the parent chromophores. The UV-VIS wavelength is for the MLCT 
and the emission is the luminescence when excited at this wavelength.  
 
Table 5. 2 The spectroscopic and photophysical data of all ruthenium complexes synthesised 
Peptide Linker Dye 
UV-VIS 
(nm) 
Emission 
(nm) 
Lifetimes 
Deaerated 
(µs) 
Lifetimes 
Aerated 
(µs) 
Magainin 2 Ahx [Ru(bpy)2PIC]ClO4 455.4 607 0.94±0.02 0.55±0.04 
Magainin 2 Ahx [Ru(dpp)2PIC]ClO4 456.0 611 3.72±0.04 0.98±0.02 
Parent - [Ru(bpy)2PIC]ClO4 455 606 1.02±0.02 0.16±0.03 
Parent - [Ru(dpp)2PIC]ClO4 466 614 3.90±0.03 0.20±0.04 
 
 
5.4.1 Absorbance 
 
Figure 5. 1 below shows the overlaid absorbance spectra for the ruthenium (II) 
peptide (Magainin 2) conjugates synthesised. The UV-VIS spectra of the two Magainin 
2 complexes are distinguished by a ruthenium π to ligand π* MLCT transition at ~460 
nm (individual values shown in Table 5.2) Again we can see the further evidence of a 
MLCT transition within the [Ru(bpy)2PIC]ClO4 conjugates at approximately 245nm. 
The strong absorbance band at approximately 285 nm may be assigned to π-π* 
transitions originating within the polypyridal ligands, whereas the shoulder at 
approximately 330 nm is attributed to the π-π* transitions of the carboxy-
phenylphenanthroline ligands containing the two ionisable protons on the imidazole 
ring. There is an increase in the absorbance of the conjugates compared to the parent 
complexes between 270-300nm due to the conjugation to the peptide.  The absorbance 
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profile of these conjugates are almost identical to that of the parent complexes 
[Ru(bpy)2PIC]ClO4 and [Ru(dpp)2PIC]ClO4 seen by our group previously.  
 
 
Figure 5. 1 Overlaid absorbance of the synthesised chromophore-peptide conjugates and parent 
complexes in water 
 
5.4.2 Emission 
 
The emission spectrum of the Ru(II) polypyridal peptide conjugates, Figure 5.2, 
exhibits a maxima emission at 607nm for Ru(bpy)2PIC- Magainin 2 conjugate  and 
611nm for Ru(dpp)2PIC- Magainin 2 conjugate when excited into the MLCT absorbance 
bands outlined in Table 5.2. All emission decays follow monoexponential kinetics with a 
lifetime in aerated samples shorter than in degassed solutions, as seen with 
Ru(bpy)2PIC- Magainin 2 the lifetime in aerated is 0.55µs whereas deaerated is 0.94  µs. 
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Figure 5.2 Overlaid emission of the synthesised chromophore-peptide conjugates 
 
The emission decays conform to monoexponential kinetics recorded when in 
aqueous solution at room temperature.  The deaerated samples were prepared by 
bubbling nitrogen through the solution for ~20minutes before measurements were 
recorded. The deaerated lifetimes are longer than the aerated as seen in Table 5.2, and as 
noted that the Ru(dpp)2PIC- Magainin 2 conjugate  lifetime is longer than that of for 
Ru(bpy)2PIC- Magainin 2 conjugate due most likely to the greater rigidity of this 
structure, i.e. reduced non-radiate decay . The increase in lifetime in absence of oxygen 
is also indication of the triplet MLCT character of the emission. [6] There is no 
significant difference in the lifetimes in relation to the length of peptides. The peptides 
in Chapter 3 contain between 7-10 amino acids where as the peptide in this chapter is 23 
amino acids long.  This was actually a little surprising, as we might have expected that 
the longer peptide residues might offer some protection from O2, but this was not the 
case. 
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5.5 Cellular Uptake of Chromophores-Peptide Conjugates  
 
As Magainin 2 has been known to target the mitochondria and nuclei, cell 
imaging was performed to investigate if it could direct the Ru polypyridal chromophores 
to these regions of the cell. In order to assess and compare the ability of the compounds 
to transport across the cell membrane of CHO cells, the latter were cultured separately 
on 35 mm glass bottom culture dishes and seeded at 5 x 105 cells in 2 ml media.  They 
were then grown for 24 hours before imaging. Incubation of the ruthenium complexes 
(40 μM) was performed at 37 oC overnight. Images were acquired using a Zeiss LSM510 
Confocal microscope, 63x oil immersion lens, 458nm laser line for Ru.  
 
Interestingly, no uptake of the Ru(bpy)2 PIC-Magainin 2 peptide conjugate could 
be observed from the imaging results, indicating that the Ru(bpy)2 PIC-Magainin 2 
peptide conjugate is unable to cross the cell membrane.  This was unexpected for an 
antimicrobial peptide such as Magainin 2, which was shown to transport across the 
membrane of CHO-K1 cells in previous studies.[3]  It would seem that the metal complex 
inhibits uptake, possibly by preventing the formation of a pore required to access the 
cytoplasm.[7, 8] The use of the N-amino terminus for the conjugation of the complex 
could also have contributed to this result.[9-11] As outlined in Chapter 1 Matsuzaki et al 
used TAMRA as their fluorophore and achieved cell penetration in CHO-K1 cells.[3] 
TAMRA-Magainin 2 exhibited membrane-permeabilizing activity comparable to that of 
the parent peptide. TAMRA is also very hydrophobic like the Ru polypyridal complexes 
and has a molecular weight of 430.45g/mol. The molecular weight of the two Ru 
polypyridal complexes we used are 753.7g/mol [Ru(bpy)2PIC]ClO4 for and 1106.2g/mol  
for [Ru(bpy)2PIC]ClO4. 
 
Interestingly though, on the other hand, the [Ru(dpp)2 PIC-Magainin 2] peptide 
conjugate did cross the membrane (Figure 5. 3). Following uptake it was found to be 
distributed throughout the cell and had concentrated within a section of the nucleus that 
may be the nucleolus, as seen previously with [Ru(dpp)2PIC]ClO4 in Chapter 3.  This 
concentration within the nucleus, we believe to be a feature of the [Ru(dpp)2PIC]ClO4 
metal complex as opposed to the localisation properties of the peptide it is conjugated to. 
There also appears to be a lot of cell debris and looks as though the [Ru(dpp)2 PIC-
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Magainin 2] peptide conjugate is killing the cells. This is confirmed by the cytotoxicity 
results in section 5.6. 
 
 
Figure 5. 3 Luminescent confocal images (λex = 458nm) of live CHO cells incubated with 
Ru(dpp)2 PIC-Magainin 2 peptide conjugate overnight in PBS at room temperature. Arrows 
show concentration within the nucleus. (Image courtesy of Dr. Róisín Moriarty) 
 
 
5.6 Cytotoxicity 
 
With the evidence of toxic effects following incubation with the [Ru(dpp)2 PIC] 
as described in Chapter 3, it was deemed important to assess the potential toxic effects 
of these chromophore-peptide conjugates complexes on this cell line. The effect of these 
complexes on the viability of the cells was tested using the alamar blue/resazurin 
cytotoxicity assay which is explained in detail in section 2.5.14. As seen in Figure 5. 4 it 
is evident from the results that the Ru(dpp)2 PIC peptide conjugates are cytotoxic to a 
degree which  is well above that of the Ru(bpy)2 PIC peptide conjugates. This is 
confirmed by evidence of cell debris as shown in Figure 5.3. However compared to the 
Ru(bpy)2 PIC NLS sequences, the Ru(bpy)2 PIC Magainin 2 sequence was more toxic. 
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This is almost certainly a contribution of the cytotoxic characteristics of the peptide 
itself.  As the peptide Magainin 2 alone, interacts with cancer cells at an intracellular 
target, the mitochondrion. It is therefore not surprising that the Ru(bpy)2 PIC which 
cannot penetrate the cytoplasmic membrane, has moderate effects on the viability of 
CHO cells (% cytotoxicity ~25%) as seen in Figure 5.4.  
 
 
 
Figure 5. 4 Cytotoxicity assay with CHO cells treated with Chromophore-peptide conjugates 
(Data prepared by Dr. Róisín Moriarty) 
 
 
 
5.7 Conclusion 
 
This chapter details the conjugation of ruthenium (II) polypyridyl chromophores 
to a mitochondria targeting peptide, Magainin 2. The synthesis of the chromophore-
peptides was completed by standard techniques and proceeded with good yields and 
purities greater than 85%. 
 
The photophysical results were similar to those obtained with shorter peptide 
conjugates and were relatively unchanged compared to the parent complexes.  As 
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expected, the luminescent lifetimes for the Ru(dpp)2PIC polypyridyl peptide conjugates 
were longer than the corresponding Ru(bpy)2PIC polypyridyl peptide conjugates and the 
de-aerated lifetimes were longer for all Ru(II) polypyridyl peptide conjugates than the 
aerated samples. 
 
Prior to peptide conjugation, neither parent complex exhibited efficient transport 
across the cell membrane of CHO cells and only the Ru(dpp)2 PIC complex conjugate 
crossed the cell membrane of CHO cells after conjugation to the Magainin 2 sequence. 
In general, this did not lead to localisation of the dyes within the cell’s mitochondria, the 
expected target of the peptide component; however co-localising experiments will be 
required to confirm this result. The corresponding Ru(bpy)2 PIC Magainin 2 conjugate 
did not cross the membrane, which would indicate that there might exist a threshold of 
hydrophobicity of the cargo  controlling the cellular uptake of the conjugate, as both 
Ru(bpy)2 PIC and Ru(dpp)2 PIC complexes should have the same effect on the N-
terminal capping of the peptide and its ability to form a transmembrane pore. 
 
The Ru(dpp)2 PIC peptide conjugates distribute throughout the entire cell. It is 
possible that it’s interaction with the mitochondrial membrane triggers rapid cell death 
and cannot be imaged. The Ru(dpp)2 PIC peptide conjugates may be useful in 
therapeutics as it targets the nucleus and could potentially result in the apoptosis of 
cancer cells. We believe it to concentrate further within the nucleolus, however further 
imaging and localising studies must be completed. Also as the Magainin 2 peptide can 
penetrate bacterial cells, the use of the Ru(II) polypyridyl Magainin 2 conjugate in 
imaging will be extended to bacterial cells, although the rapid killing mechanism 
induced by Magainin 2 in prokaryotic cells might make this application challenging.  
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Chapter 6: 
Small molecule Inhibitors of Bcl-2 
family proteins 
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6.1 Introduction  
 
Protein-protein interactions (PPIs) are essential to most biological processes and 
their modulation can be exploited as targets for human therapeutics. PPIs are a great interest 
to drug discovery, in particular when they can be disrupted by molecules of low molecular 
weights which are orally available. However, these small molecule therapeutics can have 
some drawbacks as potential drug candidates. Small molecule therapeutics that target PPIs 
can be difficult to manufacture and have poor cell permeability and solubility in water.
[1, 2]
 
 
There are challenges associated with finding a suitable small molecule inhibitor 
(SMI) for protein-protein interactions. One such challenge is to find lead compounds which 
selectively disrupt interaction surfaces that can be extended and discontinuous. Research 
into protein-protein interactions is focused on drug discovery through structure-based 
design, in silico screening and fragment based discovery, all of which have led to the 
identification of small-molecule antagonists of protein -protein interactions.
[3]
 
 
Most protein-protein interfaces are large, flat and have a lack of clear pockets, making PPI 
difficult targets for therapeutic purposes.
[4]
 The discovery of ‘hot spots’ was a major advance 
in the progress of small molecule PPI inhibitors.
[5]
 Small molecules targeting hot spot sites 
on protein-protein interfaces can disrupt their interaction. Small molecules, shown in Figure 
6. 1, targeting these interactions are currently in clinical trials.
[6]
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Figure 6. 1 Examples of small molecules that inhibit protein–protein interactions. 
 
6.1.2 Protein interactions between the Bcl-2 family proteins 
 
As previously discussed in Chapter 1, the Bcl-2 family of proteins contain members 
that are important regulators of cell death. The proteins of this family react with each other, 
generating pro-apoptotic and anti-apoptotic members. One example of this is the anti-
apoptotic protein Bcl-XL which binds to a 26 residue α-helical section of a pro-apoptotic 
member BAD and inhibit thereby apoptosis (Figure 6.2).
[6]
 In Figure 6.2 Bcl-XL is rendered 
as a filled surface (grey) with the contact surface shown in green, while the binding protein 
or peptide is represented as a ribbon diagram (yellow), with selected side-chains shown as 
sticks (with carbon in yellow, oxygen in red and nitrogen in blue). The small molecule 
inhibitor of the anti-apoptotic proteins Bcl-2, Bcl-XL and Bcl-w, ABT-737, is shown in stick 
format, with the contact surface shown in orange. In the central figure, the small molecule 
ABT 737 is shown superimposed on the pro-apoptotic protein in the conformation in which 
it binds to its natural anti-apoptotic protein or peptide partner, and the contact surface (on the 
target protein) of the natural interaction is shown in green. On the left figure is Bcl-XL bound 
to a peptide derived from one of its natural protein partners, BAD. 
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Figure 6. 2 The structures of protein–protein or protein–peptide complexes of pro- and anti-
apoptotic proteins. 
[6]
 
 
 
Inhibitors of anti-apoptotic proteins mimicking BAK and BAD are potential drug 
candidates for the treatment of cancer. Generating small molecule inhibitors that mimic the 
α-helix residues of BAD has therefore received much attention. [7-9] Abbott laboratories in 
particular developed the BH3 mimetic inhibitor ABT 737, as described in Chapter 1.
[10]
 It 
was discovered using a fragment-based nuclear magnetic resonance (NMR) method known 
as SAR by NMR and its properties improved by using NMR-structure-guided medicinal 
chemistry. An orally available derivative of ABT-737, ABT-263, is in phase I/II clinical 
trials for cancer treatment.
[11]
  
 
6.2 ABT 737 and 263 
 
Major differences are observed in both potency and selectivity of the various small 
molecule Bcl-2 inhibitors for the different anti-apoptotic Bcl-2 proteins.
[10, 12-21]
 By far the 
most potent small molecule inhibitors described to date are the BAD-like BH3 mimetics, 
ABT-737 and its orally available analogue ABT-263.
[22]
 For this reason they were chosen as 
low molecular weight candidates to perform localisation studies by cellular imaging with Ru 
(II) polypyridal probes alongside functional studies. These small molecules bind with very 
high affinities to Bcl-2, Bcl-XL and Bcl-w but with much lower affinities to Mcl-1 or 
Bcl2A1. 
[18, 23]
 Most detailed mechanistic studies on Bcl-2 inhibitors have been carried out 
using ABT-737 and it is proving to be a very valuable tool for such fundamental studies.
[24]
 
The development of an orally bioavailable Bcl-2 inhibitor, such as ABT-263, with the ability 
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to inhibit specifically BH3-Bcl-2 protein-protein interactions at low nanomolar 
concentrations, potentially marks a significant development in cancer therapy.  
 
The synthetic pathway described in a patent developed by Abbott laboratories was 
used as a reference for the synthesis of ABT-263
[25]
 while the synthetic pathway described 
by Oltersdorf et al
[10]
 was used for ABT-737.  The objective of this synthetic work was 
ultimately to avail, by adapting the original synthetic route(s), if required, of a synthetic 
method for the preparation of labelled analogues of ABT-263/737. The synthetic strategy 
adopted to synthesise ABT-737 is shown in the scheme on page 163. It involves a 13 step 
convergent synthetic route based on three different synthons. The synthesis of ABT-263 was 
initially investigated according to the scheme presented on page 164. ABT-263 has slight 
structural variations which improve the oral bioavailability of ABT-737. The structural 
differences between ABT-737 and ABT-263 are outlined in Figure 6. 3.  One of these sites 
was also proposed as a potential conjugation point for the Ru(II) polypyridal probe. The 
intermediates synthesised have proton NMRs matching those reported by Oltersdorf and 
their carbon NMR signals are described for the first time.  
 
 
Figure 6. 3 Structures of ABT-737 and ABT-263 with differences pointed out with arrows. 
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6.3 Synthetic Route 1(red) of ABT 737 
6.3.1 Preparation of N-benzyloxycarbonyl-D-aspartic acid anhydride 
 
 
 
 
Procedure: N-benzyloxycarbonyl-D aspartic acid (5.0328 g, 18.83 mmol) (Merck) and 
acetic anhydride (11ml, 116 mmol) were placed in a 100 ml round bottom flask and stirred 
gently overnight under argon . Dry dioxane (12ml) was added to the flask and the solvent 
mixture was reduced by high vacuum by maintaining the flask in a water bath whose 
temperature was not allowed to exceed 38°C, until gelation had occurred. This procedure 
was repeated using dry toluene. (both dioxane and toluene form an azeotrope with acetic 
acid). The product was dried finally on a freeze-dryer. The solid obtained was used in the 
next step without purification.  
 
6.3.2 Preparation of (R)-benzyl (5-oxotetrahydrofuran-3-yl)carbamate, Compound 
1 ABT 737 (Compound 1 ABT 263) 
 
 
 
 
Procedure: To a stirred slurry of sodium borohydride (0.711g, 18.7 mmol) (Sigma) in THF 
(30 ml) kept at 0°C was added N-benzyloxycarbonyl-D-aspartic anhydride, compound 1 
(4.65g, 18.7 mmol) in THF (35 ml) over a 3 hours period. After stirring at room temperature 
for 1 hour, the reaction mixture was acidified to pH 2 using 6M HCl and then concentrated 
to approximately ¼ the initial volume using a rotary evaporator. The resulting solution was 
diluted with water and extracted with four portions of ether. The combined organic layers 
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were then concentrated under reduced pressure to a heterogeneous yellow residue. The latter 
was taken up in toluene (30ml) containing p–TsOH (30mg) and water was then 
azeotropically removed using a Dean-Stark apparatus. After the mixture had refluxed for 5 
hours, the toluene was removed by rotary evaporation to afford a viscous orange residue 
which gave light brown crystals upon trituration with ether. The solid material was collected 
by vacuum filtration. The filtrate was concentrated under reduced pressure and triturated 
with ether to afford a second crop of crystals (140mg, 45.7% combined yields).  
 
1
H NMR (DMSO-d6, 400MHz)  2.38 (dd, J = 18, 4 Hz, 1H), 2.83 (dd, J = 18, 9 Hz, 1H), 
4.09 (dd, J = 9, 3 Hz, 1H), 4.30 (m, 1H), 4.41 (dd, J = 9, 6 Hz, 1H), 5.03 (s, 2H), 7.36 (m, 
5H), 7.88 (br d, J = 7 Hz, 1H).  (Appendix Figure 36) 
 
13
C NMR (DMSO-d6, 100.6MHz), 33.94, 47.47, 65.52, 72.97, 127.87 136.79 , 155.67, 
175.68. (Appendix Figure 37) 
 
HRMS m/z: found 258.075 [M + H]+, calculated for C12H13NO4Na 258.074 (Appendix 
Figure 38) 
 
6.3.3 Preparation of (R)-benzyl (4-(dimethylamino)-1-hydroxy-4-oxobutan-2-
yl)carbamate, Compound 2 ABT 737 
 
 
Procedure: A solution of 2.0 M N,N-dimethylamine in THF was added to compound 2 
(500mg, 2.12 mmol) at room temperature until a solution was obtained (~5ml).  After 
stirring at room temp for 14h, the reaction mixture was concentrated to dryness, loaded on a 
plug of silica and eluted first with 1:1 ethyl acetate:hexanes (fraction discarded) and then 
with acetone.  Concentration of the acetone eluent gave 548 g (91%) of the desired product 
as thick colourless oil that solidified upon standing.  
 
1
H NMR (CDCl3, 400MHz)  2.43 (dd, Hz, 2H), 2.7 (s, 3H), 2.9 (s, 1H), 3.3 (m, 2H), 3.91 
(m, 1H), 5.03 (s, 2H), 7.16 (br d, 1H), 7.32 (m, 5H). (Appendix Figure 39) 
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13
C NMR (CDCl3, 100.6MHz), 29.54, 36.74, 50.60, 62.76, 65.11, 128.09 137.25 , 155.55, 
171.88. (Appendix Figure 40) 
 
m/z= 281.52 (100%, [M + H]
+
)  calculated for C14H20N2O4 280.1423(Appendix Figure 41) 
 
6.4. Synthetic Route 2 (green) of ABT 737 
6.4.1 Preparation of 4-fluoro-3-nitrobenzene-1-sulfonyl chloride, Compound 6 
ABT 737 
 
 
 
Procedure: A solution of 1-fluoro-2-nitrobenzene (1.0 g, 5.7 mmol) in chlorosulfonic acid 
(4 mL) was heated at 80 °C overnight and poured onto crushed ice. The mixture was diluted 
with ethyl acetate, and the layers were separated. The aqueous layer was extracted with ethyl 
acetate (×2), and the combined organic layers were dried over MgSO4, filtered, and 
concentrated to give a crude product (1.4 g, 93%), which was used in the next step without 
further purification.  
 
6.4.2 Preparation of 4-fluoro-3-nitrobenzenesulfonamide, Compound 7 ABT 737 
 
 
 
Procedure: To a solution of the sulfonyl chloride, Compound 6 (1.4 g, 5.3 mmol) in 20 mL 
of THF-MeOH (1:1) cooled to -50 °C was added ammonium hydroxide (28% aqueous 
solution, 1.8 mL, 26.5 mmol). The reaction mixture was allowed to warm to 0 °C, and the 
157 
 
solvent was removed in vacuo. The residue was purified by chromatography (SiO2, 20% 
ethyl acetate in hexanes) to give a yellow powder (704 mg, 60.4% over two steps).  
 
1
H NMR (DMSO-d6, 400MHz) δ 7.75 (s, 2H), 7.81 (dd, J = 8.72, 10.9 Hz, 1H), 8.20 (ddd, J 
= 2.4, 4.06, 8.84 Hz, 2H), 8.52 (dd, J = 2.2, 6.9 Hz, 2H) (Appendix Figure 42) 
 
13
C NMR (DMSO-d6, 400MHz) δ 158.7, 140.86, 133.46, 133.36, 124.02, 120.00 (Appendix 
Figure 43) 
 
HRMS m/z: found 218.9873 [M-H]
+
, calculated for C6H5FN2O4S 219.9954 (Appendix 
Figure 44) 
 
6.5 Synthetic Route 3 (blue) of ABT 737 
6.5.1 Preparation of ethyl 4-(piperazin-1-yl)benzoate, Compound 8 ABT 737 
(Compound 8 ABT 263) 
 
 
 
 
 
Procedure: DMSO (10ml) was added to piperazine (5.2g, 60mmol) to prepare a suspension 
to which ethyl-4-fluorobenzoate (2.5g, 0.015 mmol) was added at room temperature. The 
reaction mixture was stirred at 120˚C for 20hrs. After this time the reaction mixture was 
taken up in DCM (~250ml) and washed 3 times with saturated NaHCO3 (x3) and once with 
saturated NaCl and water. The organic layer was concentrated under reduced pressure to 
yield a cream solid. (2.774g, 78.9%).  
 
1
H NMR (CDCl3, 400MHz) δ: 1.36 (t, J = 7.05 Hz, 3H), 3.04 (m, 4H), 3.27 (m, 4H), 4.31(q, 
J = 7.02Hz, 2H), 6.86 (d, J = 9.07 Hz, 2H), 7.92 (d, J = 8.99 Hz, 2H) (Appendix Figure 45) 
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13
C NMR (CDCl3, 400MHz) δ: 14.46, 45.87, 48.68, 60.37, 113.67, 120.17, 131.14, 154.51, 
166.70.  (Appendix Figure 46) 
 
HRMS m/z: found 235.1451 [M + H]
+
, calculated for C13H18N2O2 234.1368 (Appendix 
Figure 47) 
 
6.5.2 Preparation of ethyl 4-(4-(2-bromobenzyl)piperazin-1-yl)benzoate, 
Compound 9 ABT 737 
 
 
 
Procedure: To Compound 8 (58.06 mg, 0.248 mmol) in acetonitrile (20 ml) was added 2-
bromobenzylbromide (92.97mg, 0.372 mmol) and DIEA (65μl, 0.372 mmol). and the 
resulting mixture was allowed to stir at room temperature overnight. The product was 
isolated as a white powder by filtration. (41 mg, 41%) 
 
1
H NMR (CDCl3, 400MHz) δ: 1.36 (t, J = 7.05 Hz, 3H,), 2.68 (m, 4H), 3.35 (m, 4H), 3.67 
(s, 2H), 4.32 (q, J = 7.02 Hz, 2H), 6.86 (d, J= 9.07 Hz,  2H), 7.15 (t, J= 8.15 Hz, 1H) 7.30 (t, 
J= 7.02 Hz, 1H) 7.49(d, J= 7.80 Hz, 1H) 7.57 (d, J= 8.15 Hz, 1H) 7.92 (d, J= 8.99 Hz, 2H) 
(Appendix Figure 48) 
 
13
C NMR (CDCl3, 400MHz) δ:14.09, 47.81, 52.97, 60.53, 61.74, 113.63, 120.04, 124.72, 
127.49, 128.59, 130.47, 131.44, 133.17, 137.27, 154.18, 166.70. (Appendix Figure 49) 
 
 
HRMS m/z: found 403.1036 [M + H]
+
, calculated for C20H23BrN2O2 402.0943 (Appendix 
Figure 50) 
 
CHN: Theoretical C 59.56%, H 5.75%, N 6.95%  Experimental C 59.56%, H 5.73%, N 
6.91% (Appendix Figure 51) 
 
 
159 
 
6.5.3 Preparation of ethyl 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1-
yl)benzoate, Compound 10 ABT 737 
 
 
Procedure: To a suspension of  compound 9 (0.812 g, 2 mmol), 4- chlorophenylboronic 
acid (0.375 g, 2.4 mmol) and aqueous sodium carbonate (2M, 2.5 mL, 2.4 mmol) in DME-
H2O-EtOH (7 mL-3 mL-2 mL) was added PdCl2(PPh3)2 (56 mg,  0.8 mmol). The mixture 
was heated at 85 °C for 3 h under nitrogen atmosphere and filtered through a pad of Celite. 
The filter cake was washed with ethyl acetate and the combined filtrates were concentrated. 
The crude product was crystallised from MeOH to yield white crystals. (1.77 g, 89%). 
 
1
H NMR (CDCl3, 400MHz) δ: 1.32 (t, J = 7.05Hz, 3H,), 2.39 (m, 4H), 3.24 (m, 4H), 3.39 (s 
2H), 4.23 (q, J = 7.02Hz, 2H), 6.89 (d, J= 9.07Hz, 2H), 7.15 (t, J= 8.15Hz, 1H) 7.30 (t, J= 
7.02Hz, 1H) 7.49(d, J= 7.80Hz, 1H) 7.57 (d, J= 8.15Hz, 1H) 7.39 (d, J= 8.99Hz, 2H) 
(Appendix Figure 52) 
 
13
C NMR (CDCl3, 400MHz) δ:14.27, 46.70, 51.38, 59.24, 59.83, 113.67, 118.39, 127.20,  
127.46, 127.92, 129.68, 130.03, 130.61, 131.06, 131.86, 135.12, 139.68, 153.81, 165.62. 
(Appendix Figure 53)  
 
HRMS m/z: found 435.1818 [M + H]
+
, calculated for C26H27ClN2O2 434.1761 (Appendix 
Figure 54) 
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6.5.4 Preparation of 4-(4-((4'-chloro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-
yl)benzoic acid, Compound 11 ABT 737 
 
 
Procedure: A suspension of compound 10 (945 mg, 2.17 mmol) and LiOH (41.96 mg, 8.68 
mmol) in water (7ml) and dioxane (45ml) was heated at 100°C for 18 hours. The dioxane 
was removed by evaporation and the resulting solution was diluted with water and heated to 
reflux for 1 hour. The solution was neutralized with 2M HCl and the resulting white solid 
collected by filtration and dried to yield the desired product, (796 mg, 87%). 
 
1
H NMR (CDCl3, 400MHz) δ: 2.39 (m, 4H), 3.24 (m, 4H), 3.39 (s 2H), 6.90 (d, J= 9.07 Hz, 
2H), 7.15 (t, J= 8.15 Hz, 1H) 7.30 (t, J= 7.02Hz, 1H) 7.49(d, J= 7.80 Hz, 1H), 7.52 (s, 4H), 
7.57 (d, J= 8.15Hz, 1H), 7.41 (d, J= 8.99 Hz, 2H). (Appendix Figure 55) 
 
13
C NMR (CDCl3, 400MHz) δ: 46.02, 52.01, 113.30, 120.17, 131.14, 153.65, 
167.23(Appendix Figure 56) 
 
HRMS m/z: found 407.1543 [M + H]
+
, calculated for C24H23ClN2O2 406.1448 (Appendix 
Figure 57) 
 
6.6 Synthetic procedures of ABT 263 
6.6.1 Preparation of (R)-benzyl (1-hydroxy-4-morpholino-4-oxobutan-2-
yl)carbamate, Compound 2 ABT 263 
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Procedure: (R)-benzyl (5-oxotetrahydrofuran-3-yl)carbamate (1.459 g, 6.2 mmol) and 
morpholine were added to a microwave vial (15 ml vial) filled to the required volume using 
dioxane. Using the microwave synthesizer, Biotage Initiator 2.5, the reaction was run for 4.5 
hrs at 90°C with pre-stirring of 1min, adsorption level normal and fixed hold time on. After 
this time the solution was concentred yielding a clear gel. The product was purified by 
column chromatography on silica gel using 10% MeOH and ethyl acetate. Yield 73%, 
1.462g.  
 
1
H NMR (CDCl3, 400MHz) δ: 2.71 (dd, J=5.8Hz, 2H), 3.66 (m, 11H), 3.97 (m, 1H), 5.09 (s, 
2H), 7.35 (m, 5H) (Appendix Figure 58) 
 
 
13
C NMR (CDCl3, 100.6MHz) 34.4, 46.0, 50.0, 63.8, 66.8, 67.5, 128.0, 128.2, 128.50, 136.3, 
156.3, 169.9. (Appendix Figure 59) 
 
m/z=325.63 (100%, [M + H]
+
) calculated for C16H22N2O5 323.1529 (Appendix Figure 60) 
 
6.6.2 Preparation of 1-bromo-4,4dimethylcyclohex-1-ene-carbaldehyde, 
Compound 9 ABT 263 
 
 
 
Procedure: A magnetically stirred solution of DMF (18.2 mmol, 1.411 ml) in anhydrous 
chloroform (10 ml) at 3°C was carefully treated with phosphorus tribromide (18.2 mmol, 
4.93 g). The resulting pale yellow liquid was warmed to room temperature and was allowed 
to stir for an additional 20 min.  
 
A solution of 4, 4-dimethyl cyclohexanone (4.5 mmol, 574 mg) in anhydrous 
chloroform (9ml) was added dropwise to the reaction mixture. It was then heated to 60˚C for 
1hr resulting in a red/orange solution. The solution was then poured into ice and neutralised 
with solid sodium bicarbonate. The product was extracted with ether which was washed with 
brine twice, dried using MgSO4 and evaporated to yield a yellow oil. Yield: 38% 380mg  
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1
H NMR (CDCl3, 400MHz) δ: 0.88 (s, 6H), 1.45 (t, J= 6.54 Hz, 2H), 2.01 (s, 2H), 2.69 (m, 
2H), 9.96 (s, 1H). (Appendix Figure 61) 
 
13
C NMR (CDCl3, 400MHz) δ: 27.62, 28.48, 36.76, 38.29, 50.92, 134.02, 142.77, 194.00.   
(Appendix Figure 62) 
6.6.3 Preparation of ethyl 4-(4-((2-bromo-5,5-dimethylcyclohex-1-en-1-
yl)methyl)piperazin-1-yl)benzoate, Compound 10 ABT 263 
 
 
 
Procedure: 1 bromo-4,4-dimethyl cyclohexene carbaldehyde (0.737 g, 3.4 mmol) and ethyl 
4-(piperazin-1-yl)benzoate (0.830 g, 3.5 mmol) in MeOH (~40ml) was treated with sodium 
cyanoborohydride (0.440 g, 7.1 mmol) adjusted to pH 5 with acetic acid and stirred for 
18hrs. After this time the solution was concentrated to yield a cream solid. Yield 73%, 
1.077g  
 
1
H NMR (CDCl3, 400MHz) δ: 0.924 (s, 6H), 1.36 (t, J=7.34 Hz, 3H), 1.43 (t, J=6.69 Hz, 
2H), 1.99 (s, 2H), 2.49 (t, 2H), 3.40 (m, 4H), 3.57 (m, 4H), 4.20 (s, 2H), 4.32 (q, J=7.3 Hz, 
2H), 6.88 (d, J=8.39, 2H), 7.95 (d, J=8.39 2H)  (Appendix Figure 63) 
 
 
13
C NMR (CDCl3, 400MHz) δ: 14.38, 27.77, 29.18, 34.47, 37.13, 42.82, 43.69, 45.28, 60.74, 
66.34, 114.96, 120.23, 131.37, 133.93, 152.81(Appendix Figure 64) 
 
m/z=435.57 (100%, [M + H]
+
) calculated for C22H31BrN2O2 434.1569 (Appendix Figure 65) 
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6.7 Results and Discussion 
6.7.1 ABT 263 
 
The synthetic routes for ABT 263 and ABT 737 are similar. ABT 263 was initially 
selected as it belongs to a newer generation of BH3 mimetic inhibitors, orally available and 
which has progressed to clinical trials.
[11]
 The literature available for the synthesis of this 
candidate is limited to a patent to Abbott laboratories, which was used as a reference for the 
synthetic procedures. Limited details of the synthetic protocols and characterisation data 
were disclosed in this document.  
6.7.1.1 Route 1 ABT 263 
 
Scheme 6. 1 Route 1 of ABT 263: Synthesis of 4-morpholino-1-(phenylthio)butan-2-amine (5) 
 
Route 1 was investigated separately originally, but to benefit of the advantages of a 
convergent synthesis, the preparation of the 3 main synthons was in due course performed in 
parallel. The required N-benzyloxycarbonyl-D aspartic acid anhydride (1) was prepared 
through the reaction of N-benzyloxycarbonyl-D-aspartic acid with acetic anhydride by the 
method of Lutz and co-workers
[26]
 as this step was not described in the patent. This 
dehydration reaction involves the conversion of the carboxylic acids to an acid anhydride. 
The starting material, N-benzyloxycarbonyl -D-aspartic acid, is protected by the Bergmann-
Zervas benzyloxycarbonyl group. The electron withdrawing nature of the carbonyl group 
exerted on the nitrogen’s lone pair of electrons, is reduced by the donation of a lone pair of 
electrons from the oxygen, which also renders the carbonyl carbon less susceptible to 
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nucleophiles. Liberation of the amino group will occurs upon completion of route 1 by 
treatment with hydrobromic acid (HBr) of the labile carbon-oxygen bond. This can also be 
achieved cleanly by catalytic hydrogenation producing carbon dioxide and toluene as side 
products. Due to the sensitivity of the anhydride to hydrolysis, it was used directly in the 
next step after freeze-drying without purification. This step consistently produced low yield 
(~40%) of materials and was very time consuming as the removal of the azeotropic solvents 
could not be performed above 38°C and could take up to 3 weeks on the high vacuum line. 
Alternative methods were therefore investigated.  
 
An alternative reaction for the formation of the acid anhydride used thionyl chloride. 
Thionyl chloride would convert the carboxylic acid to the acyl chloride, followed by 
addition-elimination mechanism in which the chloride anion is the leaving group. In the 
initial reaction step, the carboxyl oxygen reacts by nucleophilic attack with the considerably 
electrophilic acyl halide's carbonyl carbon. As a result, a tetrahedral intermediate is formed. 
In the second reaction step, a chloride - a good leaving group - is eliminated from the 
tetrahedral intermediate resulting in the closed ring structure. This reaction gave us similar 
low yields and due to the harmful properties of thionyl chloride, the first reaction option was 
maintained.  
 
The next step required the selective reduction of the anhydride to form the 3-(R) 
carboxybenzyl-amino-butyrolactone (1). As described in the patent this was achieved by 
treatment with sodium borohydride (NaBH4) and resulted in the regiospecific reduction  of  
the anhydride to obtain the desired product (1). Sodium borohydride is a common reducing 
agent for carbonyl compounds. It is a simple, safe, inexpensive reagent and reduction can be 
achieved within 3-4hrs. Operational simplicity makes this procedure generally attractive. It 
does not require anhydrous conditions and avoids the use of an inert atmosphere, unlike the 
powerful reducing agent lithium aluminum hydride. The regioselectivity of this approach 
has been shown by McGarvey et al. 
[27]
 These two combined steps to form 3-(R)-N-
benzyloxycarbonyl -amino-butyrolactone (1) gave yields up to 50%.  
 
The next step required the nucleophilic reaction of the morpholine ring with the 
lactone group of 3-(R)-N-benzyloxycarbonyl-amino-butyrolactone (1) to form (R)-benzyl (1-
hydroxy-4-morpholino-4-oxobutan-2-yl)carbamate (2). This was first attempted by the 
method reported in the patent and involved the reaction of 3-(R)-N-benzyloxycarbonyl-
amino-butyrolactone (1) in the presence or 2 molar equivalence of morpholine in dioxane 
stirred for 24 hours at 65°C. On the first attempt the reaction did not go to completion and a 
significant amount of starting material remained, resulting in yields as low as 16%. The 
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reaction was repeated and monitored by TLC, using a total of 16 molar equivalents of 
morpholine, added over 60hrs. The reaction failed again to go to completion. Several 
attempts to alter the reaction conditions all remained unsuccessful and microwave activation 
was then considered. 
[28]
  
 
There are numerous reports in the literature showing that microwave heating can 
intensely reduce reaction times, increase product purities and improve product yields by 
decreasing unwanted side-reactions when compared to conventional heating methods.
[29, 30]
 
In principle, any chemical reaction that involves heat can be achieved under microwave 
conditions has been largely accepted as a fact by the scientific community.
[31]
 The short 
reaction times provided by microwave synthesis make it ideal for rapid reaction scouting and 
optimization of reaction conditions. Having had success with microwave-assisted peptide 
synthesis, this reaction was first attempted on a small scale (2-5ml vial).  
 
The reaction took place in the Biotage Initiator 2.5 microwave synthesizer. A 
reaction time of 4.5hrs, with a fix hold time, which means that the time of the reaction does 
not start until the reaction reaches the target temperature, were selected, according to the 
manufacturer’s guidelines. Pre-stirring was set to 1 minute and dioxane was used as the 
solvent, as its boiling point is 101°C, while the reaction was conducted at 90°C. After 
purification this small scale reaction gave a yield of 63%. This increase in yield and 
reduction in reaction time was consistent with previous reports on microwave-assisted 
organic synthesis. When conducted on a larger scale the yield was further increased to 73%. 
This is as far as Route 1 ABT 263 proceeded. Multiple attempts performed to convert the 
hydroxyl into a phenylthio group consistently failed.  
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6.7.1.2 Route 3 ABT 263 
 
Scheme 6. 2 Synthesis of 4-(4-((4'-chloro-4,4-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-
yl)methyl)piperazin-1-yl)benzoic acid (12) 
 
4-Piperazin-1-ylbenzoic acid ethyl ester (8) was directly performed as the starting 
material of this synthetic route by Abbott laboratories in their patent. However, the cost of 
this material proved to be prohibitive for our studies and as this starting material can be 
conveniently prepared in a single step from readily available reagents, it was decided to 
synthesise this intermediate. The simple aromatic substitution reaction was carried out 
according to Kubota et al. and isolated yields up to 79% were obtained.
[32]
 The product and 
impurities were first taken up in DCM and washed with a mild base, sodium bicarbonate, 
resulting in  deprotonation of the amine resulting in the product 4-piperazin-1-ylbenzoic acid 
ethyl ester (8). After a wash with brine the product was isolated by rotary evaporation. The 
reaction gave no noticeable side-products and therefore produced an intermediate used in the 
next step without purification. 
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The first attempt to synthesise 1-bromo-4,4-dimethylcyclohexane-carbaldehyde (9) 
was performed according to the method reported in the patent. A crude yield of 32% was 
obtained and NMR analysis showed evidences of a large amount of starting material 
remaining in this crude product. This was confirmed by the low yield for the purified 
product (5%). This reaction proceeds by first forming the Vilsmeier reagent from DMF in 
the presence of phosphorus tri-bromide (Scheme 6.4) 
[33, 34]
. The Vilsmeier reagent is utilized 
to form both the intermediate and the final product. This reaction cannot be monitored by 
TLC as the final product is made during the work-up. The reaction conditions described in 
the patent consisted in stirring the preformed Vilsmeier reagent with 4,4 dimethyl-
cyclohexanone at room temperature for 18 hours. However, as reported by Xiang et al., 
when the reaction was conducted at higher temperatures (60°C) the reaction time was 
reduced (1 hour) and the yield increased (38%).
[35]
 The product was also obtained with a 
good purity, as shown by NMR analysis, and could proceed to the next synthetic step 
without purification. 
 
 
Scheme 6. 3 Formation of the Vilsmeier reagent 
 
 
4-[4-(2-Bromo-5,5-dimethyl-cyclohex-1-enylmethyl)-piperazin-1-yl]-benzoic acid 
ethyl ester (10) is formed by reductive amination (Scheme 6.5). This involves the conversion 
of the carbonyl group of 1-bromo-4,4-dimethylcyclohexane-carbaldehyde (9) to 
an amine via an intermediate imine. The amine source is 4-piperazin-1-ylbenzoic acid ethyl 
ester (8). This reaction was carried out by a one-pot procedure, with the imine formation and 
reduction occurring consecutively. In this case sodium cyanoborohydride (NaBH3CN) was 
chosen as the reducing agent. Good yields of crude materials (93%) were obtained for this 
step. These materials were relatively pure with residual acetic acid being the main impurity.  
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Scheme 6. 4 Formation of the 4-[4-(2-Bromo-5,5-dimethyl-cyclohex-1-enylmethyl)-piperazin-1-
yl]-benzoic acid ethyl ester by reductive amination. 
 
 This is as far as the synthesis of ABT 263 was attempted. Independent difficulties 
occurring in the preparation of another synthon, attempted according to Route 2 of the 
overall synthetic scheme for ABT 263 shown in green on page 164. The synthesis of 4-
fluoro-3-trifluoromethanesulfonyl-benzenesulfonamide requires the use of trifluoromethyl 
iodide, a gas that ultimately couldn’t be handled safely. Considering also the potential 
formation of hydrogen fluoride from this reagent and the high cost of another starting 
material for this synthetic route 2 of ABT 263 (2-fluorothiophenol), the 4-fluoro-3-
trifluoromethanesulfonyl-benzenesulfonamide synthon was replaced by 4-fluoro-3-
nitrobenzenesulfonamide. This involves the synthesis of ABT 737 in place of ABT 263, but 
as the other 2 synthons in their synthetic route are similar, most of the work completed to 
this point could be transferred to the new synthetic route. In term of their ultimate 
application,   ABT 737 and ABT 263 differ by their oral biovailability, a factor that doesn’t 
impact on the investigation of the localisation and function of a BH3 mimetic inhibitor 
labelled with a ruthenium probe in cell culture studies. 
 
6.7.2 ABT 737 
  
The synthesis of ABT 737 proceeded as described by Oltersdorf et al
[10]
 with a few 
changes as outlined below. Route 1 had been partly investigated previously for the synthesis 
of ABT 263, but could not be progressed further due to time constraints. Route 2 and 3 were 
prioritised and completed.  
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6.7.2.1 Route 1 ABT 737 
 
 
Scheme 6.6 Route 1: Synthesis of (R)-3-amino-N,N-dimethyl-4-(phenylthio)butanamide 
 
Route 1 of ABT 737 is identical to Route 1 of ABT 263 as far as intermediate 1. 
This has been described previously in section 6.7. The next step of route 1 for ABT 737 
involved the nucleophilic substitution by reaction of N,N-dimethylamine with 3-(R)-N-
benzyloxycarbonyl-amino-butyrolactone (1) to form (R)-benzyl-(4-(dimethylamino)-1-
hydroxy-4-oxobutan-2-yl) carbamate. Oltersdorf’s procedure[10] involved bubbling gaseous 
dimethylamine into a solution of 3-(R)-N-benzyloxycarbonyl-amino-butyrolactone (1), 
however the use of a  dimethylamine solution was favoured to meet health and safety 
standards with the equipment available in the laboratory. Yields up to 91 % were obtained in 
these conditions, but the next step could not be investigated due to a lack of time. 
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6.7.2.2 Route 2 ABT 737 
 
 
Scheme 6.7 Route 2 Synthesis of 4-fluoro-3-nitrobenzenesulfonamide 
 
The shortest of the three converging routes, route 2 begins with 1-fluoro-2-
nitrobenzene. The nitro groups meta directing effects forms the sulfonic acid intermediate 4-
fluoro-3-nitrobenzene-1-sulfonyl chloride (6). This compound reacts in the next step with 
ammonium hydroxide to form the corresponding sulphonamide (7). This route 2 for ABT 
737 proceeded to completion and gave yields of 60% over the two steps.   
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6.7.2.3 Route 3 ABT 737 
 
Scheme 6. 8 Synthesis of 4-(4-((4'-chloro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)benzoic 
acid. 
 
In route 3 of ABT 737, ethyl 4-(piperazin-1-yl)-benzoate intermediate (8) is the 
same as the previously described in Route 3 of ABT 263. The next step in of the synthesis of 
ABT 737 involves an amine alkylation. The alkyl halide in this case is 1-bromo-2-
bromomethylbenzene. This nucleophilic aliphatic substitution reaction forms the higher 
substituted amine. N,N-Diisopropylethylamine was added as a base to assist the 
deprotonation of the amine. As a tertiary amine is formed the reaction does not require as 
much control as if the desired product was to be a primary or secondary amine and therefore 
equal molar equivalents of the amine to the halide is added to form the desired product ethyl 
4-(4-(2-bromobenzyl)piperazin-1-yl)benzoate (9).  
 
Suzuki coupling is used to form the next intermediate, ethyl 4-(4-((4'-chloro-[1,1'-
biphenyl]-2-yl)methyl)piperazin-1-yl)benzoate (10). The first step in the Suzuki reaction is 
the oxidative addition of the palladium, PdCl2(PPh3)2 to the previous intermediate ethyl 4-(4-
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(2-bromobenzyl)piperazin-1-yl)benzoate (9). This forms an organopalladium species which 
reacts with the base, sodium carbonate forms another organopalladium species, via 
transmetalation with the chlorophenylboronic acid. This is then reduced, reforming the 
palladium catalyst and the desired product ethyl 4-(4-((4'-chloro-[1,1'-biphenyl]-2-
yl)methyl)piperazin-1-yl)benzoate (10).  
 
The final step of this route is the deprotection of the ethyl ester in (10) to form the 
corresponding carboxylic acid, 4-(4-((4'-chloro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-
yl)benzoic acid (11). This is achieved by using LiOH-promoted hydrolysis to form the 
carboxylate. The free carboxylic acid (11) is formed by acidification with HCl, giving yields 
for (11) of 87%.  
 
 
6.8 Photophysical Results 
 
The use of the ABT 263 molecule was initially intended for cellular localisation and 
function studies, by modifying the morpholino substituent by a ruthenium label conjugated 
through a linker by an amide bond, once the synthetic procedures for the parent BH3 
mimetic inhibitor had been optimised. The intention was also to apply this approach to the 
ABT 737 candidate, by replacement of the dimethylamino group. However the structure of 
the ABT 737 molecule itself led us to believe that the molecule may be capable of 
fluorescence. Therefore the photophysics was explored with two of the fully assembled 
synthons. The final intermediate of Route 3 for ABT 737, 4-(4-((4'-chloro-[1,1'-biphenyl]-2-
yl)methyl)piperazin-1-yl)benzoic acid (11) contained biphenyl rings and had therefore a 
promising structure as a ridged molecule with an extended π system, that might be capable 
of absorbing light resulting in a π-π* transition.  
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 The final intermediates in Route 2 and Route 3 of ABT 737, were investigated for 
their photophysical properties, the compounds are shown in Scheme 6.9. 4-Fluoro-3-
nitrobenzenesulfonamide (7) from route 2 used in a 2.3 mM aqueous solution presented a 
UV-VIS spectra distinguished by a signal at 248 nm and a shoulder at 296 nm, likely to 
originate from * and nitro based transitions respectively.  On the other hand, it did not 
emit in aqueous solution. The material was incubated with CHO cells and confocal imaging 
attempted, but as expected resulted in no compound visible within the cells. 
 
 
Scheme 6.9 ABT 737 Route 2 Final molecule 7 and Route 3 Final molecule 11 
 
 
Figure 6. 1 UV-VIS spectrum of ABT 737, 4-fluoro-3-nitrobenzenesulfonamide (7)  (2.3mM) 
 
 The UV-VIS spectra of (11) is distinguished by a signal at 289 nm. Interestingly, 
when the molecule was excited at this wavelength it gave a dual emission at 363 nm and 704 
176 
 
nm, to our knowledge, the emission of ABT derivatives has not been reported previously. 
Both emissions are genuine as confirmed by excitation studies. The dual emission was very 
interesting and we believed it had potential for direct cellular imaging for localisation and 
functional studies, without conjugation to a chromophore. However, as cell testing was 
conducted the emission was found not to be sufficiently strong to be distinguished from the 
background. Therefore conjugation to a chromophore is required for future work involving 
confocal imaging. 
 
 
Figure 6. 3 UV-VIS spectrum emission of spectrum of ABT 737 Route 3 Final Molecule in 
aqueous solvent. 
 
 
 
6.9 Cytotoxicity 
Preliminary cytotoxicity was conducted for the final molecules in Route 2 (7) and 
Route 3 (11) of ABT 737 as outlined in Chapter 3. Synthon (11) proved to be non toxic 
whereas synthon (7) proved to be very toxic. Synthon (7) of ABT 737 induces cellular 
toxicity (in CHO cells) at concentrations above 10μM when incubated overnight at 37°C. 
Further studies to investigate if cell death is occurring though apoptosis or necrosis are 
currently conducted. 
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Figure 6. 4 Cytotoxicity assay with CHO cells treated with Route 2 Final molecule (7)  (Data 
collected by Dr. Róisín Moriarty) 
 
6.10 Conclusions  
 
This work was commenced in order to investigate the location and functional of 
ABT 263 by confocal microscopy. Originally the ABT 263 molecule was chosen for 
investigation. This seemed to be an ideal small molecular inhibitor to select for investigation 
as it is in stage 3 clinical trials, however due to difficulties in its synthesis, the close 
analogue ABT 737 was selected for synthetic and labelling feasibility studies. Using the 
information disclosed in a patent proved to be challenging due to the absence of some 
synthetic details in the protocols implemented and of some analytical data. ABT 737 has the 
same target and therefore cellular localisation as ABT 263 and therefore could be used for 
the same purpose in term of cellular imaging. There have been many difficulties to be 
addressed to complete the assembly of 2 of the 3 synthons of ABT 737, leading to the 
inability to complete the synthesis the final molecule. One major hurdle remainig in the 
synthesis of ABT 737 is to initiate Route 1. Its first intermediate (1) proved to be a very 
unstable molecule to be isolated through a long and low yielding work-up.   
 
Due to the growing cost of the synthesis, it was decided to discontinue the synthesis 
of these BH3 mimetic inhibitors and to focus on the inherent potential photophysical 
properties of the molecule ABT 737. We aimed to achieve our original goal of cellular 
imaging with the synthesised fragments obtained from the completed routes 2 and 3. 
Although the synthon from the latter gave promising photophysical results, this intermediate 
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failed to give a strong dual emission with two peaks an intense emission around 380 nm and 
a weaker transition, which at 700 nm.  Unfortunately, the requirement for UV excitation to 
generate these emissions meant it was still unsuitable for applications in cell imaging. Route 
2 final intermediate (7) molecule had poor photophysical results and proved moreover to be 
very toxic to CHO cells.  
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7.0 Conclusions and Future Work 
 
Peptide labelled metal complex luminophores for imaging and exploring the 
environment of living cells is a relatively new topic of research. It is driven by the many 
advantages such complexes have over conventional imaging dyes, including Stoke-shifts 
tuneable emission and environmental sensitivity. This thesis is part of on-going research 
by our group that focussed on the development of ruthenium (II) polypyridyl –peptide 
conjugates for cellular imaging. This thesis focusses on the synthesis, characterisation and 
identification of novel ruthenium complex-peptide bioconjugates suitable for 
applications in cellular imaging and the investigation of their sub-cellular targeting and 
localisation. The compounds can be considered supramolecular dyads, A-L-B 
containing, A, the photoactive sensing unit, L, in this case a benign linker and B the 
targeting and/or transport peptide. 
 
Chapter 1 overviewed the assembly of supramolecular bioconjugates of metal complexes for 
application in targeted cellular imaging. Chapter 2, outlined the experimental methods used.  
Chapter 3 detailed the synthesis and a detailed comparative study of the preparation of 
nuclear localisation peptides, NF-κB and SV-40, and their conjugation to ruthenium (II) 
polypyridyl chromophores. The desire to direct Ru(II) to the nucleus was driven by the 
extensively reported interactions of such complexes with DNA.  Many Ru(II) polypyridyl 
complexes bind strongly to DNA through electrostatic and intercalative interactions and 
have been demonstrated, in solution, to photocleave DNA.  Therapeutic exploitation of these 
interactions requires that the complex can be directed to the cell nucleus. 
 
Six novel Ru II polypyridyl peptide conjugates were synthesised by standard SPPS 
Assembly of the peptide sequence and elongation with a (2 or 5 carbon) linker was 
performed by automated synthesis, with final N-terminal deprotection. The Ru II polypyridal 
complex was conjugated by manual coupling. Cleavage of the Ru (II) polypyridal peptide 
conjugates from the resin took place by treatment with TFA in the presence of scavengers. 
Semi-preparative HPLC on a reverse phase polymeric support was used to achieve purities 
of the metal conjugates >85%. The Ru (II) polypyridal peptide conjugates were 
characterised by mass spectroscopy. The effect of the identity of the linker between the 
metal complex and the peptide was also investigated with β-alanine, a 2 carbon linker and 6-
amino-hexanoic acid, a 5 carbon linker compared. Photophysical studies showed that the 
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emission characteristics of the conjugates were comparable to those of the parent 
chromophores.  
Prior to peptide conjugation, neither parent complex exhibited efficient transport 
across the cell membrane of CHO cells. Both Ru(II) chromophores coupled to the NF-κB 
sequence underwent diffusion across the cell membrane of CHO cells and their uptake was 
not affected by the length of the linker. In general, this led to the localisation of the dyes 
within the cells’ nucleus. Not all NLS peptides are able to promote the cellular uptake of 
ruthenium (II) polypyridyl chromophores. The Ru(bpy)2 PIC-SV-40 conjugate for example 
did not exhibit efficient transport across the cell membrane.  On the other hand, the Ru(dpp)2 
PIC-SV-40 conjugate did penetrate the cell membrane however we believe that this occurred 
through its disruption of the cell membrane, eventually leading to cell death. This is 
supported by preliminary cytotoxicity studies which showed Ru(dpp)2PIC polypyridyl 
peptide conjugates have a higher cytotoxicity than the corresponding Ru(bpy)2PIC 
polypyridyl peptide conjugates. 
 
The Ru(bpy)2PIC polypyridyl peptide conjugates show promise as imaging agents. 
They also exhibit efficient nuclear localisation and low cytotoxicity. The Ru(dpp)2PIC 
polypyridyl peptide conjugates do not appear to be as efficient as imaging agents as the 
Ru(bpy)2PIC polypyridyl peptide conjugates due to their higher toxicity. The Ru(dpp)2PIC 
polypyridyl peptide conjugates also remain mainly associated with the cell membrane. This 
suggests that the toxic nature of the dye occurs through its higher hydrophobicity and 
interaction with the cell membrane. The ability of its conjugates to impart nuclear 
localization is affected by the nature of the cargo, with larger and more positively charged 
ruthenium complex being more difficult to direct than smaller ones. The Ru(dpp)2 PIC 
peptide conjugates may be useful as therapeutics if their effects on the cell membrane could 
be alleviated by conjugation to alternative peptide sequence or use of another delivery 
technique such as liposomes or polymeric vectors and if their accumulation in the nucleus 
result in the apoptosis of cancer cells.  This work will continue with detailed studies on the 
ability of both conjugates to induced photo-stimulated cell death in living cells. 
 
 Chapter 4 described the synthesis of 11 overlapping BID peptide sequences 
spanning the complete protein (tBid). Most of these peptides could not be prepared by 
routine techniques. This stepwise elongation was successful for 2 sequences, BID 155-177 
and BID 78-101. For the other 9 BID sequences with a higher content of hydrophobic 
residues this method failed. For these 9 BID sequences, the peptide was assembled on the 
synthesiser up to the longest stretch of hydrophobic amino acids and then transferred to a 
syringe for completion by manual synthesis. This method allowed the use of longer reaction 
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times and higher equivalents of amino acids and coupling reagents to force the reaction to 
completion. Both the coupling and deprotection reactions were monitored by Kaiser test. 
When this elongation of the peptide sequence became difficult, as shown by mixed results 
from a Kaiser test, coupling and deprotection reactions were completed in the Biotage 
Initiator 2.5 microwave synthesizer. This was carried out for BID 175-195, residue 176 (N) 
and BID137-157, residue 143 (E). The 11 BID sequences coupled to biotin were 
successfully synthesised, purified and characterised and available for protein binding studies 
which will be conducted through an independent collaborative project.  
 
Two of the BID sequences, BID 137-157 and BID 155-177, were chosen for 
conjugation with [Ru(dppz)2PIC]ClO4 on the basis of their high hydrophobic amino acid 
contents. The synthesis and purification of these proved to be more difficult than the biotin-
labelled analogues, requiring a change in the coupling chemistry to overcome the low 
reactivity of the carboxyl group from the ruthenium complex. The optimal conditions for 
[Ru(dppz)2PIC]ClO4 conjugation were identified and should be successfully applied to any 
of the other BID sequences which would show promising results from the protein binding 
studies. These studies addressed in particular the choice of the linker between the label and 
the peptide to ensure sufficient solubility in aqueous media of the conjugates. Photophysical 
and imaging studies were conducted with BID 155-177 and showed that the properties of the 
parent complex are not significantly modified by the conjugation to the peptide sequence.  
Unlike its unconjugated complex, Ru(dppz)2PIC BID 155-177  underwent diffusion across 
the cell membrane of Kelly neuroblastoma cells, with no accumulation in the nucleus, but 
also showed significant toxicity which could result from its interaction with the cell 
membrane and/or uptake in the cytoplasm. 
 
This work will continue with protein binding studies with the 11 BID-Biotin peptide 
conjugates will be performed by the group Prof. Jochen Prehn in the Department of 
Physiology and Medical Physics at the Royal College of Surgeons in Ireland.  Further 
studies with Ru(dppz)2PIC-BID 155-177 by confocal microscopy, to determine its sub-
cellular localisation, and by the cytotoxicity assay, to elucidate the chronology of the uptake 
and toxicity events are currently being performed. 
 
Chapter 5 detailed the conjugation of the hydrophilic and hydrophobic ruthenium 
(II) polypyridyl chromophores to a cationic antimicrobial peptide with mitochondria 
targeting ability, Magainin 2.  The peptide was synthesized on the Applied Biosystem ABI 
433A Synthesizer and the bio-conjugation of chromophore to peptide took place on the resin 
with PyBOP as the coupling reagent. Cleavage of the Ru(II) polypyridal peptide conjugates 
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from the resin took place in TFA in the presence of scavengers. Semi-preparative HPLC was 
used to achieve purities >83%.  The Ru(II) polypyridal peptide conjugates were 
characterised by mass spectroscopy.  
As these complexes are O2 and pH sensitive, it is important to be able to target them 
to organelles where such measurements will be of benefit in cell metabolic studies.   The 
photophysical results showed the complexes did not change significantly on peptide 
conjugation, compared with the parent complexes. Prior to peptide conjugation, neither 
parent complex exhibited efficient transport across the cell membrane of CHO cells and only 
the [Ru(dpp)2 PIC]
2+
 complex conjugate crossed the cell membrane of CHO cells after 
conjugation to the Magainin 2 sequence. In general, this did not lead to localisation of the 
dyes within the cell’s mitochondria, the expected target of the peptide component; however 
co-localising experiments will be required to confirm this result. The corresponding 
Ru(bpy)2 PIC Magainin 2 conjugate did not cross the membrane, which would indicate that 
there might exist a threshold of hydrophobicity of the cargo that controls the cellular uptake 
of the conjugate, as both [Ru(bpy)2 PIC]
2+
 and [Ru(dpp)2 PIC]
2+
 complexes should have the 
same effect on the N-terminal capping of the peptide and its ability to form a transmembrane 
pore. 
 
The [Ru(dpp)2 PIC]
2+
 peptide conjugates remains associated with the entire cell 
membrane. It is possible that it’s interaction with the mitochondrial membrane triggers rapid 
cell death and cannot be imaged. The parent complex was also successful in passing through 
the cell membrane. The [Ru(dpp)2 PIC]
2+
 peptide conjugate may be useful in therapeutic 
applications as it targets the nucleus and could potentially result in the apoptosis of cancer 
cells. We believe it to concentrate further within the nucleolus, however further imaging and 
localising studies must be completed. Also as the Magainin 2 peptide can penetrate bacterial 
cells, the use of the Ru(II) polypyridyl Magainin 2 conjugate in imaging will be extended to 
bacterial cells, although the rapid killing mechanism induced by Magainin 2 in prokaryotic 
cells might make this application challenging.  
 
Chapter 6 examined the synthesis of small molecule inhibitors of the Bcl-2 family 
proteins. Originally the ABT 263 molecule was selected for investigation, with the objective 
of applying an imaging agent to it to follow its localisation. This seemed to be an ideal small 
molecular inhibitor as it is in stage 3 clinical trials, however due to difficulties in its 
synthesis, the close analogue ABT 737 was selected for synthetic and labelling feasibility 
studies. This was again a very challenging synthesis work to date and has led to the 
assembly of 2 of the 3 synthons of ABT 737, however the synthesis of the final molecule 
was not achieved. One major hurdle remaining in the synthesis of ABT 737 is to initiate the 
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preparation of the (R)-3-amino-N,N-dimethyl-4-(phenylthio)butanamide synthon. Its first 
intermediate N-benzyloxycarbonyl-D aspartic acid anhydride proved to be a very unstable 
molecule to be isolated through a long and low yielding work-up.   
 
Due to time and resource limitations, it was decided to discontinue the synthesis of 
these BH3 mimetic inhibitors and to focus on the inherent potential photophysical properties 
of the molecule ABT 737. We aimed to achieve our original goal of cellular imaging with 
the 4-fluoro-3-nitrobenzenesulfonamide (7) and 4-[4-(4'-Chloro-biphenyl-2-ylmethyl)-
piperazin-1-yl]-benzoic acid (11) synthons produced. Although the latter synthon gave 
promising photophysical results, this intermediate failed to give an emission which could be 
excited with the visible wavelengths conventionally used in confocal imaging. Route 2 final 
intermediate (7) molecule did not emit, but interestingly proved to be very toxic to CHO 
cells.  
 
The supramolecular synthetic strategies attempted in this thesis have shown that 
coordination compound peptide labelled probes can be readily made using solid state peptide 
synthesis. The conjugates synthesised in Chapter 3 show promise as nuclear imaging agents, 
with particularly in the case of the NLS peptides, the ability to target the complexes to 
specific organelles. Although the work described in Chapter 4 is still awaiting protein-
binding studies, we have developed the synthetic approach to identify the functional motifs 
of a protein. Chapter 5 has investigated a mitochondria targeting peptide with Ru(II) 
complexes. These conjugates require further imaging before a conclusive statement can be 
made on their application. Chapter 6 outline how difficult it was to achieve a probe 
conjugated to a small molecule inhibitor and unfortunately this had to be abandoned. In 
conclusion, this thesis detailed the ongoing intense efforts to develop imaging probes for cell 
imaging, to aid biochemical understanding of cellular processes and medical diagnostics and 
described potential molecular probes capable of making advances in these areas. 
Appendix 1: NMR, HPLC and Mass 
Spectrometry Results
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Chapter 3: Luminescent Chromophores for Cellular Imaging 
 
Figure 1: Purity of NF-κB (βA-VQRKRQKLMP-NH2) [Ru(dpp)2PIC] conjugate 
 
 
 
Figure 2: MALDI-TOF of NF-κB (βA-VQRKRQKLMP-NH2) [Ru(dpp)2PIC] conjugate using 
α-cyano-4-hydrxycinnamic acid matrix 
III 
 
 
 
 
 
 
Figure 3: Mass Spectrum of NF-κB (βA-VQRKRQKLMP-NH2) [Ru(bpy)2PIC] conjugate  
 
 
Figure 4: Purity of NF-κB (Ahx-VQRKRQKLMP-NH2) [Ru(dpp)2PIC] conjugate 
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Figure 5: Purity of NF-κB (Ahx-VQRKRQKLMP-NH2) [Ru(bpy)2PIC] conjugate 
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Figure 6: Mass Spectra of NF-κB (Ahx-VQRKRQKLMP-NH2) [Ru(bpy)2PIC] conjugate  
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Figure 7: Purity of SV-40[Ru(dpp)2PIC]ClO4 
 
 
 
 
 
 
Figure 8: Mass Spectra of Sv-40 (Ahx-PKKKRKV-NH2) [Ru(bpy)2PIC] conjugate 
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Chapter 4: BH3 Interacting Domain Death Agonist 
 
 
Figure 9: MALDI-TOF of biotinylated BID 1-20 using α-cyano-4-hydrxycinnamic acid matrix 
 
Figure 10: HPLC of biotinylated BID 1-20 
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Figure 11: MALDI-TOF of biotinylated BID 18-36 using α-cyano-4-hydrxycinnamic acid 
matrix 
 
Figure 12: HPLC of biotinylated BID 18-36 
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Figure 13: MALDI-TOF of biotinylated BID 29-48 using α-cyano-4-hydrxycinnamic acid 
matrix 
 
Figure 14: HPLC of biotinylated BID 29-48 
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Figure 15: MALDI-TOF of biotinylated BID 46-64 using α-cyano-4-hydrxycinnamic acid 
matrix 
 
Figure 16: HPLC of BID biotinylated 46-64 
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Figure 17: MALDI-TOF of biotinylated BID 62-82 using α-cyano-4-hydrxycinnamic acid 
matrix 
 
Figure 18: HPLC of biotinylated BID 62-82 
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Figure 19: MALDI-TOF of biotinylated BID 78-101 using α-cyano-4-hydrxycinnamic acid 
matrix 
 
Figure 20: HPLC of biotinylated BID 78-101 
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Figure 21: MALDI-TOF of biotinylated BID 97-117 using α-cyano-4-hydrxycinnamic acid 
matrix 
 
Figure 22: HPLC of biotinylated BID 97-117 
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Figure 23: MALDI-TOF of biotinylated BID 116-137 using α-cyano-4-hydrxycinnamic acid 
matrix 
 
Figure 24: HPLC of biotinylated BID 116-137 
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Figure 25: MALDI-TOF of biotinylated BID 137-157 using α-cyano-4-hydrxycinnamic acid 
matrix 
 
Figure 26: HPLC of biotinylated BID 137-157 
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Figure 27: MALDI-TOF of biotinylated BID155-177 using α-cyano-4-hydrxycinnamic acid 
matrix 
 
Figure 28: HPLC of biotinylated BID 155-177  
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Figure 29: MALDI-TOF of biotinylated BID 175-195 using α-cyano-4-hydrxycinnamic acid 
matrix 
 
Figure 30: HPLC of biotinylated BID 175-195  
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Figure 31: MALDI-TOF of BID 155-177 coupled to Ru(dppz)2PIC using α-cyano-4-
hydrxycinnamic acid matrix 
 
 
Figure 32: HPLC of BID 155-177 coupled to Ru(dppz)2PIC 
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Chapter 5: Targeting Mitochondria with Luminescent Chromophores 
 
Figure 33: Purity of Magainin 2 (Ahx-GIGKKLHSAKKFGKAFVGEIMNS-NH2) 
[Ru(dpp)2PIC] conjugate 
 
Figure 34: Purity of Magainin 2 (Ahx-GIGKKLHSAKKFGKAFVGEIMNS-NH2) 
[Ru(bpy)2PIC] conjugate 
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Figure 35: Mass Spectra of Magainin 2 (Ahx-GIGKKLHSAKKFGKAFVGEIMNS-NH2) 
[Ru(bpy)2PIC]  conjugate 
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Chapter 6: Small molecule Inhibitors of Bcl-2 family proteins 
 
Figure 36: Proton NMR of (R)-benzyl (5-oxotetrahydrofuran-3-yl)carbamate in DMSO-d6 
Figure 37: Carbon NMR of (R)-benzyl (5-oxotetrahydrofuran-3-yl)carbamate in DMSO-d6 
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Figure 38: Mass Spectra of (R)-benzyl (5-oxotetrahydrofuran-3-yl)carbamate 
 
 
 
Figure 39: Proton NMR of (R)-benzyl (4-(dimethylamino)-1-hydroxy-4-oxobutan-2-
yl)carbamate in CDCl3 
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 Figure 40: Carbon NMR of (R)-benzyl (4-(dimethylamino)-1-hydroxy-4-oxobutan-2-
yl)carbamate in CDCl3 
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Figure 41: Mass Spectra of (R)-benzyl (4-(dimethylamino)-1-hydroxy-4-oxobutan-2-
yl)carbamate 
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Figure 42: 4-fluoro-3-nitrobenzenesulfonamide proton NMR in DMSO-d6 
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Figure 43: 4-fluoro-3-nitrobenzenesulfonamide carbon NMR in DMSO-d6 
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Figure 44: Mass Spectra of 4-fluoro-3-nitrobenzenesulfonamide  
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Figure 45: ethyl 4-(piperazin-1-yl)benzoate proton NMR in CDCl3 
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Figure 46: ethyl 4-(piperazin-1-yl)benzoate carbon NMR in CDCl3 
 
 
Figure 47: Mass spectra of ethyl 4-(piperazin-1-yl)benzoate 
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Figure 48: Proton NMR of 4-(4-(2-bromobenzyl)piperazin-1-yl)benzoate in DMSO-d6 
 
Figure 49: Carbon NMR 4-(4-(2-bromobenzyl)piperazin-1-yl)benzoate in DMSO-d6 
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Figure 50: Mass Spectra of 4-(4-(2-bromobenzyl)piperazin-1-yl)benzoate  
 
Figure 51 : Elemental Analysis of 4-(4-(2-bromobenzyl)piperazin-1-yl)benzoate 
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Figure 52 : Proton NMR 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1-yl)benzoate in 
DMSO-d6 
 
Figure 53: Carbon NMR 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1-yl)benzoate in 
DMSO-d6 
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Figure 54: Mass spectra of 4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazin-1-yl)benzoate  
 
 
Figure 55: Proton NMR of 4-(4-((4'-chloro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)benzoic 
acid in DMSO-d6 
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Figure 56: Carbon NMR 4-(4-((4'-chloro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)benzoic 
acid in DMSO-d6 
 
Figure 57: Mass spectra of 4-(4-((4'-chloro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)benzoic 
acid 
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Figure 58: Proton NMR of (R)-benzyl (1-hydroxy-4-morpholino-4-oxobutan-2-yl)carbamate in 
CDCl3 
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Figure 59: Carbon NMR of (R)-benzyl (1-hydroxy-4-morpholino-4-oxobutan-2-yl)carbamate in 
CDCl3 
 
Figure 60: Mass spectra of (R)-benzyl (1-hydroxy-4-morpholino-4-oxobutan-2-yl)carbamate 
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Figure 61: Proton NMR 1-bromo-4,4dimethylcyclohexane-carbaldehyde in CDCl3 
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Figure 62: Carbon NMR 1-bromo-4,4dimethylcyclohexane-carbaldehyde in CDCl3 
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Figure 63: Proton NMR ethyl 4-(4-((2-bromo-5,5-dimethylcyclohex-1-en-1-yl)methyl)piperazin-
1-yl)benzoate in CDCl3 
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Figure 64: Carbon NMR ethyl 4-(4-((2-bromo-5,5-dimethylcyclohex-1-en-1-
yl)methyl)piperazin-1-yl)benzoate in CDCl3 
 
Figure 65: Mass spectra of ethyl 4-(4-((2-bromo-5,5-dimethylcyclohex-1-en-1-
yl)methyl)piperazin-1-yl)benzoate 
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